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Abstract

Non-Small Cell Lung Cancer (NSCLC) is often characterized by mutually exclusive mutations in epidermal
growth factor receptor (EGFR) or KRAS. The mutual exclusivity of these mutations is due to synthetic
lethality, revealing a potential therapeutic vulnerability if possible to selectively activate EGFR in KRAS
mutant cells. This thesis work demonstrates a previously unidentified mechanism of EGFR signal regulation
through palmitoylation, the addition of the 16-carbon palmitate. The palmitoyltransferase, DHHC20,
catalyzes this palmitoylation to Cys1025, Cys1122 and Cys1034 on the C-terminal tail of EGFR. Loss of
EGFR palmitoylation leads to hyperactivation of the receptor, but decreased cell growth of KRAS mutant
cancer cells. While KRAS is still an elusive therapeutic target, here we report that disrupting EGFR
palmitoylation by ablation of DHHC20 or expression of a palmitoylation-resistant EGFR mutant blocks
tumorigenesis in a KRAS-driven mouse model of lung adenocarcinoma. Mechanistically, we show that in the
presence of oncogenic KRAS, unpalmitoylated, active EGFR increases signaling through the MAP Kinase
pathway while simultaneously reducing PI3K/AKT signaling leading to a severe decrease in expression of the
central proliferation-associated transcription factor, Myc, similarly as impossible to therapeutically target as
KRAS. We find that the dysregulation of EGFR palmitoylation from DHHC20 loss disrupts the delicate
balance of MAPK and PI3K signaling leading to detrimental loss of Myc expression and subsequent loss of
cell growth. Initially, we discovered that inhibiting EGFR palmitoylation increases sensitivity to the EGFR
tyrosine kinase inhibitor, gefitinib, in cell lines specifically harboring mutant KRAS and interestingly, in cells
harboring the drug-resistant EGFR gatekeeper mutation through a mechanism that is still unclear. We have
now determined that inhibition of DHHC20 induces sensitivity of KRAS mutant cells to a clinically available
pan-PI3K inhibitor, Buparlisib, more effective than gefitinib in inducing cell death by directly blocking the
residual, necessary PI3K signaling. Thus, this previously unappreciated mechanism of receptor signaling
modulation driven by the palmitoyltransferase, DHHC20, can be exploited to treat the currently incurable
mutant KRAS NSCLCs.
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ABSTRACT
THE REGULATION OF EGFR SIGNALING AND KRAS TUMORIGENESIS BY
RECEPTOR PALMITOYLATION
Akriti Kharbanda
Eric Witze

Non-Small Cell Lung Cancer (NSCLC) is often characterized by mutually
exclusive mutations in epidermal growth factor receptor (EGFR) or KRAS. The mutual
exclusivity of these mutations is due to synthetic lethality, revealing a potential
therapeutic vulnerability if possible to selectively activate EGFR in KRAS mutant cells.
This thesis work demonstrates a previously unidentified mechanism of EGFR signal
regulation through palmitoylation, the addition of the 16-carbon palmitate. The
palmitoyltransferase, DHHC20, catalyzes this palmitoylation to Cys1025, Cys1122 and
Cys1034 on the C-terminal tail of EGFR. Loss of EGFR palmitoylation leads to
hyperactivation of the receptor, but decreased cell growth of KRAS mutant cancer cells.
While KRAS is still an elusive therapeutic target, here we report that disrupting EGFR
palmitoylation by ablation of DHHC20 or expression of a palmitoylation-resistant EGFR
mutant blocks tumorigenesis in a KRAS-driven mouse model of lung adenocarcinoma.
Mechanistically, we show that in the presence of oncogenic KRAS, unpalmitoylated,
active EGFR increases signaling through the MAP Kinase pathway while simultaneously
reducing PI3K/AKT signaling leading to a severe decrease in expression of the central
proliferation-associated transcription factor, Myc, similarly as impossible to
therapeutically target as KRAS. We find that the dysregulation of EGFR palmitoylation
from DHHC20 loss disrupts the delicate balance of MAPK and PI3K signaling leading to
detrimental loss of Myc expression and subsequent loss of cell growth. Initially, we
discovered that inhibiting EGFR palmitoylation increases sensitivity to the EGFR tyrosine
vi

kinase inhibitor, gefitinib, in cell lines specifically harboring mutant KRAS and
interestingly, in cells harboring the drug-resistant EGFR gatekeeper mutation through a
mechanism that is still unclear. We have now determined that inhibition of DHHC20
induces sensitivity of KRAS mutant cells to a clinically available pan-PI3K inhibitor,
Buparlisib, more effective than gefitinib in inducing cell death by directly blocking the
residual, necessary PI3K signaling. Thus, this previously unappreciated mechanism of
receptor signaling modulation driven by the palmitoyltransferase, DHHC20, can be
exploited to treat the currently incurable mutant KRAS NSCLCs.
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CHAPTER 1: Introduction
Genesis
The epidermal growth factor receptor (EGFR) and its downstream signaling has
been studied for decades establishing a textbook understanding of how EGFR signaling
is modulated and how EGFR mutant disease arises. Similarly, KRAS signaling and
mutant KRAS disease has been equally well-studied. Despite all this knowledge and
subsequent clinical advances made in personalized therapy, there is still a highly
remarkable unmet clinical need to treat KRAS-driven non-small cell lung cancer
(NSCLC), which still remains refractory to pharmacological inhibition. In fact, NSCLC
remains the leading cause of cancer related death with a mortality rate of 1.6 million
annual deaths worldwide, especially for those with a KRAS mutation. (1) Upon entering
graduate school, I believed that I understood EGFR and KRAS signaling to the fullest
extent. However, I discovered that there was still much to learn. Some well-studied posttranslational modifications of EGFR include phosphorylation of the C-terminal tyrosines
and N-terminal glycosylation. Palmitoylation of EGFR had never been studied. I sought
to determine the role of EGFR palmitoylation and as a cancer biologist, to determine
how palmitoylation of EGFR affected receptor signaling capacity in a disease setting. I
found an exciting role of EGFR palmitoylation in governing mutant KRAS tumorigenesis.
The goal quickly became to identify a targetable means to manipulate EGFR
palmitoylation to eradicate mutant KRAS NSCLC. I trust that this thesis can convince the
scientific community of the extraordinary ability of palmitoylation to regulate EGFR
signaling. I hope the proposed mechanism will cultivate new therapeutic strategies to
revolutionize outcomes in patients with KRAS-driven NSCLC in the near future.
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The Epidermal Growth Factor Receptor (EGFR)
Regulation of EGFR
Receptor tyrosine kinases (RTK) are widely deregulated in cancer, including
breast, lung, pancreatic and colon cancer. Furthermore, increased RTK signaling
contributes to a variety of human malignancies. Members of the ErbB family play critical
roles in response to extracellular growth cues and initiating downstream signaling
cascades through effector pathways (2-4) . The epidermal growth factor receptor
(EGFR) is one of four members of the ErbB family and is known to facilitate
tumorigenesis and cancer progression.
Almost all cell types, except hematopoietic cells, possess EGFR or another ErbB
family member to maintain normal developmental and maturation processes. EGFR is
structurally composed of an extracellular ligand binding domain, a transmembrane
region, a tyrosine kinase domain, and an unstructured C-terminal tail that harbors
receptor auto-phosphorylation sites (5). Ligands including the epidermal growth factor,
EGF, bind to the extracellular domain of EGFR leading to a conformational change that
facilitates homo- and heterodimerization with members of the ErbB family (5).
Subsequently, tyrosine kinase activity of the receptor is initiated leading to autophosphorylation of C-terminal tyrosines. The phosphorylated tyrosine residues serve as
docking sites for adaptor proteins that link the receptor to downstream signaling
pathways including Ras-Raf-MEK-ERK, PI3K-AKT, Src and JAK-STAT culminating in
the regulation of cell migration, proliferation and survival (5).
EGFR signaling is in part mediated by receptor clathrin-mediated endocytosis. In
response to stimulation, EGFR is trafficked through early and late endosomes in route to
lysosomes for signal termination and ubuiquitin- mediated receptor degradation, and/or
2

recycling. Studies have suggested that activated EGFR can continue to signal from
endosomes, indicating that there may be pathways that actively require EGFR
endocytosis (6). Furthermore, studies have shown the distinct localization of EGFR in
the nucleus and the presence of this nuclear EGFR correlates with the proliferation
status of cells in certain tissues, such as the regenerating liver. There is now evidence to
support a role of nuclear EGFR as a transcription factor to activate genes required to
regulate the cell cycle (7). Despite the decades of study on EGFR receptor, there are still
pieces to the complex signaling scheme that further investigation.
EGFR and Lung Cancer
Lung cancer is the leading cause of cancer related mortality in the United States,
with an estimated 234,030 new cases and 154,050 deaths in 2018. About 85% of lung
cancers are non-small cell lung cancers (NSCLC). The largest subset of NSCLC, lung
adenocarcinoma (LUAD), is the most common type of lung cancer seen in non-smokers
and is particularly aggressive. LUAD is characterized by many driver mutations. The
most frequent mutation being an activating mutation in EGFR closely followed by an
activating mutation in KRAS. These two oncogenic mutations in NSCLC are mutually
exclusive, they do not exist together. Activating and amplifying EGFR mutations are
involved in progression of triple-negative breast cancer (TNBC), pancreatic and
colorectal cancer, and glioblastoma multiforme. However, due to the integral connection
between EGFR mutations and lung cancer progression, LUAD is often used to study
EGFR and the molecular mechanisms that drive EGFR-driven tumorigenesis.
In the clinic, patients diagnosed with LUAD are tested for these two particular
driver mutations so that therapy can be effectively chosen. If a patient has an EGFR or
another receptor, such as ALK, mutation, patients are treated with targeted therapy in
3

the form of tyrosine kinase inhibitors (TKIs) as first-line treatment. Second-line therapy is
using TKIs in combination with radiation or chemo. Finally, when all else fails, patients
are enlisted into clinical trials for new targeted therapies being developed. Contrastingly,
if a patient has a KRAS mutation, the only first-line therapy available is chemotherapy or
a suitable clinical trial. There are no targeted therapies currently available for mutant
KRAS LUAD. As such, if a patient has a KRAS mutation, survival prognosis is poor.
EGFR Oncogenic Mutations and Tyrosine Kinase Inhibitors (TKIs)
As discussed, dysregulation of EGFR is a common event in cancer, specifically
LUAD. Mutations causing amplification or constitutive activation of EGFR that enhance
signaling and drug resistance have been identified in breast and lung cancer (3).
Activating EGFR point mutations in exon 21, such as L858R, and deletions of exon 19
are often predictors of response to EGFR TKI therapy with Gefitinib or Erlotinib (8).
While most EGFR mutations commonly reside within the extracellular (EGFR-vIII) and
kinase (L858R, T790M) domains, recent studies identified EGFR mutations within the Cterminal tail (9). Deletion of EGFR exons 25-27 was recently identified in lung cancer
and glioblastoma multiforme (10-12) . Studies showed that ectopic expression of EGFR
lacking exons 25 and 26 promotes anchorage-independent colony formation and
increases ligand-independent EGFR and AKT activation. Furthermore, deletion of exons
25-27 confers EGFR TKI sensitivity in glioblastoma xenograft assays (10,12). However,
the mechanism of regulation of EGFR through these sites and how loss of these sites
leads to constitutive receptor activation remained unknown.
Although patients with NSCLCs harboring activating EGFR mutations initially
respond well to EGFR TKIs, the majority of these patients relapse within 10 to 16
months of treatment (13,14). In over half of these patients, resistance to EGFR TKI
4

therapy is associated with the acquisition of a secondary T790M mutation in the EGFR
tyrosine kinase domain. The T790M mutation alters interaction of reversible TKIs with
the ATP-binding pocket (8,15). Research focus has shifted to clinically validating a new
generation of EGFR TKIs, such as Afatnib, that irreversibly inhibit the EGFR kinase
domain as new first-line therapy (16-17). Recently, there has been development of new
mutant selective pyrimidine-based third-generation EGFR-TKIs, which irreversibly block
T790M-mutant and Exon19 deletion-mutant of EGFR, revealing the potential to
overcome drug resistance. However, acquired resistance to these new EGFR TKIs after
prolonged use is effusively predicted (18). Significant efforts are still underway to define
first-line therapeutic strategies that maximize patient survival; potentially, combining
EGFR TKIs with new targeted agents or targeting alternative pathways that feed into
mutant EGFR dependency.
EGFR Downstream Pathways
The phosphorylated tyrosine residues of EGFR serve as docking sites for
adaptor proteins which link the receptor to downstream signaling pathways, mainly RasRaf-MEK-ERK (MAPK) and PI3K-AKT pathway (5). The adaptor protein Grb2 and the
guanine nucleotide exchange protein, Sos, link active EGFR to RAS. RAS initiates a
cascade through several MEK protein kinases ultimately leading to the phosphorylation
of MAPK, also known as ERK. Activated ERK then translocates to the nucleus to
transactivate transcription factors leading to reprogramming of the transcriptional profile
of the cell to promote growth, differentiation or mitosis (19) (Figure 1).
Similarly, activated EGFR directly stimulates the PI3K catalytic subunit,
p110alpha bound to EGFR via the regulatory subunit, p85 or other less prevalent
adapter molecules. Active PI3K then facilitates conversion of several phospholipid
5

components in the plasma membrane leading to phosphorylation of AKT at threonine
308 (T308) priming and partially activating AKT. Phosphorylation of AKT at serine 473
(S473) in the hydrophobic carboxy-terminal motif anchored in the plasma membrane by
mTOR kinase leads to full activation of AKT. Fully active AKT initiates substrate-specific
phosphorylation events in the cell promoting growth, survival, transcription, and
apoptosis programs (20).
Ligand binding to EGFR stimulates a multitude of other signaling cascades
perhaps to a lesser extent or in conjunction with RAS/MAPK and/or PI3K/AKT activation.
A few examples of these parallel signaling cascades are the JAK/STAT pathway and the
PLC-1-PKC pathways. Similar to the main signaling cascades, the Janus Kinases
(JAKs) transmit their signal through a cascade of phosphorylation events to eventually
activate the Signal Transducer and Activator of Transcription (STAT) proteins. STATs
translocate to the nucleus where they act as transcription factors. The growth factor
ligands or signals to active the PLC-gamma-1/PKC pathway are slightly different in that
the main goal of this pathway is to induce intracellular calcium release. As expected, this
cascade is necessary for vasculogenesis, fibroblast transformation, muscle fiber
contraction and neuronal activity. EGFR or another dimerized ErbB family receptor
phosphorylates PLC-1 at specific tyrosines. Once the receptor recruits PLC-1 to the
plasma membrane and activates the protein, PLC-1 hydrolyzes PIP2 in the membrane
into free intracellular 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). These
secondary messengers, IP3 and DAG, bind to IP3-receptors at the endoplasmic
reticulum to induce intracellular calcium release (21). This multitude of complex
cascades clearly demonstrates the powerful capacity of one receptor, EGFR, to combine
and transmit a complex array of signals through protein cross-talk culminating at the
appropriate growth response.
6

In human cancers, both the MAPK and the PI3K-AKT pathways are commonly
mutated and these mutations are sufficient for cell transformation. Mutations in KRAS,
predominantly an amino acid substitution at codon 12 or 13, lead to upregulation of the
KRAS/MAPK signaling and ERK activation to drive cell division. Similarly, the PI3K
pathway is often mutated in the p110α catalytic subunit (PIK3CA) in multiple domains,
such as E545K in the helical domain and H1047R in the catalytic domain, leading to
activation of AKT and promoting cell survival (22). While mutations in RAS are common
in cancer, it has been challenging to therapeutically target RAS directly. The initial
consideration for anti-RAS therapy were developing GTP antagonists, which failed
because of the RAS nucleotide-binding pocket’s very high affinity for GTP. As such,
efforts have been made to target the analogous ATP-binding pocket of RAS downstream
effector kinases, but these therapies often lead to paradoxical activation of neighboring
proliferation pathways or drug resistance (23). PI3K inhibitors, in turn, are currently used
in the clinic and more PI3K inhibitors are under clinical investigation. However, PI3K
inhibition has been challenging due to the compensatory effect of the various isoforms of
the catalytic subunit of PI3K, p110. As a result, single-agent clinical efficacy has been
modest at best (24). Efforts are being directed towards investigating PI3K inhibitors in
combination with different therapeutic agents.

7
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Introduction Figure 1: Simplified EGFR signaling pathway. Ligands are EGF, TGF-β,
and Epiregulin (ER). The two main pathways are the PI3K/AKT/mTOR and
RAS/RAF/MAPK cascades which transmit extracellular stimuli into the cell to promote
cell survival and proliferation. Activating mutations in EGFR and downstream effectors
(red) lead to lung tumorigenesis. Both pathways lead to regulation of the cell proliferation
associated transcription factor, Myc. Figure modified from (66).
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KRAS and Myc: Critical Nodes in Cancer
Understanding KRAS
The RAS family of proteins encompass three members, NRAS, HRAS and
KRAS, encoded for by oncogenes of the same name. Oncogenic NRAS and HRAS
mutations exist in various tumor types, however, KRAS is the most commonly mutated
member of the RAS family. In fact, KRAS was one of the first human genes to be labeled
as a putative oncogene and is now known as one of the most frequently mutated
oncogenes in cancer. The RAS genes encode small GTPases, which are turned on and
off by transitioning between GDP or GTP-bound states in response to stimulation of
receptors, such as EGFR. The GTPases are composed of: (i) an N-terminal lobe or the
effector lobe, which has two switch regions to modulate RAS binding to effectors and
regulators downstream, such as RAF and more recently suggested, PI3K. (ii) The
catalytic domain of Ras proteins, which shares more than 90% sequence identity across
the three family members. And (iii) The C-terminal lobe containing the hypervariable
region (HVR), which as suggested is the most variable between the RAS family
members and is particularly involved in RAS membrane association and localization
(25). The association of RAS to the membrane is critical for its function because at the
membrane RAS can bridge extracellular cues from receptors into the important cellular
events, such as cell growth, proliferation, differentiation, and survival.
The variation in the HVR between NRAS, HRAS and KRAS defines the unique
compartmentalization and membrane localization that may explain specificity in the
functions between the three family members. Every RAS protein contains a cysteine in
the HVR that is farnesylated, the addition of a 15-carbon hydrophobic fatty acid chain,
during post-translational processes. HRAS and NRAS are also palmitoylated on other
9

HVR cysteine residues. The KRAS oncogene encodes two isoforms of KRAS, KRAS-4a
and KRAS-4b, through mRNA splice variation. Interestingly, only KRAS-4a is
palmitoylated in addition to the C-terminal farnesylation whereas the KRAS-4b HVR has
a strong positive charge allowing a favorable interaction with the negatively charged
phospholipids in the plasma membrane. As will be discussed in the next section,
palmitoylation is the addition of a 16-carbon hydrophobic fatty acid chain, which is very
similar to farnesylation except for the fact that palmitoylation is reversible whereas
farnesylation is not. These are two dedicated localization signals driving RAS to the
membrane, but the reversibility of palmitoylation also allows for removal of RAS from the
membrane when the protein needs to be recycled or degraded (26).
KRAS Mutations
Given the cell proliferation driving events following RAS activity, it is no surprise
that alterations in RAS are responsible for the transition of healthy cells to malignant
cells, defined by uncontrolled growth. In addition to the frequent mutation of RAS genes
occurring in many type of cancers, there are molecular alterations of many other
components downstream of RAS, such as RAF (27). Early studies on the RAS family of
proteins clearly indicated that different human tumor types showed preferential
oncogenic activation of a specific RAS. NRAS mutations occur at a high-frequency in
acute leukemias and neuroblastomas. HRAS mutations are common in thyroid and
bladder cancers. KRAS mutations occur at a very high frequency in pancreatic, colon
and lung cancer, whereas in these tumor types HRAS and NRAS mutations are
extremely rare (28). Both KRAS splice variants are conserved across mammalian
genomes and are ubiquitously expressed in normal tissue types, but studies indicate that
KRAS-4a and KRAS-4b also act differently in different physiological contexts. For
10

example, some studies demonstrated that KRAS-4a is expressed at greater levels than
KRAS-4b in colorectal-derived tumor cell lines and in primary human colorectal
adenocarcinoma tissues (29). More importantly, in vivo lung oncogenesis may be
mediated by mutant KRAS-4a whereas mutant KRAS-4b alone is insufficient to initiate
tumorigenesis (26). However, as both KRAS-4a and KRAS-4b are oncogenic when
KRAS is mutated, there is no evidence to suggest that one splice variant is more
oncogenic than the other.
As mentioned, mutations in KRAS frequently define some of the cancers that are
particularly aggressive, including Pancreatic Ductal Adenocarcinoma (PDAC), colorectal
cancer (CRC) and NSCLC. Studies indicate that KRAS mutations occur early in PDAC
progression and in fact, KRAS mutations might be the driving mutation in PDAC
tumorigenesis followed by loss of the tumor suppressor p53 for the transition from
premalignant lesions to adenocarcinoma. Although not as evidenced as in PDAC
studies, studies of CRC have suggested that KRAS mutations may also be early events
driving progression from premalignant polyps to full-blown CRC. Regardless, KRAS
mutations are detected in 45% of all CRC diagnoses samples showing that KRAS is
clearly an important protein for tumor development (30). NSCLCs also display a high
frequency of KRAS mutations, specifically about 25-30% of all NSCLCs patients show
indication of a KRAS mutation. As formerly discussed, most KRAS mutations occur in
codon 12 or 13 where the glycine (G) coded for in either codon is mutated to code for
commonly aspartate (D), valine (V) or cysteine amongst others. Particularly, G12C,
G12V and G12D account for about 80% of all KRAS mutations especially in generation
of NSCLCs (27). These mutations result in a conformation of KRAS that lead to
stabilization of GTP binding to the small GTPase. The GTP cannot be hydrolyzed to
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GDP thereby leaving KRAS in a constitutively active state driving constitutive activation
of the downstream MAPK cascade.
Targeting KRAS
Due to the clear relationship between KRAS mutations and progression of
aggressive malignancies, many of sought to generate therapies that block KRAS activity.
However, direct pharmacologic inhibition of KRAS at the nucleotide-binding pocket has
been extremely difficult compared to inhibiting other kinases with a similar ATP-binding
pocket. This is due to the extremely high affinity of GTP to RAS in stoichiometric ranges
far below the efficacious concentrations of a small molecule in a human body.
Alternatively, the community shifted gears to work towards indirectly targeting steps of
RAS activation particularly its necessity to be at the plasma membrane. As farnesylation
of the HVR of RAS is one of the membrane localization signals, efforts were directed
towards generating inhibitors to block RAS farnesylation. This effort brought about the
discovery of the farnesyltransferase protein that catalyzes the modification and
generation of farnesyltransferase inhibitors (FTIs). However, it was found that FTIs did
not inhibit the activity of the most commonly mutated RASs in tumors, KRAS and NRAS,
due to the presence of other compensating transferases, such as the
geranylgeranyltransferase, and other compensating, membrane-localizing lipid
modifications, such as palmitoylation (31).
Many groups have recently discovered and developed small molecule
modulators of RAS using the protein crystal structure as a guide. Some of these
modulators are able to bind RAS and block necessary protein-protein interactions, such
as the interaction with the guanine exchange factor, SOS, or the interaction with RAF.
However, these small molecules have other impediments, such as their weak affinity to
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RAS, their lack of selectivity to specific RAS family members and the lack of specificity to
mutant RAS especially. More recent efforts are geared toward the development of highly
selective and potent inhibitors of different downstream RAS effectors, such as RAF,
MEK, ERK, PI3K and AKT inhibitors, but the hurdle here is the possible activation of
compensatory pathways or generation of secondary mutations with prolonged use of
these inhibitors.
While targeting RAS itself or specific RAS effector pathways is one rational
therapeutic strategy, an alternative approach is to exploit the concept of synthetic
lethality, in which vulnerable gene products are identified that when inhibited cause cell
death only in the presence of an oncogenic mutation. Thereby, manipulating synthetic
lethal targets in cancer may reduce the potential for side effects as cells harboring
oncogenic mutations will be particularly sensitive to the manipulation compared to
normal cells that don’t have the mutation. Many groups have shifted their focus to
identifying these synthetic lethal targets in mutant KRAS conditions. In KRAS-mutant
tumors, oncogenic KRAS signaling alters the state of the cell by inducing KRAS effector
signaling, adapting to oncogenic stress, and reprogramming of transcription and the
metabolism (32). The key to synthetic lethality is identifying these reprogrammed targets
that when inhibited will disrupt this new KRAS-driven cell state and subsequently impair
the proliferation of these KRAS-mutant cells.
Studies have shown that KRAS mutant cells acquire an increased dependence
on RTK signaling pathways. Interestingly, specifically in NSCLC, mutations in the RTK,
EGFR, are mutually exclusive with mutations in KRAS. Contrastingly, mutations in PI3K
are not mutually exclusive with either EGFR or RAS. The explanation canonically
understood for the mutual exclusivity is that both components signal in the same or
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overlapping pathways, and hence are functionally redundant. However, more recent
studies show that oncogenic mutations in both EGFR and KRAS in the same cell leads
to cellular death. Activating EGFRL858R mutation was expressed in lung adenocarcinoma
cells harboring an activating KRASG12D mutation and vice versa. Co-expression of the
two activating mutations led a significant decrease in lung adenocarcinoma cell viability
(33). This inhibition of growth due to perturbation of both these genes has been identified
as synthetic lethality. Synthetic lethality explains the mutually exclusivity of EGFR and
KRAS mutations and why the presence of both mutations is selected against in tumor
development. However, the underlying molecular mechanisms that cause this synthetic
lethality are still unknown (33). The presence of mutant EGFR has proven to be a
potential vulnerability in the mutant KRAS cell state, however, this vulnerability still
poses a major challenge in terms of therapy. The challenge resides in developing a drug
that will activate rather than inhibit EGFR in mutant KRAS tumor cells.
Despite the valiant efforts being made, there are still no clinically available drugs
with anti-cancer efficacy that target RAS proteins directly or act on RAS-driven human
cancers. Tumors harboring RAS mutations still remain the most difficult to treat, are
usually excluded from targeted therapy treatment and represent a poor survival
prognosis.
New Understanding of Oncogenic KRAS Signaling
The RAS community understands that Ras GTPases function as binary
molecular switches, cycling between inactive GDP-bound and active GTP-bound states.
In the basal state, Ras is predominantly GDP bound but activation of a receptor tyrosine
kinases (RTK) recruits guanine nucleotide exchange factors (GEF), such as SOS, to
promote the exchange of bound GDP for GTP on nearby Ras molecules. The oncogenic
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mutations of RAS lead to constitutively active RAS with an impaired rate of GAPmediated GTP hydrolysis and consequently deregulated RAS signaling. In this case, it is
commonly assumed that mutant KRAS is active and no longer requires the activity of an
RTK, such as EGFR. In fact, clinical studies show that having oncogenic KRAS
mutations predict resistance to TKIs; hence, treatment options for KRAS mutant cancers
do not include the use of TKIs. However, a new understanding of mutant RAS regulation
has recently surfaced. Although there is a mutation in one allele of RAS rendering it
mutant, the remaining 2 isoforms of RAS remain wildtype and subject to regulation by
GAPs and GEFs. These isoforms are thereby contributing to the overall RAS signaling
output. Recent studies have discovered distinct roles for oncogenic and wildtype RAS in
regulating signaling in cancer cells harboring oncogenic RAS mutations. They show that
oncogenic RAS regulates the basal signaling, but unexpectedly wildtype RAS regulates
the growth factor dependent signaling. Thereby, although oncogenic RAS is
constitutively activating MAPK signaling, activation of EGFR, for example, can further
enhance this signaling by stimulating GTP loading onto wildtype RAS. Furthermore, the
study suggests that oncogenic RAS mediates a feedback suppression of RTKs whereas
the wildtype RAS activates the upstream signaling in the form of compensation. These
results support the idea of targeting oncogenic KRAS in combination with an EGFR
inhibitor in KRAS mutant NSCLC (34). This approach will simultaneously block EGFRmediated activation of wildtype KRAS signaling and the sustained MAPK signaling from
oncogenic KRAS.
The Final Destination: Myc
The ultimate destination of an RTK signal cascade is the nucleus, which results
in the signal being read and understood by the transcriptional machinery of the cell.
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Depending on the signal, the protein that has finally reached the nucleus acts on
transcription factors, which can then adjust transcription of certain genes based on what
the signal has transmitted. Upon ligand binding, whether that be epidermal growth factor
(EGF) or transforming growth factor-alpha (TGFA) or epiregulin (EREG), EGFR signals
heavily through the RAS/MAPK. The final kinase in the cascade is the extracellular
signal-regulated kinase (ERK). ERK has the capacity to translocate to the nucleus and
phosphorylate many cell proliferation-associated transcription factors, such as cAMPresponse element (CREB), c-Fos and c-Myc. After activation, many of these
transcription factors can amplify transcription of their own representative genes in a selfregulatory loop. By altering the levels and activities of transcription factors, ERK
eventually leads to altered transcription of genes that are important for the cell cycle and
thereby cell growth.
One of the most vital cell proliferation associated transcription factors
downstream of the MAPK cascade is c-Myc. The proto-oncogene, myc, is at the center
of many growth associated signaling pathways and is an immediate early response gene
downstream of many RTKs. The regulation of myc expression is tightly controlled by a
number of mechanisms involving many transcriptional regulatory motifs found within its
proximal promoter region. Also, the myc mRNA and Myc protein are similarly tightly
regulated as the dysregulation of Myc is the beginning of many cellular disabilities. The
Myc protein contains an N-terminal transcriptional regulatory domain, a nuclear
localization signal and a C-terminal region with a basic DNA binding domain with a helixloop-helix dimerization motif. Myc dimerizes with another helix-loop-helix protein, Max, to
bind DNA. Upon dimerization, Myc-Max binds DNA at specific E-box binding motifs (5’CACGTG-3’) and recruit complexes composed of other transcription factors and histone
modifying proteins to repressively or actively control gene transcription (35). Myc-binding
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sites are amazingly conserved among different cell types and Myc binds a similar
population of high-affinity targets in both tumor and primary cells. Myc-target genes
belong to diverse functionally categories, including tissue remodeling, growth ligands
and receptors, metabolism and other transcription factors (36).
In cancer cells, myc activation can result from constitutive activation of a
pathway, such as pathways that regulate B-catenin and APC. B-catenin is a coactivator
for the transcription factor, Tcf, which directly activates myc transcription, when the
negative control on β-catenin by APC is removed. Additionally, myc activation can result
from direct alterations to the myc gene, such as amplifications or chromosomal
translocations. For example, myc is consistently altered by chromosomal translocation in
Burkitt lymphomas and multiple myelomas, and is one of the most highly amplified
oncogene amongst many human cancers, including lung, breast and colon carcinomas.
Interestingly, inhibition of PI3K leads to myc amplification as a form of drug resistance,
indicating that Myc is downstream of PI3K in tumorigenesis. Myc expression is estimated
to be elevated or signaling deregulated in up to 70% of human cancers. Particularly,
high levels of Myc expression have been linked to aggressive triple negative breast
cancer (TNBC) (37). Scientific models of Myc-mediated tumorigenesis suggest that
established tumors have an oncogene addiction to Myc making Myc a strong candidate
to target for cancer therapeutics.
As Myc is a vulnerable drug target, many forms of inhibitors have been
developed and are currently being aggressively clinically tested. Approaches to inhibit
Myc activity include inhibiting Myc expression, interrupting Myc-Max dimerization,
inhibiting Myc-Max DNA binding, and interfering with key Myc target genes, such as cJun (35). Directly inhibiting Myc or the Myc-Max dimerization has proved to be difficult
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due to an abnormally large protein-protein interface of the heterodimer and the lack of a
defined ligand-binding domain. Thereby, focus has shifted towards impeding Mycdependent transcription and/or blocking activity of myc co-activator proteins. Studies
discovered that bromodomain (BRD)-containing proteins from the BET family, including
BRD4, act as regulatory factors of Myc. BET inhibition by the developed bromodomain
inhibitor, JQ1, has shown to downregulate myc transcription and genome-wide
downregulation of Myc target genes. JQ1 has shown efficacy in murine models of
multiple myeloma and Burkitt’s lymphoma, and has proved effective in other in vivo
preclinical studies (38). Furthermore, BET bromodomain inhibition has recently proved to
be efficacious in GEMM of mutant KRAS NSCLC (39). The preliminary success of JQ1
in the disruption of cancer progression constitutes the great therapeutic value of
inhibiting Myc. Hence, although direct inhibition of KRAS has remained a challenge in
the drug discovery field, inhibiting or deregulating the ultimate destination of RAS
signaling, Myc, may prove to be more fruitful.

Palmitoylation
What is Palmitoylation?
Palmitoylation, the most common form of protein acylation, is a post-translation
protein lipid modification that requires the formation of a thioester bond between a
cysteine thiol side chain and the saturated 16-carbon fatty acid, palmitic acid.
Palmitoylation may also occur through a covalent attachment of palmitic acid to serine or
threonine residues of proteins although this is much less frequent than cysteine
palmitoylation. Unlike the other lipid modifications, such as myristoylation, prenylation,
farnesylation, and addition of cholesterol, palmitoylation is reversible as the thioester
bond is readily reactive (40). Palmitic acid modifies mainly membrane associated
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proteins, both integral and peripheral membrane proteins. A meta-analysis of various
studies produced a collection of approximately 2,000 mammalian proteins that have
been shown to be palmitoylated and this collection is called the palmitoylome. About
40% of synaptic proteins were found in the palmitoylome (41), understandably so as
palmitoylation of mammalian proteins was first discovered in neurons. The discovery in
neurons, where specific proteins must locate to the plasma membrane during synapse
formation, led to an understanding of the primary function of palmitoylation, localizing
and associating proteins to membranes.
As the scientific community began to appreciate the significance of lipid
modifications to specific proteins in cellular signaling pathways, the study of
palmitoylation became a focus. Now, the recognized functions of palmitoylation are to
regulate protein localization, trafficking, stability, segregation to membrane
compartments, and protein-protein interactions (40). The reversibility and hydrophobicity
of palmitoylation is the key to these functional roles of palmitoylation in the cell. The
addition of palmitic acid to proteins increases their hydrophobicity, which contributes to
the membrane association of these proteins. The reversibility permits rapid cycling of
palmitoylation and depalmitoylation which allows proteins to be easily shuttled between
the plasma membrane and the Golgi apparatus, where these proteins are modified, to
regulate many cellular functions.
Emerging Regulatory Roles of Acylation
For many years, palmitoylation was known to simply regulate subcellular
trafficking of proteins to membrane compartments. Recent studies have shown that
there are many more regulatory roles to acylation, including palmitoylation, and that
palmitoylation of proteins can affect cellular signaling processes. Studies have shown
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that the major signaling protein, Wingless/Integrated (Wnt), is modified by a 16-carbon
cis-unsaturated fatty acid called palmitoleic acid on a serine. This type of lipid
modification is called palmitoleoylation (42). Wnt signaling is evolutionarily conserved
from metazoans to humans. It is critical during development and functions to regulate
tissue homeostasis. Canonically, signaling is initiated when the secreted, lipid-modified
Wnt glycoprotein interacts with the extracellular N-terminal cysteine-rich domain (CRD)
of the Frizzled (Fzd) G-Protein coupled receptor (GPCR). Fzd then directly interacts with
the cytoplasmic phosphoprotein, Dishevelled (Dsh). In the canonical Wnt signaling
pathway, Dsh, through interaction with other proteins in a complex, can block the
degradation of β-catenin. As a result, β-catenin accumulates in the cytoplasm and
translocates to the nucleus to activate transcription of genes associated with body axis
patterning, cell fate specification, cell proliferation and cell migration (43).
Palmitoleoylation of Wnt is critical for its secretion to the extracellular
environment as a paracrine or autocrine ligand and for its activity. Further study showed
that the high-affinity interaction between Wnt and Fzd occurs at two distinct contact
sites, one being a protein–fatty acyl interface and the other a canonical protein–protein
interface. The protein-fatty acyl interaction is required for efficient activation of Fzd by
Wnt. A recent study has discovered that the palmitoleic acid modification of Wnts can be
recognized by multiple CRDs from multiple Fzd receptors at one time. Furthermore, the
acyl modification allows for the bridging of two CRD monomers showing that the binding
of lipid-modified Wnt mediates Fzd receptor dimerization (44). The study proves the
existence of this new acylated Wnt-Fzd interface by isolating a crystal structure of the
human Fzd5 CRD bound to a 16-carbon cis-unsaturated fatty acid in a lipid binding
groove with a U-shaped geometry. Moreover, this crystal structure revealed a dimeric
arrangement of the Fzd5 CRD with both monomers containing the lipid-binding groove
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(44). This study represents that fatty acid modifications of proteins are recognized by
specific flexible cavities which facilitate specific protein-protein interactions and this
interaction can stimulate downstream signaling.
A more recent study showed that the tyrosine kinase, c-Abl, has a binding pocket
for the hydrophobic myristoyl group on the N-terminus and the loss of this myristoylation
leads to dramatically higher kinase activity compared to the myristoylated c-Abl (45).
This suggests that myristoylation of c-Abl is required to regulate the activity of c-Abl. This
demonstrates a new role for myristoylation, the addition of a 14-carbon saturated fatty
acid, involving the regulation of a cell signaling molecule. c-Abl is a modular signaling
protein that has many roles, including the regulation of the actin cytoskeleton and the
integration of DNA damage responses in the nucleus. Abl is mostly well-known in the
context of Bcr-Abl. A reciprocal translocation of genetic material on chromosome 9 and
chromosome 22 leads to the generation of a stunted chromosome named the
Philadelphia chromosome (Ph). The Ph contains a fusion gene encoding the fusion
protein, Bcr-Abl. As a result of the fusion, Bcr-Abl becomes an oncogenic tyrosine kinase
that is constitutively active uncontrollably driving myeloid progenitor cell transformation
leading to initiation and progression of chronic myelogenous leukemia (CML). Clinically,
treatment of CML has been revolutionized due to the development of the ATPcompetitive inhibitors for the Abl kinase domain, such as the renowned imatinib
(Gleevec). Imatinib works in part by trapping the Abl kinase active site in a specific
inactive conformation and has been revolutionary in the treatment of CML.
c-Abl is closely related to the Src family of kinases which are regulated by
phosphorylation at a conserved tyrosine in the C-terminal tail of the protein. This
phosphorylation causes self-association with the kinases SH2 domain. This leads to a
21

series of intra-kinase conformational changes that result in an inactive conformation of
the activation loop. Ligand binding to the SH2 domain interferes with this inactive
conformation and allows for activation of the kinase. This allows for controlled regulation
of signals and prevents unrestrained catalytic activity in a form of autoinhibition. c-Abl
kinase is regulated in a similar intramolecular interaction, but the SH2 domainphosphorylated tail association is replaced by an interaction of the N-terminal myristoyl
group with the kinase domain through a hydrophobic binding pocket at the base of the
kinase domain (45).
The mechanism of myristoylation of the N-terminal tail looping around and
binding to an orthotopic binding pocket is specific to c-Abl and an Abl-parlog, Arg. This
myristoyl group binding helps stabilize the inactive form of c-Abl. The other Src family
kinases, such as c-Src, are myristoylated at the N-terminal domain, however, this
myristoylation functions canonically by only allowing c-Src to localize to the plasma
membrane. In both c-Src and c-Abl, the inactivation to activation of the kinases are
coupled with conformational changes in the kinase domain with which the mouth of the
kinase domain is either flexed or open. In c-Abl, the myristoyl group helps stabilize the
inactive form of c-Abl. Gleevec has been shown to be very selective to c-Abl which is
why it has been so effective in treating and often resulting in remission. Now, it has been
established that this drug specificity comes from the interaction of inactive c-Abl with the
myristoylated N-terminal tail. When the myristoylation is released from its binding pocket,
the kinase domain of c-Abl conforms into a different activation structure distinct from
other Src kinases and Gleevec has a specific binding motif in that particular activation
structure (46). This study shows that myristoylation, which is concurrent to
palmitoylation, has the ability to regulate kinase activity by associating to the kinase
domain at a specific motif and can thereby affect the binding and efficacy of a kinase
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inhibitor. With this discovery, there is now a scientific initiative to identify new signaling
roles for acylation, especially palmitoylation, that can lead to the development of new
therapeutic approaches for palmitoylation dependent diseases, including cancer.
Regulation of Palmitoylation
Although palmitoylation was discovered in 1979, the enzymes that catalyze
protein palmitoylation were only discovered recently in 2002. Palmitoylation is regulated
by two classes of enzymes, the DHHC (Asp-His-His-Cys) domain containing protein
acyl-transferases or palmitoyltransferases (PAT), which mediate the addition of palmitate
to target substrates, and the acyl-protein thioesterases (APT) which remove palmitate
(47). The DHHC proteins were first discovered in yeast, Saccharomyces Cerevisiae, as
a Ras palmitoyltransferase and then an ankyrin-repeat-containing protein and a SNARE
protein. In mammals, DHHC proteins were also originally identified and studied in
neuronal cells as many SNAP and SNARE proteins are palmitoylated to associate with
plasma membrane at synapse formation (48). There are increasing examples of the
critical role for protein palmitoylation in cell signaling. Protein palmitoylation plays a role
in determining receptor levels and localization in neurons and immune cells. For
example, the turnover of glutamate receptors at neuronal synapses is promoted by
depalmitoylation of the postsynaptic density protein (PSD-95) in response to glutamate
receptor activity. Twenty-three PATs have been identified in mammals and some have
been shown to have biomedical relevance as their palmitoylated substrates are involved
in the pathogenesis of neurological disorders, such as Huntington’s disease (DHHC17)
and schizophrenia (DHHC8) (49). However, many DHHC enzymes have not been
studied and their substrates have not been identified.
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Palmitoylation in Cancer
Palmitoylation and the DHHC proteins have not to date been well-studied in the
context of development or progression of cancer. Recently, studies have discovered that
these enzymes modulate the function and location of important oncoproteins and tumor
suppressors. Subsequently, analysis of The Cancer Genome Atlas (TCGA) revealed that
alterations in expression and function of several of these PATs occurs in a variety of
cancers (48, 51, 52). The role of palmitoylation in cancer has mostly focused on the
palmitoylation of HRAS and NRAS (52). A cycle of palmitoylation and depalmitoylation of
RAS proteins in mammalian cells regulates the trafficking of these proteins between
intracellular compartments and the plasma membrane, where RAS is required to be for
activity. As previously discussed, this modification of RAS led to development of, albeit
unsuccessful, farnesyltransferase inhibitors (FTIs) to attempt inhibition of RAS acylation
and thereby RAS localization to the plasma membrane.
Recently, studies have linked palmitoylation in a functional capacity driving
tumorigenic signaling pathways. Mutations in the Notch signaling pathway have a strong
relationship with human T lymphoblastic leukemias (T-ALL) genesis, and have been
shown to be involved in solid tumor progression, such as breast, lung, gastric and liver
cancer. As previously discussed, disruptions in Wnt signaling are heavily implicated in
carcinogenesis of colorectal cancer through loss of APC. Palmitoylation of Wnt ligands
are critical to their function as they are required to localize to the membrane to be
secreted or to crosstalk with their receptors (42). New findings demonstrate that the
cycle of palmitoylation and depalmitoylation of Notch and Wnt is a major mechanism of
asymmetric cell division maintaining Notch and Wnt-associated protein dynamics and
cellular functions (53). A disruption in this cycle leads to altered or restricted Notch and
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Wnt signaling eventually causing transformation. Study of palmitoylation is becoming
more prevalent in the context of carcinogenesis however, more work is required to prove
the necessity of therapeutically targeting palmitoylation or acylation in general.
Palmitoylation Assays
At its discovery, protein palmitoylation was the first example of a covalent lipid
modifications of proteins in eukaryotic cells. In the following years, many more lipid
modifications of proteins, such as myristoylation, prenylation, farnesylation and
cholesterol addition, were discovered and shown to have a regulatory function. Protein
palmitoylation was also thought to have various regulatory functions in the cell. However,
a key difference between palmitoylation and the other forms of lipid modifications is that
palmitoylation is reversible. Furthermore, despite the many scientific technological
advancements, antibodies detecting palmitoylated proteins have not been generated,
unlike the readily available antibodies detecting phosphorylated proteins. Therefore,
tools to study palmitoylation are limited and difficult to perform (54). The first stipulated
qualitative method to measure protein palmitoylation was in vivo metabolic radiolabeling
of proteins with tritiated palmitate, [H3]-palmitate, and then detection by fluorography
(55). Although effective to identify palmitoylated proteins and assess the palmitoylation
level of a certain protein in living cells, the method is excruciatingly long and often does
not produce a quantifiable result. New methods of a similar nature use metabolic
incorporation of alkynyl fatty acid analogues, such as 17-octadecynoic acid (17-ODYA).
After metabolic labeling, the extent of proteins labeled with the azido-group containing
palmitoyl group is monitored by simple copper-catalyzed click chemistry to azide-linked
reporter tags, such as rhodamine-azide or biotin-azide. The labeled palmitoylated
proteins are then separated using SDS-PAGE or affinity enriched for mass
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spectrometry-based proteomics. This method is faster and is especially useful for
monitoring the on-off rates of palmitoylation using a pulse-chase approach (56), but still
not easy to quantify.
The generation of a new method called the acyl-biotin exchange (ABE) method
made it possible to study protein palmitoylation faster and in a quantifiable way. The in
vitro ABE method rapidly replaced the traditional metabolic labeling methods. In this
method, cell lysates are first subjected to N-ethylmaleimide (NEM) treatment which
blocks any free thiols on available proteins. Then the lysates are subjected to
hydroxylamine (HAM) which cleaves the cystein-palmitoyl thioester linkages on
palmitoylated proteins. The newly freed thiols on the originally palmitoylated proteins are
then labeled with biotin-HPDP (Biotin-HPDP-N-[6-(Biotinamido)hexyl]-3'-(2'pyridyldithio)propionamide. The biotin-HPDP labeled proteins are then affinity-purified
with streptavidin-agarose beads and subjected to SDS-PAGE analysis with western
blotting for suspected palmitoylated proteins or high-throughput, tandem mass
spectrometry (57). The work in this thesis primarily utilized the ABE method followed by
mass spectrometry or immunoprecipitation of the protein of interest.
DHHC20
Our lab discovered that the melanoma cell adhesion molecule (MCAM) is
depalmitoylated in response to Wnt5a, which promotes melanoma cell invasion. (58). A
previous proteomic study of WM239A melanoma cells identified only two PAT, DHHC20
and DHHC5. We proceeded to study DHHC20 by genetic means and discovered that it
palmitoylates MCAM. Although most PAT activity has been observed in the posttranslational modifying compartments, such as the Golgi and endoplasmic reticulum,
studies have shown that human DHHC20 also displays distinct plasma membrane
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localization. In fact, DHHC20 in one of only three out of the 23 palmitoyltransferases that
localizes to the membrane, the other two being DHHC5 and DHHC21 (59). This
localization at the membrane allows DHHC20 to access and associate with membrane
localized proteins, such as receptor tyrosine kinases. Thus began the journey to
understand this palmitoyltransferase and how it functions to palmitoylate receptors on
the plasma membrane.
Studies have shown that DHHC20 has a tissue-specific expression pattern.
These studies observed that DHHC20 was expressed at high levels in the testis,
placenta thyroid, colon and prostrate, at lower levels in the brain, heart, liver, lungs,
thymus, leukocytes ovary and breast, and not expressed at all in skeletal muscle and the
small intestine (60). Another study performed quantitative PCR analysis of DHHC20
expression level in normal human tissue versus tumors. These studies demonstrated
that DHHC20 expression is significantly upregulated in breast, colon, lung and prostate
tumors in comparison with organ-matched normal tissues (61). Furthermore, they found
that many potential targets of DHHC20 are potently transforming when constitutively
activated in breast cancer and several other potential targets of DHHC20 have elevated
expression and activity in colorectal carcinomas (61). Analysis of The Cancer Genome
Atlas (TCGA) reveals that alterations in DHHC20 expression including deletions,
amplifications and mutations occur in cancers of the breast, lung and prostate. Many
studies have determined that expression of DHHC20 is sufficient to cause cellular
transformation. A group mutated the catalytic cysteine in DHHC20 to a serine, DHHS20,
rendering it catalytically inactive. They showed that NIH3T3 cells expressing the
catalytically inactive DHHS20 were unable to grow in soft agar, whereas cells expressing
DHHC20 were able to. Soft agar growth depicts an anchorage-independent growth
pattern which is characteristic of cellular transformation and cellular transformation is the
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first step to malignancy. Therefore, this study proved that overexpression of catalytically
active DHHC20 causes transformation of NIH3T3 cells in vitro (61). Taken together,
these findings show that human DHHC20 is expressed in a tissue-specific manner and
is upregulated in certain tumor tissues correlating with the expression of its tumorigenic
intracellular targets. These results associate DHHC20 with the development of human
cancer setting a strong precedence to study DHHC20 and its enzymatic targets.
The recent publication of the first three-dimensional structure of DHHC20
sparked a new interest in the palmitoylation field. The structure explains how DHHC
proteins function and offers a map to efficiently design drugs against DHHC20. This
study describes the DHHC20 structure as being the canonically known 4-pass
transmembrane protein but with a newly discovered hydrophobic cavity formed by the
transmembrane domain where the acyl chain logically binds. The active site containing
the DHHC motif is at the membrane-cytosol interface of the cavity. The active site of the
enzyme then catalyzes the thioester-exchange to targets by using fatty acyl–coenzyme
A. This transmembrane cavity with the cytosolic active site explains why cysteines of
proteins that are in or close to the membrane are ideal candidates for palmitoylation
(62). These structures were published at a time when the entire field of protein
palmitoylation suffers from the lack of small molecule probes and inhibitors for the DHHC
family proteins, including efficient antibodies to experimentally study. Thus, this new
understanding of the shape of DHHC20 is a starting point to develop therapeutic
inhibitors using a structure-guided approach.
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Mouse Models of Lung Adenocarcinoma
The Origins
The analyzes of genetics on many cancers and their experimental study from the
last two decades has taught us one important lesson about cancer: specific cancer types
most often depend on the dysregulation of only a limited set of signaling cascades,
which are often unique for a particular tumor type. A few examples of cancer types in
fact show an extremely high incidence for a distinct driver mutation, e.g. BCR-ABL
translocations in chronic myeloid leukemia (CML), KRAS mutations in pancreatic cancer
or BRAF mutations in melanoma. With this lesson learned, the scientific community was
able to generate mouse models that recapitulated most of the unique characteristics of
the desired tumor type simply by introducing a number of tumor-specific driver mutations
into the appropriate target cell that represents the desired tumor type. In this manner, the
community was able to ask and answer questions pertaining to the influence of
individual mutations on tumor development and progression. The generation of these
mouse models has been a critical achievement for the targeted drug development field
as it is clear that it was impossible to perform efficacy studies in human patients.
Initially, the mouse model community generated tools to derive and culture
embryonic stem cells followed by mutating specific genes in those derived mouse
blastocytes using SV40 viral DNA. Finally, through germline transmission, transgenic
mice harboring specific mutations were generated (63). Today, we have tools available
to conditionally activate or inactivate genes in distinct cell types at any desired moment
using small molecules, such as doxocycline or tamoxifen. We have methods to regulate
expression of introduced genes or shRNAs against genes of interest using small
molecules. We can mark the switched cells using fluorescent reporters, such as green
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fluorescent protein (GFP). We can even read out distinct signaling pathways using either
fluorescent or bioluminescent reporters and conduct lineage tracing of stem cells from a
chosen tissue. With the development of these new genetically engineered mouse
models (GEMMs) of cancer, we have a newfound facility to quickly assess the
contribution of distinct mutation combinations to tumor development and design
appropriate targeted therapy.
The Model of Choice
Many or most of the driver mutations found in human NSCLC have been
introduced into the mouse individually and in combination with others. Some examples
of the driver mutations introduced include Kras, Braf, Egfr, Lkb1, Rac1, NfkappaB, and
p53. The combinations of driver mutations have been particularly revealing as they have
allowed the community to study the interdependencies of driver mutations leading to
altered disease phenotypes, making the mouse models more and more similar to human
disease. Most of the successful mouse models of lung cancer have focused on the
adenocarcinoma subtype of NSCLCs made by using a Lox-Stop-Lox (LSL) conditional
KrasG12D mutation genetically engineered into the endogenous Kras locus leaving one
allele to be wildtype Kras. With the introduction of viral, whether that be adenoviral or
lentiviral, Cre recombinase into the desired cells of LSL-KrasG12D mice, the mutant
KrasG12D allele is expressed at relatively endogenous levels. The advantage of the
control of the endogenous locus allows for the closest recapitulation of spontaneous
human tumor initiation and the subsequent processes pertaining to tumor progression,
making the study of human cancer much easier (64). However, a disadvantage of the
LSL-KrasG12D/+ model is the low frequency of activation, which results in a low
probability of and delayed tumor initiation.
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The activation of the oncogenic KrasG12D is sufficient to initiate tumorigenesis.
However, an additional deletion or point mutation of tumor suppressor, p53, significantly
enhances tumor progression, leading to a more rapid development of adenocarcinomas
with features of a more advanced disease. The deletion of p53 is achieved by genetically
engineering two loxP sites flanking the mouse Trp53 gene at its endogenous locus. The
mice are then cross-bred with the LSL-KrasG12D containing mice to generate mice that
will activate KrasG12D and delete p53 by introduction of viral Cre recombinase at the
same time. This model has several advantages over the LSL-KrasG12D alone mice,
including rapid tumor progression, access to large tumors for further tissue processing,
short survival of mice for faster experiments, and a metastatic potential to study
metastases into the liver and kidneys (65).
To add an additional means of efficient scientific study, the mouse field
generated a triple conditional mouse by adding a yellow fluorescent protein (YFP)
reporter allele (Rosa26LSL-YFP). In the triple conditional mouse, the introduction of viral
Cre recombinase will express KrasG12D, delete p53 and express YFP in the same cell
at the same time. Therefore, with the addition of the YFP reporter, the cells infected with
viral Cre recombinase are marked and can be followed using immunofluorescence and
immunohistochemistry techniques. Although the YFP mark does not prove that the cells
are expressing KrasG12D and have p53 deleted, it allows for recognition of all the
infected cells, allowing quantification of the viral efficacy. The efficiency of Cre
recombinase to recombine DNA has been well-studied and established. Therefore, it can
be fairly assumed that in all the infected cells marked with YFP Cre recombinase has
allowed expression of KrasG12D and deletion of p53.
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Administration of Cre Recombinase
Initially, Cre recombinase was administered using the replication-deficient
adenoviruses expressing Cre (Adeno-Cre). There are a few advantages to using
adenoviruses. For example, it is fairly easy to generate a high and reproducible titer.
However, a disadvantage to adenovirus is that it can only be used to introduce Cre.
Recently, lentiviruses are used to administer Cre (Lenti-Cre) because lentiviruses can
integrate into the genome of infected cells. With the ability to integrate into the genome,
lentiviruses can be used to further modify tumors with stable expression of cDNAs to
overexpress, or short-hairpin RNAs to silence, genes of interest (66).
In order to recapitulate lung adenocarcinoma, Lenti-Cre has to be administered
directly to the lung so that Cre recombinase can allow expression of KrasG12D and
deletion of p53 specifically in lung cells. To deliver Lenti-Cre to the lung, a method called
intratracheal intubation (IT) is used. The advantages of IT are that the viral
administration is directly into the lung with reproducibility of delivery to ensure
consistency in number of tumors between experiments. However, the disadvantages of
IT include the requirement of specialized equipment and significant technical training. If
IT is performed incorrectly, the trachea of the mouse can be ruptured, the mouse can die
from asphyxiation, pleural effusion and/or the virus can be delivered down the
esophagus to the incorrect location (65).
IT is performed under anesthetized mice between ages 6-12 weeks. After
anesthetization, the mouse is propped up to open the mouth and the tongue is displaced
to the side. A light shined under the throat of the mouse is used to identify the trachea,
which is situated above the esophagus. A catheter is inserted into the trachea and the
virus composed in phosphate-buffered saline solution in injected into the catheter. The
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mouse then inhales the solution into the lungs. The mice are allowed to recover from the
anesthesia and kept in an appropriate environment for 12-16 weeks to allow tumor
initiation and progression. To isolate the tumors, after 12-16 weeks, the mice are
euthanized and the whole lungs are isolated for analysis.
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Abstract
Inappropriate activation of the receptor tyrosine kinase EGFR contributes to a
variety of human malignancies. Here we show a mechanism to induce vulnerability to an
existing first line treatment for EGFR driven cancers. We find that inhibiting the
palmitoyltransferase DHHC20 creates a dependence on EGFR signaling for cancer cell
survival. The loss of palmitoylation increases sustained EGFR signal activation and
sensitizes cells to EGFR tyrosine kinase inhibition. Our work shows that the reversible
modification of EGFR with palmitate “pins” the unstructured C-terminal tail to the plasma
membrane; impeding EGFR activation. We identify by mass spectrometry palmitoylated
cysteine residues within the C-terminal tail where mutation of the cysteine residues to
alanine is sufficient to activate EGFR signaling promoting cell migration and
transformation. Our results reveal that the targeting of a peripheral modulator of EGFR
signaling, DHHC20, causes a loss of signal regulation and susceptibility to EGFR
inhibitor induced-cell death.

Introduction
Receptor tyrosine kinases (RTK) are widely deregulated in cancer and increased
RTK signaling contributes to a variety of human malignancies. Members of the ErbB
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family play critical roles in responding to extracellular cues and initiating downstream
signaling cascades through effector pathways (Lemmon et al., 2014; Roskoski, 2014;
Walton et al., 1990). The epidermal growth factor receptor, EGFR, is one of four
members of the ErbB family and is known to facilitate tumorigenesis and cancer
progression. EGFR is structurally comprised of an extracellular ligand binding domain, a
transmembrane region, a tyrosine kinase domain, and an unstructured C-terminal tail
that harbors receptor auto-phosphorylation sites (Seshacharyulu et al., 2012). Ligands
including the epidermal growth factor, EGF, bind to the extracellular domain of EGFR
causing a conformational change that facilitates homo- and heterodimerization with
members of the ErbB family (Seshacharyulu et al., 2012). Dimerization induces
activation of the tyrosine kinase activity of the receptor leading to auto-phosphorylation
of C-terminal tyrosines. The phosphorylated tyrosine residues serve as docking sites for
adaptor proteins that link the receptor to downstream signaling pathways including RasRaf-MEK-ERK, PI3K-AKT, Src and JAK-STAT culminating in the regulation of cell
migration, proliferation and survival (Seshacharyulu et al., 2012). Spatial and temporal
control of EGFR signaling is mediated by receptor endocytosis. In response to EGF,
EGFR is trafficked through early and late endosomes in route to lysosomes for signal
termination and receptor degradation, in a process that serves as a well-regulated
mechanism for tempering signaling responses.
Dysregulation and inappropriate activation of EGFR is a common event in cancer
and increased expression and mutations in EGFR that enhance signaling and resistance
to therapy have been identified in breast and lung cancer (Roskoski, 2014). While EGFR
mutations commonly reside within the extracellular (EGFR-vIII) and kinase domains
(L858R, T790M), recent studies identified EGFR mutations within the C-terminal tail
(Pines et al., 2010). Deletion of EGFR exons 25-27 was found in lung cancer and
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glioblastoma multiforme (Cho et al., 2011; Ekstrand et al., 1992; Imielinski et al., 2012).
Ectopic expression of EGFR lacking exons 25 -26 promotes cell transformation and
increases EGFR and AKT activation (Imielinski et al., 2012); however the mechanisms
involved remain unknown.
Palmitoylation is the reversible modification of cysteine residues with a 16-carbon
fatty acid which regulates protein localization, trafficking, stability and protein-protein
interactions (Aicart-Ramos et al., 2011). Palmitoylation is regulated by two classes of
enzymes, the DHHC domain containing protein acyl-transferases (PAT) which mediate
the addition of palmitate to target substrates, and the acyl-protein thioesterases (APT)
which remove palmitate (Conibear and Davis, 2010). Twenty three PATs have been
identified in mammals and alterations in the expression and function of several PATs
have been observed in cancer (Conibear and Davis, 2010; Greaves and Chamberlain,
2011; McCormick et al., 2008).
The role of palmitoylation in cancer has mostly focused on the palmitoylation of
H-Ras and N-Ras which facilitates Ras localization to the plasma membrane and is
required for activity (Swarthout et al., 2005). Analysis of The Cancer Genome Atlas
(TCGA) reveals that alterations in DHHC20 expression including deletions,
amplifications and mutations occur in cancers of the breast, lung and prostate. We
found that the C-terminal tail of EGFR is palmitoylated by DHHC20. Inhibiting DHHC20
increases EGFR activation and increases the dependency on EGFR signaling for cell
survival. We identify cysteine residues 1025, 1034 and 1122 as palmitoylation sites
within the C-terminal tail. Mutation of 1025 or 1122 to alanine attenuates EGFR
palmitoylation, activates EGFR signaling and increases cell migration and anchorage
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independent growth. Finally, our results reveal a mechanism for EGFR activation caused
by mutations in the C-terminal tail of EGFR previously identified in lung cancer.

Results
Silencing DHHC20 increases EGFR mediated cell responses
The palmitoyltransferase DHHC20 is expressed in multiple human breast and
lung cancer cell lines and was found to suppress metastatic behavior in melanoma cells
(Figure S1) (Wang et al., 2015). Analysis of the TCGA database revealed DHHC20
mRNA is elevated in basal and Her2-enriched breast carcinoma compared to luminal A
and B tumors (Figure 1A). In the triple negative breast adenocarcinoma cell line MDAMB-231 DHHC20 is localized to the plasma membrane and punctate structures adjacent
to the nucleus when observed by immunofluorescence (IF) microscopy (Figure 1B). The
levels of DHHC20 staining and the abundance of a specific 32kDa band on an SDS
PAGE gel were decreased by DHHC20 shRNA (Figure 1 B-C). Expression of a shRNA
resistant isoform of DHHC20 showed a consistent staining pattern by IF and the same
molecular weight band that was reduced by shRNA, confirming this is the correct size
and localization of DHHC20 protein (Figure 1 B-C). Inhibition of DHHC20 induced a
change in cell morphology from an elongated spindle shape to a more spread
morphology with extensive membrane ruffling in MDA-MB-231 cells (Figure 1D). The
change in morphology correlated with a 3-fold increase in chemotaxis towards media
containing 10% FBS that was suppressed by stable expression of shRNA resistant
DHHC20 (Figure 1E). MDA-MB-231 cells have been shown to express high levels of
EGFR which signals to downstream pathways important in cell migration (Price et al.,
1999). We therefore asked if EGFR inhibition was sufficient to block the increase in
chemotaxis. Treatment with the EGFR inhibitor Gefitinib significantly reduced
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chemotaxis in cells expressing DHHC20 shRNA (shDHHC20) by approximately 50%,
but had a minimal effect on the chemotaxis of control shRNA cells (Figure 1F).
The relatively short exposure to Gefitininb that inhibited cell migration did not
affect cell viability in the MDA-MB-231 cells that are normally insensitive to Gefitinib
(Figure S2). We next asked if silencing DHHC20 increased the cytotoxic effects of
Gefitinib at longer time points. Treating MDA-MB-231 cells with
Gefitinib for 72 hours increased cell death in DHHC20 shRNA cells (22.1%)
compared to control shRNA cells (6.9%) (Figure 1G). Similar results were observed
using SW1573 lung adenocarcinoma cells (Figure 1G, Figure S3). The small molecule
2-bromo-palmitate (2BP) inhibits palmitoyltransferases (Figure S4) (Jennings et al.,
2009). We therefore asked if 2BP produced an effect on Gefitinib sensitivity similar to
silencing DHHC20. Treatment of MDA-MB-231 cells with 500nM 2BP resulted in 4.9%
cell death after 72 hours. When treated in combination with 10µM Gefitinib the
percentage of cell death increased (26.2%) compared to Gefitinib alone (13.3%) (Figure
1H). Increasing the concentration of 2BP to 5µM in combination with Gefitinib elevated
the percentage of dead cells (48.9%) compared to 5µM 2BP alone (10.9%) (Figure 1H).
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Figure 1. Silencing DHHC20 increases EGFR-dependent cell migration and enhances Gefitinibinduced cytotoxicity. (A) DHHC20 mRNA expression is altered in human breast cancer subtypes.
The TCGA database was used to analyze global patterns of ZDHHC20 expression in human breast
invasive carcinoma; Basal-like (n=98), HER2-enriched (n=58), Luminal A (n=230), Luminal B (n=125)
and Normal-like (n=8). (B-C) DHHC20 expression is silenced with shRNA. MDA-MB-231 shControl,
shDHHC20 and shDHHC20+DHHC20 stable cell lines were generated by lentiviral infection. (B)
Immunofluorescence staining of DHHC20 (green) and DAPI (blue) show expression of DHHC20 at the
plasma membrane (arrow) and perinuclear region. (C) Immunoblotting with a DHHC20 specific
antibody shows inhibition of the DHHC20 band (arrow). (D) Silencing DHHC20 in MDA-MB-231 cells
induces cell spreading with increased membrane ruffling. (E) Knockdown of DHHC20 increases
chemotaxis towards DMEM + 10% FBS which is rescued by expression of shRNA resistant DHHC20
(mean +/-StDev). (F) EGFR signaling is required for the increased chemotaxis of shDHHC20 cells.
Migration of MDA-MB-231 shControl and shDHHC20 cells in the presence of DMSO or 10µM Gefitinib
was determined using a transwell chemotaxis assay (mean +/-StDev). (G) Gefitinib increases
cytotoxicity in DHHC20 silenced cells. MDA-MB-231 (gray bars) and SW1573 (black bars) cells were
treated with DMSO or 10µM Gefitinib and cell viability was measured by Trypan Blue (mean +/-StDev).
(H) Blocking palmitoylation with 2BP increases Gefitinib induced cytotoxicity. MDA-MB-231 cells were
treated with 10µM Gefitinib alone or in combination with 500nM or 5µM 2BP and cell viability was
measured by Trypan Blue (mean +/-StDev
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Inhibition of DHHC20-mediated palmitoylation increases EGF-induced EGFR
activation
The increased sensitivity to Gefitinib shown by silencing DHHC20 suggests that
decreased DHHC20 expression increases the dependence of cells on EGFR signaling.
Under resting conditions the activation state of EGFR in shDHHC20 cells measured by
phosphorylation of EGFR (tyrosines1068, 1148 and 1173) and the downstream signaling
component AKT (serine 473) was similar to control cells (Figure 2A). However, upon
EGF stimulation silencing DHHC20 dramatically increased the amplitude and duration of
EGFR activation (Figure 2A). Furthermore, the level of phosphorylated AKT in
shDHHC20 cells was elevated and sustained through the four hour time course of EGF
treatment compared to shControl cells (Figure 2A). In contrast to AKT phosphorylation
the levels of phosphorylated ERK were higher in resting DHHC20 shRNA expressing
cells relative to the shControl cells and did not increase further with EGF stimulation
(Figure 2A). These results are rescued by expression of shRNA resistant DHHC20
(Figure S5A). Similar results were observed in SW1573 lung adenocarcinoma cells
(Figure S5B).
We next asked if inhibition of DHHC20 increased the sensitivity to EGF
stimulation compared to control cells. Cells were treated with varying concentrations of
EGF and phosphorylation of EGFR and AKT was measured. While phosphorylated
EGFR was detected in shControl cells at EGF concentrations as low as 10ng/ml, EGFR
was activated in shDHHC20 cells at 5ng/ml of EGF (Figure S6). Although the level of
EGFR was elevated by 2-fold in the DHHC20 shRNA cells the ratio of phosphorylated
EGFR/total EGFR was increased by nearly 6-fold indicating a higher level of receptor
activation (Figure S6). The elevated level of EGFR activation in shDHHC20 cells
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suggested higher doses of Gefitinib might be required to inhibit EGFR signaling.
Although the shDHHC20 cells had a much higher amount of activated EGFR, treatment
with 0.1µM Gefitinib reduced EGFR and AKT phosphorylation to the same level in both
the control and the DHHC20 shRNA expressing cells (Figure 2B). The increase in cell
death with Gefitinib treatment in shDHHC20 cells may be the result of the greater overall
decrease in EGFR signaling. Unexpectedly, ERK phosphorylation was not inhibited by
Gefitinib suggesting ERK is activated through an alternative signaling pathway.
However, inhibition of EGFR expression by shRNA reduced ERK activation in DHHC20
silenced cells demonstrating it is dependent on EGFR (Figure 2C).
We next asked if acute inhibition of palmitoylation with 2BP increases EGFR
activation and downstream signaling. After 1 hour AKT activation rapidly increased in
cells treated with 500nM 2BP which returned to basal levels by 12 hours (Figure 2D). In
contrast, ERK activation in response to 2BP was induced later, at 6 hours, and was
maintained throughout the 24 hour time course (Figure 2D). In the presence of EGF,
treatment with 2BP increased the phosphorylation of EGFR compared to vehicle control
(Figure 2E).
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Figure 2. DHHC20 knockdown increases EGFR activation and signaling. (A) Silencing
DHHC20 in MDA-MB-231 cells increases EGFR expression and the phosphoryation of EGFR
and AKT. Serum starved MDA-MB-231 shControl and shDHHC20 cells were treated with
100ng/ml EGF for the indicated time points and protein expression was determined by SDSPAGE. (B) Gefitinib inhibits activation of EGFR and AKT. MDA-MB-231 cells were serum starved
in the presence of 10µM gefitinib, treated with EGF for 15 minutes and activation of EGFR, AKT,
and ERK was determined by SDS-PAGE. (C) The increased phosphorylation of ERK observed in
DHHC20 silenced cells is dependent on EGFR signaling. MDA-MB-231 shControl and
shDHHC20 cells were infected with shRNA targeting EGFR. Cells were serum starved and
activation of ERK and AKT was analyzed by SDS-PAGE. (D) 2BP increases AKT and ERK
activation. MDA-MB-231 cells were treated with 500nM 2BP and the activation of AKT and ERK
was analyzed by SDS-PAGE. (E) 2BP increases EGF-induced EGFR activation. MDA-MB-231
cells were serum starved, treated with 500nM 2BP for 3 hours and then stimulated with EGF
for15 minutes. Activation of EGFR, AKT, and ERK was analyzed by SDS-PAGE.
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Inhibition of DHHC20 expression disrupts EGFR endocytic trafficking
Ubiquitylation of EGFR serves as an endosomal trafficking signal to facilitate
lysosomal degradation (Katzmann et al., 2002). Cells expressing shDHHC20 had higher
levels of ubiquitylated EGFR compared to shControl cells (Figure 3A). IF staining was
used to examine the effect of DHHC20 expression on the endocytic trafficking of EGFR.
In resting cells EGFR is predominantly localized at the plasma membrane in both
shControl and shDHHC20 cells (data not shown). Upon EGF stimulation of shControl
cells EGFR was internalized and clustered around the perinuclear region of the cell
containing the lysosomal membrane protein LAMP-1 (Figure 3B). In contrast, in
shDHHC20 cells the internalized vesicles maintained a peripheral distribution and failed
to localize with LAMP-1 positive vesicles after 15 minutes of EGF stimulation (Figure
3B). Expression of shRNA resistant DHHC20 partially restored the wild type perinuclear
localization and lysosomal targeting of EGFR in response to EGF (Figure 3B). In
shDHHC20 cells, EGFR containing vesicles localized to the cell periphery and lacked
markers of early (EEA1, Rab5) or late (Rab7) endosomes within 15 minutes of EGF
stimulation (Figure S7A-F). Additionally, EGFR localization did not overlap with the
recycling endosome marker Rab11 indicating that the aberrant EGFR trafficking was not
the result of increased receptor recycling (Figure S7G). Live imaging of fluorescently
tagged EGF indicates EGF is internalized in DHHC20 cells similar to control cells. After
internalization, the localization of the EGF containing endosomes in the DHHC20 shRNA
expressing cells is static at the periphery of the cell (Figure 3C). This is in contrast to
control cells where EGF is rapidly trafficked to lysosomes (Figure 3C). To determine if
the altered trafficking is specific to EGFR, cells were labelled with fluorescently tagged
transferrin. We found that unlike EGF the trafficking of the endocytosed transferrin is
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similar between DHHC20 silenced cells and control cells and the accumulation of
enlarged endosomes that formed with EGF did not form with transferrin (Figure S8).
After internalization EGFR is thought to continue to signal until the receptor is
sequestered into multivesicular bodies (MVB). Endosome specific signaling to ERK and
AKT has been demonstrated for EGFR following the endosomal recruitment of scaffold
proteins such as Grb2 (Murphy et al., 2009). We asked if the increased amount of EGFR
in the endosomal pool actively signals in shDHHC20 cells by examining endogenous
Grb2 localization by IF. After 15 minutes of EGF treatment the EGF containing
endosomes in the DHHC20 silenced cells localized with very high levels of Grb2
compared to control cells that contained low levels of endosomally localized Grb2
(Figure 3D). These findings suggest that the accumulation of endosomal EGFR likely
contributes to the sustained signaling responses observed in shDHHC20 expressing
cells.
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Figure 3. Silencing DHHC20 expression disrupts EGFR endocytic trafficking.
(A) Ubiquitination of EGFR is increased in shDHHC20 cells in response to EGF. Serum starved
MDA-MB-231 cells were treated with 100ng/ml EGF and EGFR was immunoprecipitated using
anti-EGFR (sc-120). Ubiquitylation was determined by SDS-PAGE. (B) Silencing DHHC20
decreases EGF-induced EGFR trafficking to LAMP-1 positive lysosomes, which is rescued by
exogenous
expression
of
DHHC20.
MDA-MB-231
shControl,
shDHHC20
and
shDHHC20+DHHC20 cells were treated with EGF for 15 minutes and stained for EGFR (green),
LAMP-1 (red) and DAPI (blue). Confocal images were obtained and colocalization of EGFR and
LAMP-1 was measured by Mander’s Overlap Coefficient; shControl (0.403), shDHHC20 (0.242),
shDHHC20+DHHC20 (0.395). (C) Live cell trafficking of EGF to lysosomes is disrupted in
shDHHC20 cells. MDA-MB-231 shControl and shDHHC20 cells were incubated with 50nM
lysotracker (red) and 25µg/ml Alexa-fluor488 labeled EGF (green) and images were obtained
every 10 seconds for 20 minutes. (D) Silencing DHHC20 increases Grb2 localization to EGFpositive endosomes. MDA-MB-231 shControl and shDHHC20 cells were incubated with Alexafluor488 labeled EGF (green), fixed and stained for Grb2 (red) and DAPI (blue). Confocal images
were obtained and colocalization between EGFR and LAMP-1 was measured by Mander’s
Overlap Coefficient; shControl (0.627), shDHHC20 (0.723).
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DHHC20 palmitoylates EGFR within the C-terminal tail
Since EGFR was recently reported to be palmitoylated, we asked if EGFR is the
target of DHHC20 (Bollu et al., 2015). To detect palmitoylated EGFR we performed an in
vitro acyl-biotinyl exchange (ABE) assay on MDA-MB-231 cells. The ABE assay
removes palmitate from cysteine residues with hydroxylamine followed by substitution
with biotin. In the presence of hydroxylamine, EGFR was detected in the streptavidin
pull-down fraction compared to the negative control without hydroxylamine indicating the
presence of palmitoylated EGFR (Figure 4A). Treatment with 2BP effectively inhibited
EGFR palmitoylation (Figure 4B). Palmitoylation of EGFR in MDA-MB-231 cells was also
observed by metabolically labelling cells with palmitic acid azide as a second approach
to confirm EGFR palmitoylation (Figure 4C). Silencing DHHC20 reduced EGFR
palmitoylation indicating that DHHC20 is required for wild type levels of EGFR
palmitoylation (Figure 4C). Overexpression of DHHC20 was sufficient to increase EGFR
palmitoylation in HEK293T cells expressing wild type (WT) EGFR compared to vector
control cells (Figure 4D). Consistent with palmitoylation inhibiting EGFR signaling, when
protein depalmitoylation is blocked with the small molecule Palmostatin B EGFR
palmitoylation is increased and EGFR and AKT phosphorylation is inhibited (Figure S9A,
B).
EGFR contains nine cysteine residues within the intracellular domain, six of
which are located within the tyrosine kinase domain and three within the C-terminal tail
(Figure 4F). An EGFR truncation mutation which deletes amino acids 1024-1186
including the three cysteine residues within the C-terminal tail completely abolished
EGFR palmitoylation in HEK293T cells ectopically expressing DHHC20, indicating that
the palmitoylated cysteine residues are located within the C-terminal tail (Figure 4D).
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To identify the specific palmitoylated residues by mass spectrometry (MS) the
palmitoylated peptides were purified by ABE followed by alkylation with iodoacetamide
(Figure 4E). When analyzed by MS the intracellular palmitoylated cysteine residues were
detected as carbamidomethyl (CAM) modified and the unmodified cysteine residues in
the cytosolic domains that were blocked with NEM were detected as NEM modified
based on the mass difference between NEM and CAM (Figure 4E, F). Cysteine residues
C915, C926 in the kinase domain were detected only as NEM modified indicating the
absence of the palmitoyl modification (Figure 4F, G). However, peptide ions were
identified with both NEM and CAM modifications for both C1025 and C1034 in the Cterminal tail (Figure 4H-L, data not shown). This indicates both C1025 and C1034 sites
exist in both palmitoylated and unpalmitoylated states in the cell. The large size of the
tryptic peptide containing cysteine residue C1122 prevented the identification of the
peptide by MS.
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Figure 4. DHHC20 palmitoylates EGFR within the C-terminal tail. (A) EGFR is palmitoylated.
EGFR palmitoylation in MDA-MB-231 cells was determined using an acyl-biotinyl exchange
(ABE) assay followed by immunoblotting for EGFR. (B) The palmitoyltransferase inhibitor 2BP
reduces EGFR palmitoylation. MDA-MB-231 cells were treated with 2BP for 24 hours and EGFR
palmitoylation was determined by ABE. (C) Silencing DHHC20 decreases EGFR palmitoylation in
MDA-MB-231 cells. Palmitoylation of endogenous EGFR was determined by metabolic labeling.
(D) DHHC20 palmitoylates the C-terminal tail of EGFR. HEK293T cells transiently expressing full
length EGFR (WT) or a C-terminal tail truncation mutant (Trunc) and either empty vector control
(EV) or DHHC20. Palmitoylation of EGFR was determined by metabolic labelling. (E)
Experimental strategy for detecting EGFR palmitoylation by mass spectrometry. (F) Schematic of
EGFR including the exons and cysteine residues located within the C-terminal tail and kinase
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domain. Numbering corresponds to human EGFR excluding the signal sequence. Cysteines 751,
757, 773 and 794 located in the kinase domain are not shown. (G) Selected ion chromatograms
of the [M+2H]2+ peptide (CWMIDADSRPK) with both potential carbamidomethylation (CAM, +57
Da) and N-Ethylmaleimide (NEM, +125 Da) modifications of cysteine 926. As can be seen in the
chromatograms, only a peak for the CWMIDADSRPK (+NEM) peptide was found, and no peaks
for CWMIDADSRPK (+CAM) were observed. (H) Selected ion chromatograms of the [M+2H]2+
peptide (NGLQSCPIKEDSFLQR) with both potential carbamidomethylation (CAM, +57 Da) and
N-Ethylmaleimide (NEM, +125 Da) modifications of cysteine 1034. As can be seen in the
chromatograms, both peaks for NGLQSCPIKEDSFLQR (+NEM) and NGLQSCPIKEDSFLQR
(+CAM) were observed (~ 10 min retention time shift between the species). (I) Full mass
spectrum of the parent ion corresponding to the NGLQSCPIKEDSFLQR (+CAM), and accurate
mass confirms the correct assignment. (J) Full mass spectrum of the parent ion corresponding to
the NGLQSCPIKEDSFLQR (+NEM), and accurate mass confirms the correct assignment. (K)
MS/MS spectrum of the [M+2H]2+ peptide NGLQSCPIKEDSFLQR (+CAM), with highlighted
fragment ion indicating the CAM modification on the Cys residue 1034. (L) MS/MS spectrum of
the [M+2H]2+ peptide NGLQSCPIKEDSFLQR (+NEM), with highlighted fragment ion indicating
the NEM modification on the cysteine residue 1034.
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Mutation of palmitoylated cysteine residues increases EGFR interaction with Grb2
To determine the molecular mechanism by which EGFR palmitoylation regulates
its signaling activity cysteine residues 1025, 1034 and 1122 were mutated to alanine
either alone or in combination. When expressed in MDA-MB-231 cells the C1025A,
C1122A and double cysteine mutants correctly localized to the cell membrane and were
indistinguishable from WT EGFR (Figure 5A). In contrast to the other mutants the
C1034A mutation could be detected by indirect IF microscopy in only a small number of
rounded cells that contained very high levels of phosphorylated ERK compared to cells
expressing wild type EGFR (Figure 5B). The morphology and high levels of
phosphorylated ERK in the C1034A expressing cells could indicate either a block in
mitosis or induction of cell death. As a result, the C1034A mutant could not be detected
by immunoblotting and we were therefore unable to examine this mutation in
palmitoylation and signaling assays. In all the subsequent experiments we discuss the
C1025 and C1122 sites with the knowledge that C1034 is possibly if not likely
palmitoylated. Mutation of either C1025 or C1122 markedly reduced EGFR
palmitoylation compared to the wild type receptor in HEK293T cells, but mutation of both
cysteine residues was not sufficient to completely eliminate palmitoylation indicating
these residues are at minimum required for wild type EGFR palmitoylation levels (Figure
5C). This raised the question of whether there are mutations in cancer that delete any of
the inhibitory cysteine residues that would indicate a biological function for EGFR
palmitoylation.
A mutation identified in lung cancer that deletes exons 25-26 increases EGFR
phosphorylation, downstream signaling to AKT, and anchorage independent growth
(Figure 5D) (Imielinski et al., 2012). Since this mutation removes cysteine1025, we
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asked if mutating this residue is sufficient to increase anchorage independent growth.
When NIH 3T3 cells expressing WT or the EGFR cysteine mutants were grown in soft
agar the exon 25-26 deletion increased the number of colonies by 2.4 fold compared to
cells expressing WT EGFR (Figure 5D, Figure S10). The C1025 and C1025/C1122
mutants significantly increased colony formation compared to WT EGFR by 1.7 and 1.9
fold respectively (Figure 5D). The C1122 single mutant did not have a significant effect
on colony formation. Furthermore cells expressing EGFR C1025A or C1025A/C1122A
migrate significantly faster than cells expressing WT EGFR (Figure 5E). We conclude
that the loss of palmitoylation at these cysteine residues is important for the increased
migration observed with DHHC20 shRNA and the cell transformation previously
described for the exon 25-26 deletion seen in lung cancer patients. However, the sites
are not equivalent in promoting EGFR mediated cell behavior since C1025A has a
stronger effect on colony formation and migration than C1122A.
To determine if the accumulation of EGFR and the high endosomal localization of
Grb2 observed in DHHC20 silenced cells was caused specifically by decreased EGFR
palmitoylation the EGFR C1025/1122A mutant was examined in NIH 3T3 cells. Similar
to what was observed in shDHHC20 cells the C1025/1122A mutant receptor
accumulated in peripherally localized endosomes that did not colocalize with LAMP-1
(Figure 5F). Furthermore, there was an increase in Grb2 staining in cells expressing
C1025/1122A compared to cells expressing the WT receptor (Figure 5G).
To study the mechanism of receptor activation in greater detail we examined
activation mediated Grb2 binding to the EGFR mutants. Immunoprecipitation of WT and
mutant EGFR revealed an increase in the interaction of the C1025A mutant with Grb2
compared to WT EGFR (Figure 5H-I). However, EGFR C1122A and C1025A/C1122A
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did not increase the interaction with Grb2 indicating that palmitoylation of C1025 is
unique in its ability to attenuate Grb2 binding. Grb2 binding with the exon 25-26 deletion
mutant was higher compared to WT EGFR and is strikingly similar to what was observed
with the C1025A mutant, providing further evidence that the pathway activation caused
by the exon 25-26 deletion is through decreased palmitoylation at C1025 (Figure 5H-I).
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Figure 5. Mutation in C1025 and C1122 activates EGFR, promotes cellular transformation and
increases cell migration. (A) Mutation of cysteines 1025 and 1122 does not alter receptor
localization. MDA-MB-231 cells were transfected with the indicated EGFR constructs, fixed and
stained for FLAG-tagged EGFR (red). (B) Expression of EGFR-C1034A in MDA-MB-231 cells
increases ERK phosphorylation. Cells were fixed and stained for pERK (green), FLAG-EGFR (red) and
DAPI (blue). (C) Mutation of EGFR cysteine residues 1025, 1122 and 1025/1122 decreases EGFR
palmitoylation. HEK293T cells were transfected with DHHC20 and the indicated EGFR constructs.
Palmitoylation of EGFR cysteine mutants was determined by ABE. (D) Mutation of EGFR C1025,
C1025/C1122 and deletion of exons 25-26 deletion increases colony formation in soft agar. NIH 3T3
cells expressing EGFR constructs were plated in soft agar and colonies were counted at 8 weeks.
Expression levels of each mutant are shown in Figure S10 (mean +/- StDev). (E) Mutation of EGFR
C1025 and C1025/C1122 increases cell migration. NIH 3T3 cells expressing EGFR constructs were
scratched and migration was measured at 8 hours (mean +/- SEM). (F-G) Mutation of EGFR
C1025/C1122 delays EGFR endocytosis and increases the localization of Grb2 to EGF-positive
endosomes. NIH 3T3 cells expressing doxycycline inducible EGFR constructs were serum starved in
the presence of 1µg/ml doxycycline, treated with EGF-alexafluor488 for 15 min, fixed, and stained for
LAMP-1 (F) or Grb2 (G). (H) Mutation of EGFR C1025 increases the interaction between Grb2 and
EGFR. HEK293T cells were transfected with EGFR constructs and EGFR was immunoprecipitated
with anti-EGFR (sc-120 AF488). The binding of EGFR to Grb2 was determined by SDS-PAGE.

60

EGFR palmitoylation promotes the turnover of activated EGFR and association of
the C-terminal tail with the plasma membrane.
We examined the activation of the palmitoylation defective EGFR mutants to
further understand the mechanism by which palmitoylation suppresses EGFR activation.
We first asked if the cysteine point mutations phenocopy the increase in EGFR
activation observed with DHHC20 shRNA. When transiently expressed in NIH 3T3 cells
EGFR mutants C1025A, C1122A and C1025A/C1122A increased the basal
phosphorylation of EGFR at Tyr1068, Tyr1148, and Tyr1173 and phosphorylation of
AKT compared to the WT receptor under serum starved conditions (Figure 6A). When
cells expressing mutant EGFR were treated with 10µM Gefitinib the activation of AKT
was inhibited, but ERK activation was unaffected (Figure S11). Taken together, the high
basal EGFR tyrosine phosphorylation observed in the EGFR mutants in conjunction with
Grb2 binding being specific to the C1025 mutant indicates that tyrosine phosphorylation
is not sufficient to promote Grb2 binding.
To determine how palmitoylation of EGFR is regulated we examined the levels of
palmitoylated and dually palmitoylated/phosphorylated EGFR in response to EGF
stimulation. Palmitoylated WT EGFR is detected in resting cells and increases modestly
after 5 minutes of EGF stimulation, returning to basal levels by 60 minutes (Figure 6B).
To determine the contribution of the individual palmitoylation sites the level of
palmitoylated EGFR during EGF stimulation was examined in the EGFR cysteine point
mutants. In the C1025A mutant palmitoylated C1122 peaked at 5 minutes post-EGF
treatment and subsequently decreased below basal levels at 15 minutes and returned to
basal levels at 60 minutes (Figure 6B). Unlike C1122, palmitoylation of C1025 in the
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C1122A mutant is below detection in resting cells. After 5 minutes of EGF stimulation
C1025 palmitoylation increased and then steadily decreased by 60 minutes (Figure 6B).
We next examined the phosphorylation kinetics of palmitoylated EGFR in
response to EGF and found that palmitoylated EGFR is also phosphorylated at tyrosine
1068. However, in contrast to the total level of phosphorylated WT EGFR (input) which is
does not decrease until 60 minutes, phosphorylation of palmitoylated WT EGFR rapidly
decreased between 5 and 15 minutes (Figure 6C). This suggests the dually
phosphorylated and palmitoylated receptor fraction is more rapidly turned over than the
phosphorylated unpalmitoylated receptor fraction. In the C1025A mutant palmitoylation
is restricted to C1122 and phosphorylation of the palmitoylated receptor peaked at 5
minutes of EGF stimulation, but then decreased down to basal levels by 15 minutes
(Figure 6C). In the C1122A mutant the receptor is palmitoylated at C1025 and is only
weakly phosphorylated consistent with the palmitoylation of C1025 suppressing EGFR
activation. Furthermore, in the C1122A mutant the total receptor phosphorylation (input)
is sustained and does not decrease by 60 minutes (Figure 6C). This indicates C1122
palmitoylation promotes receptor turnover. While we can’t address the function of
cysteine 1034 these results indicate that C1025 and C1122 are palmitoylated in
response to EGF with each site having a unique effect on receptor function.
The C-terminal tail is not included in current crystal structures of EGFR and
therefore little is known about how it is positioned relative to the kinase domain. Although
EGFR is membrane associated, the C-terminal tail is unstructured and thought to extend
away from the plasma membrane and into the cytosol. We reasoned that palmitoylation
could promote peripheral association of the C-terminal tail with the plasma membrane by
burying palmitate in the lipid bilayer. To test this possibility a recognition sequence for
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the protease thrombin was inserted in frame between the kinase domain and the Cterminal domain to allow the C-terminal tail to be cleaved from the plasma membrane.
Cell lysates were treated either with or without thrombin and the membrane fraction was
isolated by centrifugation and analyzed by SDS PAGE. If the C-terminal tail associates
with the plasma membrane after proteolytic cleavage then it will be detected by
immunoblotting in the membrane fraction with an antibody specific to the C-terminus of
EGFR (Figure 6D). Only after thrombin treatment is the 25kDa C-terminal tail detected in
the membrane fraction (Figure 6E). The membrane association of the cleaved Cterminal tail is dependent on palmitoylation as inhibition of DHHC20 by shRNA markedly
reduces the 25kDa fragment in the membrane fraction (Figure 6E).
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Figure 6. Palmitoylation regulates the activity of EGFR in response to EGF. (A) Mutation of
EGFR cysteines activates EGFR independent of EGF. NIH 3T3 cells were transfected with EGFR
constructs, serum starved, and stimulated with 25µg/ml EGF for 5 minutes where indicated.
Activation of EGFR, AKT and ERK was determined by SDS-PAGE. (B) EGFR palmitoylation is
increased with EGF stimulation. MDA-MB-231 cells were serum starved, treated with 100ng/ml
EGF and palmitoylation was determined by ABE. (C) Palmitoylation of the phosphorylated form of
EGFR is reduced in EGFR cysteine mutants C1025A and C1122A. MDA-MB-231 cells stably
expressing doxycycline inducible EGFR constructs were serum starved in the presence of 1µg/ml
doxycycline, treated with 100ng/ml EGF, and palmitoylation was determined by ABE. (D)
Experimental strategy of the thrombin cleavage assay. (E) Palmitoylation pins the C-terminal tail
of EGFR to the cell membrane. HEK293T cells transiently expressing EGFR-FLAG containing a
thrombin cleavage site (LVPRGS) at Gly959 were lysed in the presence or absence of thrombin
protease. The membrane fraction was isolated by centrifugation and EGFR was
immunoprecipitated from the membrane fraction. The presence of membrane bound full length
(170kDa) EGFR and the cleaved C-terminal tail (25kDa) was determined by SDS-PAGE.
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Discussion
We have identified a mechanism to regulate EGFR activation through
palmitoylation of the C-terminal tail of EGFR. We show that EGF induces palmitoylation
of EGFR and that palmitoylation facilitates receptor inactivation through two distinct
mechanisms. Mutation of cysteines 1025 and 1122 alone and in combination increase
the basal phosphorylation of EGFR, ERK, and AKT. However, only mutation of C1025
increases the binding of EGFR with the adapter protein Grb2. Furthermore, EGFR that is
palmitoylated on C1025 has very low levels of EGF induced phosphorylation indicating
that palmitoylation at C1025 blocks receptor signaling. Mutation of C1122 sustains
EGFR phosphorylation in response to EGF and both total and phosphorylated EGFR
palmitoylated on C1122 decreases precipitously after 15 minutes of EGF stimulation
consistent with a role for palmitoylation at C1122 in promoting receptor turnover. This is
consistent with the effects of silencing DHHC20 on EGFR function. When DHHC20 is
silenced by shRNA EGFR signaling is increased and sustained, there is increased
localization of Grb2 to EGFR positive endosomes, and there are increased levels of total
EGFR (Figure 7).
Our findings demonstrate that palmitoylation of EGFR C-terminal cysteines
reversibly “pins” the C-terminal tail to the plasma membrane to promote receptor
inactivation. Disrupting the membrane association of the C-terminal tail by inhibiting
palmitoylation may reduce steric hindrance or provide greater accessibility for adaptor
protein binding (Figure 7). Additionally, the interaction between EGFR and endosomal
ESCRT complex may require palmitoylation of the EGFR C-terminal tail to facilitate
endocytic proper trafficking.
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Palmitoylation is required for the endocytic trafficking and downregulation of
EGFR. The delayed endocytic trafficking of EGFR observed in DHHC20 silenced cells
may account for the elevated level of EGFR expression in these cells. The delay in
EGFR endocytosis was recapitulated in the C1025/C1122 mutant supporting that
palmitoylation of the receptor is responsible for the trafficking defect. Our findings
suggest that delayed endocytic trafficking provides a platform for EGFR to signal within
endosomal compartments. In support of this, other studies have shown that activated
receptors accumulate in endosomes and can transmit signals that are distinct from those
at the plasma membrane due to the endosomal localization of certain essential signaling
components (Murphy, PNAS, 2009). Our findings reveal that the endosomal localization
of Grb2 is increased when DHHC20 is silenced and when cysteines 1025 and 1122 are
mutated. Based on our data we argue that the slower rate of endocytic trafficking in
shDHHC20 cells allows for increased receptor signaling on endosomal compartments.
Blocking EGFR palmitoylation genetically by silencing DHHC20 or
pharmacologically by treatment with 2BP sensitizes cells to EGFR TK inhibition. While
silencing DHHC20 or mutating EGFR C-terminal palmitoylated cysteines increases
EGFR activation, Gefitinib effectively reduces receptor phosphorylation to the same level
as control cells. This marked decrease in EGFR signaling may be the mechanism
leading to the increased toxicity of Gefitinib in DHHC20 silenced cells. The clinical
implications of these findings are three-fold. First, the increase in dependency of EGFR
signaling when DHHC20 is inhibited by shRNA raises the possibility that patients with
inactivation of DHHC20 could show increased responsiveness to EGFR inhibitor
therapy. Second, inhibition of DHHC20 with a small molecule could function
therapeutically in combination with EGFR inhibitors. Third, the EGFR exon 25-26
deletion mutation identified in lung cancer increased colony formation in soft agar and
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the interaction between EGFR and Grb2 similar to what was observed with the C1025A
mutant. Therefore, loss of palmitoylation at C1025 may serve as a mechanism for the
increased EGFR activation and transforming properties of the deletion mutant. Taken
together, these data suggest that targeting of a peripheral modulator of EGFR signaling,
DHHC20, in combination with EGFR TK inhibitors may serve as an effective clinical
approach to treat cancers such as TNBC that are inherently resistant to EGFR targeted
therapy.
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Figure 7

C1025

C1122

Palmitoylation
C1025 Decreases Grb2 binding

pY
Palmitate

Grb2
C1122 Increases with EGF stimulation
Promotes receptor turnover

EGF

Figure 7. Mechanistic summary of the effects of palmitoylation on EGFR activation and
signaling. These findings support a model where palmitoylation of the C-terminus of EGFR
promotes membrane association. Palmitoylation of EGFR at C1025 impedes the binding of Grb2
to EGFR whereas palmitoylation at C1122 increases with EGF stimulation and promotes receptor
turnover.
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Figure S1. DHHC20 is expressed in breast cancer and lung cancer cell lines. Cells were
lysed and DHHC20 expression was determined by SDS-PAGE.
Figure S2. Treatment of MDA-MB-231 shControl and shDHHC20 cells with Gefitinib for 18
hours does not induce cell death. MDA-MB-231 cells were treated with 10uM gefitinib for 18
hours and the percent cell death was measured by trypan blue staining.
Figure S3. DHHC20 expression is reduced in SW1573 lung cancer cells by shRNA. SW1573
cells were infected with shDHHC20 shRNA, selected with puromycin, and protein expression was
determined by SDS-PAGE.
Figure S4. 2BP dose dependently reduces palmitoylation. MDA-MB-231 cells were treated
with 0, 0.5 or 5µM 2BP for 24 hours and palmitoylation was determined by ABE and silver stain.
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Figure S5. Elevated EGFR signaling is specific to DHHC20 inhibition and is conserved in
SW1573 cells. (A) Exogenous expression of DHHC20 partially rescues the elevated EGFR
signaling. MDA-MB-231 shControl, shDHHC20 and shDHHC20 cells stably expressing a shRNA
resistant DHHC20 construct were serum starved and treated with 100ng/ml EGF for the indicated
times. EGFR signaling was determined by SDS-PAGE. (B) EGF-induced activation of EGFR,
AKT and ERK is sustained in DHHC20 silenced lung adenocarcinoma cells. SW1573 cells were
starved, treated with 100ng/ml EGF for the indicated time points, and activation of EGFR, AKT
and ERK was determined by SDS-PAGE.
Figure S6. Silencing DHHC20 increases EGFR activation in response to low and high
doses of EGF. MDA-MB-231 shControl and shDHHC20 cells were serum starved, treated with
EGF at doses ranging from 0ng/ml - 100ng/ml for 15 minutes, and activation of EGFR and AKT
was determined by SDS-PAGE. The phosphorylation of EGFR at Y1068 was normalized to total
levels of EGFR by densitometry using ImageJ.
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Figure S7. Silencing DHHC20 decreases EGFR
localization
to
early
and
late
endosome
compartments. (A, C, E) MDA-MB-231 shControl and
shDHHC20 cells were serum starved in DMEM + 0.2%
BSA for 17 hours and treated with 100ng/ml EGF for 0,
15 and 30 minutes. Cells were fixed and stained for
EGFR (green), EEA1, Rab5 or Rab7 (red) and DAPI
(blue). Images were obtained using the Leica AF6000
microscope and the Hamamatsu ORCA R2 digital CCD
camera at 40x magnification. (B, D, F) Quantification of
the percentage of cells with EGFR localized near EEA1,
Rab5 or Rab7 positive vesicles was determined using
Leica LAS software. (G) Silencing DHHC20 does not
enhance EGFR recycling through Rab11 positive
endosomes. MDA-MB-231 shControl and shDHHC20
cells were serum starved for 17 hours in DMEM + 0.2%
BSA and stimulated with 100ng/ml EGF for the indicated
time points. Cells were fixed, stained for EGFR (green),
Rab11 (red) and DAPI (blue) and imaged as in A, C, E.
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Supplemental Figure Legends (Continued)
Figure S8. DHHC20 expression does not affect the intracellular trafficking of the
transferrin. MDA-MB-231 shControl and shDHHC20 cells were plated onto glass-bottom imaging
dishes and starved in DMEM + 0.2% BSA for 17 hours. Cells were treated with 15ng/ml EGF in
combination with 2.5µg/ml alexa-fluor488 labeled transferrin and 50nM lysotracker and incubated
on ice for 1 hour. Cells were washed with PBS and images were obtained every 10 seconds for
20 minutes using the Leica AF6000 microscope and the Hamamatsu ORCA R2 digital CCD
camera at 40x magnification.
Figure S9. Inhibition of EGFR depalmitoylation decreases EGFR signaling. (A) The
depalmitoylation inhibitor palmostatin B increases EGFR palmitoylation. MDA-MB-231 cells were
treated with 1, 10, 100 µM palmostatin B for 15 hours and EGFR palmitoylation was determined
by ABE. (B) Inhibiting depalmitoylation with Palmostatin B attenuates EGFR activation. MDAMB-231 cells were pretreated with the indicated doses of Palmostatin B for 8 hours and serum
starved in the presence of Palmostatin B for an additional 17 hours. Cells were treated with
100ng/ml EGF for 15 min, lysed and protein expression and protein phosphorylation was
determined by immunoblotting.
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Figure S10. Expression of EGFR mutants in NIH 3T3 cells. NIH 3T3 cells were transfected
with EV, EGFR WT or EGFR cysteine mutant constructs and stably selected with puromycin.
Cells were lysed and expression of EGFR was determined by SDS-PAGE.
Figure S11. Gefitinib inhibits the activation of EGFR and AKT in cells expressing EGFR
cysteine mutants. NIH 3T3 cells were transfected with EGFR WT or cysteine mutant constructs
for 30 hours followed by an 18 hour serum starvation in the presence of DMSO or 10µM Gefitinib.
Cells were lysed and activation of EGFR, AKT and ERK was determined by SDS-PAGE.

73

Materials and Methods
Cell culture and transfection
MDA-MB-231, HEK293T, and NIH 3T3 cells were cultured in DMEM containing 10%
FBS. SW1573 cells were maintained in RPMI containing 10% FBS. All transfections
were carried out using TransIT-LT1 (Mirus) according to the manufacturer’s instructions.
Antibodies
Anti-DHHC20 and anti-flag M2 antibodies were purchased from Sigma-Aldrich. AntipY1068-EGFR, pY1148-EGFR, pY1173-EGFR, EGFR, pERK, ERK, pS473-AKT, AKT,
β-actin, EEA1, Rab5, Rab7 and Rab11 were obtained from Cell Signaling Technologies.
Anti-LAMP-1 (CD107a) was purchased from BD Pharmigen. EGFR (528) Alexa Fluor
488 and EGFR (sc-120) were purchased from Santa Cruz Biotechnology. Transferrin
from Human Serum, Alexa Fluor® 488 Conjugate was purchased from ThermoFisher.
Phalloidin-594 and EGFR (528) Alexa Fluor 488 were purchased from Life
Technologies.
Analysis of TCGA data
The level of ZDHHC20 mRNA was plotted against the PAM50.SUBTYPE using the
beeswarm package in the software program “R”. Box plots were created to visualize the
median values and quartiles of each subtype. Statistics were calculated using the
function aov in “R”; (p < 2e-16).
Silencing of human DHHC20 and EGFR
The oligonucleotides for shControl, shDHHC20, and shEGFR constructs were
synthesized (Integrated DNA Technologies) and inserted into the pLKO.1 vector.
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shControl encodes the non-targeting sequence of SHC002 (Sigma), the shRNA target
sequences of human DHHC20 is 5’- GAGCTCTGCGTGTTTACTATT-3’, and the shRNA
sequences of EGFR are 5’ CACAGTGGAGCGAATTCCTTT 3’ (shEGFR 2.4) and 5’
GCTGGATGATAGACGCAGATA 3’ (shEGFR 3.2). MDA-MB-231 cells were transduced
with lentivirus encoding shControl or shDHHC20 and selected by puromycin treatment (1
μg/ml). A shRNA resistant DHHC20 construct was used to rescue expression in
shDHHC20 cells. MDA-MB-231 cells transduced with shEGFR lentivirus were harvested
72 hours post infection.
Soft Agar Colony Formation
5x103 NIH 3T3 cells were suspended in 0.4% agarose and plated onto a 0.8% solidified
agarose layer. Colonies were manually counted from triplicate wells at 4 weeks.
Cell Viability
Cells were treated with Gefitinib (10µM) and/or 2BP (500nM and 5µM) for 72hrs and
viability was measured by Trypan Blue staining. Quantification was done using a 1-way
ANOVA with Tukey’s multiple comparison post-test.
EGFR signaling
MDA-MB-231 and SW1573 cells were serum starved for 17 hours in DMEM+0.2% BSA.
Cells were stimulated with 100ng/ml of EGF and harvested in RIPA buffer containing
150mM NaF , 2mM Na3V04, 1mM PPi, 2μg/ml pepstatin A, 1μg/ml aprotinin and 1μg/ml
leupeptin. Activation of EGFR, ERK and AKT was measured by SDS-PAGE.
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Immunofluorescence microscopy
MDA-MB231 shControl and shDHHC20 cells were serum starved for 17 hours in
DMEM+0.2% BSA, treated with 100ng/ml EGF, and fixed in formalin. Cells were
permeabilized in 0.1% triton-X-100, blocked in 5% BSA and primary antibodies were
added overnight. Where indicated, cells were incubated with 1µg/ml Alexa-fluor488
labeled EGF for 1 hour on ice and transferred to 37°C for 15 minutes before fixing and
adding primary antibodies. Secondary Alexa-Fluor antibodies were used prior to
mounting the coverslips with DAPI-containing mounting media. Cells were visualized on
a Leica SP8 confocal microscope or a Leica AF6000 microscope. Images were obtained
using the Hamamatsu ORCA R2 digital CCD camera at 40x magnification. Quantification
was determined using Perkin Elmer’s Volocity software.
Live cell microscopy
MDA-MB-231 shControl and shDHHC20 cells were serum starved in DMEM + 0.2%
BSA for 17 hours and incubated with 50nM lysotracker (red) for 30 minutes. The
lysotracker was removed and cells were incubated on ice for 30 minutes with 25µg/ml
Alexa-fluor488 labeled EGF (green) or 2.5ug/mL Alexa-fluor488 labeled transferrin and
15ng/mL unlabeled EGF . Cells were washed, incubated in HBSS media (HBSS +
1mg/mL glutamine + 1% FBS + 20mM HEPES, pH 7.4), and images were obtained in a
37°C humidified chamber every 10 seconds for 20 minutes using the Leica AF6000
microscope and the Hamamatsu ORCA R2 digital CCD camera at 40x magnification.
Transwell Migration Assay
MDA-MB231 cells were plated onto the apical chamber of transwell dishes and allowed
to migrate for 17 hours towards DMEM containing 10% FBS. Where indicated, cells
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were pretreated with DMSO or 10µM Gefitinib for 30 minutes before adding the
chemoattractant. Cells were washed in PBS, fixed in methanol and stained with 0.05%
Crystal Violet for 40 minutes. Cells on the apical side of the membrane were removed
with a Q-tip and cells that had migrated to the basolateral chamber were imaged using
the Leica AF6000 microscope. Images were obtained using the Hamamatsu ORCA R2
digital CCD camera at 10x magnification and counted. Quantification was done using a
1-way ANOVA with a Tukey’s multiple comparison post-test.
Scratch Assay
NIH 3T3 cells were plated onto 6-well dishes and scratched at confluence. Images were
taken at 0hrs and 8hrs using the Hamamatsu ORCA R2 digital CCD camera at 4x
magnification. Images of four representative areas of each scratch were captured and 4
measurements were taken per image for a total of 12 measurements per scratch. The
distance migrated was calculated using Leica Microsystems LAS AF software.
Palmitoylation assay with metabolic labelling
MDA-MB-231 shControl and shDHHC20 cells were treated with 100µM palmitic acid
azide in serum free DMEM for 4 hours at 37ºC. Cells were washed in PBS and lysed in
200µl buffer (50mM Tris pH 7.5, 1% SDS, and 1µg/ml leupeptin, 1µg/ml aprotinin,
2µg/ml pepstatin A). Lysates were sonicated and centrifuged at 15,000 RPM for 10
minutes. 50µl of lysate was reacted with biotin alkyne using the Click-IT assay in a 200
µl final reaction volume. Biotinylated proteins were isolated using streptavidin agarose,
washed 5 times in wash buffer (50mM Tris pH 7.5, 0.1%SDS) and palmitoylated EGFR
was analyzed by SDS PAGE.
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Acyl-biotinyl exchange (ABE) assay
The protocol is adapted from Wan et al., 2007. Cells were harvested in lysis buffer
(50mM HEPES pH 7.4, 1% Triton X-100, 150mM NaCl, 5mM EDTA, 50mM N-ethylmaleimide (NEM), 1µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml pepstatin A). Lysates were
clarified by centrifugation at 15,000 RPM for 10 minutes. 1µg of anti-EGFR (sc-120) was
added to 200µl of lysate and incubated overnight on ice. 15µl of protein A sepharose
was added to lysates and incubated for 2 hours at 4ºC. Beads were washed in lysis
buffer without NEM. The beads were eluted in 4%SDS buffer+50mM NEM (50mM
HEPES pH 7.4, 4% SDS, 150mM NaCl, 5mM EDTA). 10µg of acetylated BSA was
added as a carrier to the eluate followed by methanol/chloroform (m/c) precipitation.
The dried pellet was resuspended in 40µl 4%SDS buffer+50mM NEM and incubated at
room temperature for 1 hour. The samples were m/c precipitated twice then
resuspended in 80µl 4%SDS buffer. The samples were split in half and 160µl of
hydroxylamine buffer (0.7M hydroxylamine pH 7.4, 50mM HEPES pH 7.4, 0.2% Triton X100, 150mM NaCl, 5M EDTA) was added to one half of the sample and control 0.2%
Triton X-100 buffer (50mM HEPES pH 7.4, 0.2% Triton X-100, 150mM NaCl, 5mM
EDTA) was added to the remaining sample and incubated at room temperature for
1hour. The samples were m/c precipitated and resuspended in 40µl 4%SDS buffer
containing 10µM Biotin-HPDP. 160µl of 0.2% Triton X-100 buffer +10µM Biotin-HPDP
was added and incubated at RT for 1hour. The samples were m/c precipitated and
resuspended in 20µl of 4%SDS buffer followed by addition of 800µl of 1% Triton X-100
buffer (50µl removed for analysis as “input”). 30µl of streptavidin agarose beads were
added to the samples and incubated overnight at 4ºC rotating. The samples were
washed in 1% Triton-X100 buffer and analyzed by SDS-PAGE.
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EGFR purification for Mass spectrometry
HEK293T cells were transfected with EGFR and DHHC20 and EGFR was
immunoprecipitated by standard methods using anti-EGFR sc-120. The acyl biotin
exchange assay was used to label palmitoylated cysteine residues with 10µM BiotinHPDP. The biotinylated proteins were isolated with streptavidin beads and eluted with
10µM dithiothriotol to break the Biotin-HPDP disulfide linker. The reduced cysteine
residues were blocked with 4mM iodoacetamide and the proteins were digested with
trypsin.
Nano-LC-MS/MS analysis and data analysis
Digestion solution was acidified by 5% formic acid, and peptides were desalted prior to
LC-MS/MS analysis using in-house C18 STAGE tips as previously described [PMID:
12585499]. Peptide samples were loaded onto a 75 µm I.D. x 20 cm fused silica
capillary column packed with Reprosil-Pur C18-AQ resin (3 µm; Dr. Maisch GmbH,
Germany) and resolved by an EASY-nLC 1000 HPLC system (Thermo Scientific)
coupled in-line with a Q-Exactive (Thermo Scientific). The HPLC gradient was 2-30%
solvent B (A = 0.1% formic acid in water; B = 0.1% formic acid in acetonitrile) for 70 min,
followed by 30% to 95% solvent B for 10 min, and then held at 95% solvent B for 10 min,
with a constant flow-rate of 300 nL/min. Full MS spectrum scans (m/z 350-1600) were
performed at a resolution of 70,000 (at 200 m/z), and the 3 most intense ions were
selected for MS/MS performed with high-energy collision dissociation (HCD) with
normalized collision energy of 25 at a resolution of 17,500 (at 200 m/z). Five target
MS/MS (508.7633, 736.3706, 1103.0043, 1104.0523 and 1470.3366) were set in case
they were missed in data-dependent acquisition mode. AGC targets of full MS and
MS/MS scans were 1x106 and 5x104, respectively. Unassigned charge states and
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singly charged species were rejected, dynamic exclusion was set to 30 seconds, and
lock mass calibration was implemented using polysiloxane ions 371.10123 and
445.12000. Mascot was used for database searching. Two trypsin miss-cleavage sites
were allowed, and precursor ion and fragment ion tolerances were set to 10 ppm and
0.02 Da, respectively. Oxidation (+15.9949) on methionine, carbamidomethylation
(+57.0215) and N-ethylmaleimide (125.0477) on cysteine were set as dynamic
modifications. A peptide score of 20 was chosen to filter the peptide identification
matches. Peptide quantification was performed on the extracted ion chromatograms
(XICs) of peptides with all charge states.
Thrombin cleavage assay
HEK293T cells expressing either shControl or shDHHC20 vectors were co-transfected
with DHHC20 and either EGFR Wt or EGFR containing a thrombin cleavage sequence
(LVPRGS) inserted at Gly959. Cells were harvested 48 hours post-transfection in 250µl
of either buffer A (10mM Tris pH 8, 1.5mM MgCl2, 10mM KCl, 100µM Palmostatin B,
150mM NaF, 2mM Na3V04, 1mM PPi, 2μg/ml pepstatin A, 1μg/ml aprotinin and 1μg/ml
leupeptin) or buffer B (10mM Tris pH 8, 1.5mM MgCl2, 10mM KCl, 100µM Palmostatin B
and 50 units of thrombin). Lysates were disrupted 7 times by passing through a 22
gauge needle and centrifuged at 800xg for 10 minutes. The thrombin containing samples
were incubated at room temperature for 1 hour and centrifuged at 45,000 rpm for 30
minutes to isolate the membrane fraction which was then resuspended in RIPA buffer
and incubated with anti-flag beads for 1 hour. The beads were washed with lysis buffer
and the bound protein was eluted by boiling in SDS-loading buffer. Samples were loaded
on an SDS-PAGE gel and membrane bound EGFR was detected using an EGFR
antibody.
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CHAPTER 3: INDUCED SENSITIVITY TO EGFR INHIBITORS IS
MEDIATED BY PALMITOYLATED CYSTEINE 1025 OF EGFR AND
REQUIRES ONCOGENIC KRAS.
Akriti Kharbanda, Kristin Runkle, Wei Wang, Eric S. Witze. Induced sensitivity to EGFR
inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic
Kras. Biochem Biophys Res Commun. 493(1), (2017). Reprinted with the copyright
permission of Elsevier Publishing.

Abstract
Currently, there are no effective therapeutic strategies targeting Kras driven
cancers, and therefore, identifying new targeted therapies and overcoming drug
resistance have become paramount for effective long-term cancer therapy. We have
found that reducing expression of the palmitoyl transferase DHHC20 increases cell
death induced by the EGFR inhibitor gefitinib in Kras and EGFR mutant cell lines, but
not MCF7 cells harboring wildtype Kras. We show that the increased gefitinib sensitivity
in cancer cells induced by DHHC20 inhibition is mediated directly through loss of
palmitoylation on a previously identified cysteine residue in the C-terminal tail of EGFR.
We utilized an EGFR point mutant in which the palmitoylated cysteine 1025 is mutated
to alanine (EGFRC1025A), that results in receptor activation. Expression of the EGFR
mutant alone in NIH3T3 cells does not increase sensitivity to gefitinib-induced cell death.
However, when EGFRC1025A is expressed in cells expressing activated KrasG12V, EGFR
inhibitor induced cell death is increased. Surprisingly, lung cancer cells harboring the
EGFR inhibitor resistant mutation, T790M, become sensitive to EGFR inhibitor treatment
when DHHC20 is inhibited. Finally, the small molecule, 2-bromopalmitate, which has
been shown to inhibit palmitoyl transferases, acts synergistically with gefitinib to induce
cell death in the gefitinib resistant cell line NCI-H1975.
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Introduction
EGFR and other members of the ErbB family of receptor tyrosine kinases (RTKs)
play critical roles in reacting to extracellular growth cues by initiating downstream
signaling cascades through various effector pathways (1-3). Mutations in EGFR, leading
to its constant activation and subsequent uncontrolled cell growth, are detectable in 10%
to 30% of tumors from patients with non–small cell lung cancer (NSCLC)(4). Ligand
(EGF) binding to EGFR induces receptor dimerization and subsequent autophosphorylation of specific tyrosine residues on the C-terminal tail. Activating EGFR
point mutations in exon 21, such as L858R, and deletions of exon 19 are often predictors
of response to EGFR tyrosine kinase inhibitor (TKI) therapy with gefitinib or erlotinib (5).
However, the majority of patients with NSCLCs harboring these activating EGFR
mutations relapse within 10 to 16 months of treatment with EGFR TKIs (5-6). In over half
of these patients, resistance to EGFR TKI therapy is associated with the acquisition of a
secondary T790M mutation in the EGFR TK domain, which alters interaction of
reversible TKIs with the ATP-binding pocket (4,7). It is therefore critical to develop
strategies to overcome drug resistance. We have recently uncovered a previously
unknown regulation of EGFR through EGFR palmitoylation.
Protein palmitoylation is the reversible covalent attachment of a 16-carbon
saturated fatty acid palmitate onto cysteine residues. Addition of the large hydrophobic
palmitate facilitates association of proteins at the plasma membrane (PM) influencing
formation of cell signaling complexes.(8-12) Palmitoylation is mediated by a family of 23
protein acyl-transferases containing a conserved DHHC (aspartic acid, histidine,
histidine, cysteine) motif essential for catalysis (13-15). DHHC20 palmitoylates the
epidermal growth factor receptor (EGFR) on specific cysteine residues on the C-terminal
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tail, suppressing its activation. Unexpectedly, inhibition of DHHC20 in both breast and
lung cancer cells increases induction of cell death in response to the EGFR inhibitor
gefitinib, despite the fact the cells harbor activated Kras mutations and wild type EGFR
(16). Mutations in Kras, predominantly an amino acid substitution at codon 12 or 13, lead
to upregulation of the Ras/MAPK signaling and ERK activation, ultimately driving cell
division. While mutations in Ras are common in cancer it has been challenging to
therapeutically target Ras directly because of the nucleotide-binding pocket’s very high
affinity for GTP.
Here we report that using a palmitoylation defective EGFR mutant we
demonstrate the increased response to gefitinib is mediated by the palmitoylated
cysteine residue 1025, but only when in combination with activated Kras. Alternatively,
inhibition of DHHC20 also increases sensitivity to gefitinib-induced cell death in cancer
cells harboring not only activating EGFR mutations, but also the gefitinib resistant
T790M mutation, independent of activated Kras. These results demonstrate a previously
unreported mechanism to overcome mutation driven drug resistance by targeting a
recently identified modification of EGFR.

Results
Increased gefitinib-induced cell death is mediated by the palmitoylation site C1025
on the C-terminal tail of EGFR.
We reported previously that inhibition of DHHC20 increased the sensitivity of the
triple negative breast cancer cell line, MDA-MB-231, to TKI induced cell death (Fig. 1A)
(16). Although inhibition of DHHC20 by shRNA leads to an increase in sensitivity to
gefitinib-induced cell death, it is still unclear if this effect was directly mediated by
inhibiting EGFR palmitoylation or if it is the effect of another unknown target of DHHC20.
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We previously showed that EGFR is palmitoylated on the C-terminal tail and that
mutating one of the palmitoylated cysteine residues 1025 to alanine is sufficient to
reduce receptor palmitoylation, induce receptor autophosphorylation, adaptor binding
and downstream signaling to AKT and ERK when transiently expressed in NIH3T3 cells
(16). To test if blocking EGFR palmitoylation directly increases gefitinib sensitivity of
human cancer cells, we developed a conditional system for expressing wild type EGFR
(EGFRWT) or palmitoylation defective EGFR with cysteine 1025 mutated to alanine
(EGFRC1025A) in MDA-MB-231 cells with a tetracycline-inducible promoter. Induction of
the cells with doxycycline for 72 hours resulted in protein levels of EGFRC1025A is slightly
higher than EGFRWT consistent with previous findings (Fig. 1B) (16). After 24 hours of
doxycycline inductions, cells were treated with gefitinib (5µM) for 72 hours. The
percentage of dead cells expressing EGFRWT were similar to cells infected with an
empty vector control treated with gefitinib (Fig. 1C). Cells expressing the EGFRC1025A
mutant and treated with DMSO showed similar percentages of cell death as EGFRWT
expressing cells (Fig. 1C). However, when the EGFRC1025A mutant cells were treated with
gefitinib, cell death increased to 80.6% compared to the 32.4% in gefitinib treated
EGFRWT expressing cells (Fig. 1C). One potential damaging outcome when blocking
EGFR palmitoylation is increased tumor growth caused by activated EGFR. However,
expression of EGFRC1025A did not increase growth of the breast cancer cells and in fact
significantly reduced cell proliferation compared to cells overexpressing EGFRWT (Fig
1D). These results indicate that blocking EGFR palmitoylation at cysteine residue 1025
is sufficient to induce gefitinib sensitivity in triple negative breast cancer cells. This
confirms that the increased sensitivity to gefitinib-induced cell death imposed by
DHHC20 inhibition via shRNA is caused by loss of EGFR palmitoylation at cysteine
residue 1025.
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DHHC20 silencing does not increase gefitinib sensitivity in wild type Kras
expressing MCF7 breast cancer cells.
The MDA-MB-231 breast cancer cells express wild type EGFR, but harbor an
activating mutation in Kras (KrasG12D). We asked if a similar sensitivity to gefitinib is
observed in cancer cells expressing wild type Kras upon DHHC20 silencing. Silencing
DHHC20 in the breast cancer cell line MCF7 harboring a mutation in the PI3K pathway
(PIK3CAE545K) had no effect on gefitinib-induced cell death consistent with a requirement
for oncogenic Kras (Fig. 1A). However, similar to the slowed growth upon expression of
EGFRC1025A in MDA-MB-231, inhibiting DHHC20 in MCF7 cells did slow cell growth,
suggesting that DHHC20 plays a role in proliferation in the presence of a PIK3CA
mutation (Fig. 1B). Inhibiting DHHC20 did modestly increase phosphorylation of both
ERK and AKT, suggesting that the loss of DHHC20 promotes the signaling of the
constitutively active mutant PIK3CA (Supp. Fig. 1B). We next examined the gefitinib
sensitivity of downstream EGFR signaling in shControl and shDHHC20 expressing cells.
Treatment of MCF7 cells with 5 µM gefitinib decreased pERK only when DHHC20 was
silenced by shRNA, but pAKT was only slightly inhibited by gefitinib in the MCF7
shDHHC20 cells (Supp. Fig. 1B).
Since MCF7 cells were still not sensitive to gefitinib-induced cell death after
DHHC20 inhibition we asked if non-transformed cells were also resistant. When
DHHC20 was inhibited in MCF10A cells, there was no increase in the sensitivity to
gefitinib-induced cell death after 72 hours of treatment (Fig. 2C). Furthermore, inhibition
of DHHC20 in MCF10a cells had no effect on cell growth (Fig. 2D), indicating that
DHHC20 is not essential for normal cell growth. We also examined the gefitinib
sensitivity of downstream EGFR signaling in shControl and shDHHC20 expressing
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MCF10a cells. Treatment with 5 µM gefitinib decreased pEGFR and pERK in both
shControl and shDHHC20 cells as expected because gefitinib will inhibit EGFR in these
non-transformed cells (Supp. Fig. 1C). These results thus far indicate that inhibition of
DHHC20 only increases sensitivity to gefitinib-induced cell death in cancer cells with
activating mutations in Kras.
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Figure 1. Expression of palmitoylation defective EGFRC1025A mediates gefitinib-induced
cytotoxicity. (A) Gefitinib increases cytotoxicity in DHHC20 silenced Kras mutant cells MDA-MB231. (B) MDA-MB-231 (KrasG13D) cells stably expressing inducible EGFRWT or EGFRC1025A or
empty vector control (EV) were treated with doxocycline (1µg/ml) for 15 hours. Immunoblotting
with anti-FLAG shows induced expression of FLAG tagged EGFRWT and EGFRC1025A. (C) Cells
were treated with doxocycline (1µg/ml) every 24 hours for 72 hours and with DMSO or 5 µM
gefitinib at 24 hours post-seeding. Expression of EGFRC1025A induced sensitivity to gefitinib. Cell
viability was measured by Trypan Blue staining at 72 hours post-treatment (mean +/-StDev). (D)
Induced expression of EGFRC1025A in MDA-MB-231 cells reduces cell growth.
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Figure 2. DHHC20 inhibition increases gefitinib sensitivity in cells with activating
mutations and resistance mutations in EGFR. MCF7 and MCF10A are resistant to gefitinib
cytotoxicity in response to DHHC20 silencing. (A, B) shControl and shDHHC20 cells were treated
with DMSO or 5 µM gefitinib. Cell viability was measured by Trypan Blue staining at 72 hours. (C)
Knockdown of DHHC20 in MCF7 (PIK3CAE545K) cells slows growth. (D) Knockdown of DHHC20
in the non-transformed MCF10a cells has no effect on cell growth.
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Increased gefitinib-induced cell death mediated by EGFRC1025A requires mutant
KrasG12V.
To determine the requirements of gefitinib-induced cell death in shDHHC20 cells,
NIH3T3 cells were stably infected with tetracycline-inducible EGFRWT or palmitoylation
defective EGFRC1025A. The level of EGFRWT expression was lower than EGFRC1025A after
12 hours of induction (Fig. 3A). After 72 hours of induced expression of EGFRWT or
EGFRC1025A, there was no effect on cell viability after 72 hours of gefitinib treatment (Fig.
3B). Since expression of EGFRC1025A alone was not sufficient to induce gefitinib
sensitivity we asked if oncogenic Kras is required. The mutant KrasG12V was stably
expressed in NIH3T3 cells together with tetracycline-inducible EGFRWT or EGFRC1025A.
Treatment with gefitinib increased the percentage of cell death to 33.4% in KrasG12V cells
expressing EGFRC1025A compared to 11.0% in cells expressing EGFRWT and KrasG12V
(Fig. 3B). This indicates the combination of oncogenic Kras with palmitoylation defective
EGFRC1025A is required and sufficient to increase gefitinib-induced cell death. When
downstream signaling was examined, we found that cells expressing both KrasG12V and
EGFRC1025A had higher levels of pAKT compared to those with KrasWT. This increase in
pAKT is inhibited by gefitinib treatment whereas the change in EGFRC1025A KrasWT is
minimal (Fig. 3A). However, the EGFRC1025A and KrasG12V condition had lower levels of
pERK compared to EGFRC1025A and KrasWT and were reduced upon gefitinib treatment to
similar levels in both conditions (Fig. 3A). Therefore, the increase in cell death may be
more dependent on the gefitinib-induced changes in AKT activation than ERK.
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Figure 3. Mutation of the palmitoylated cysteine 1025 of EGFR in combination with
KrasG12V increases gefitinib sensitivity. (A) NIH3T3 cells stably expressing inducible full length
EGFRWT or EGFRC1025A or empty vector control (EV) with KrasWT (left) or KrasG12V (right).
Immunoblotting with EGFR shows induced expression of EGFRWT and EGFRC1025A, and
immunoblotting with HA shows expression of HA-tagged KrasG12V. (B) Induced expression of
EGFRC1025A in NIH3T3 stably expressing KrasG12V increased gefitinib-induced cell death. Cells
were treated with doxocycline (1µg/ml) every 24 hours for 72 hours and with DMSO or 5 µM
Gefitinib at 24 hours post-seeding. Cell viability was measured by Trypan Blue staining at 72
hours post-treatment (mean +/-StDev).
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DHHC20 inhibition increases gefitinib sensitivity in cells with the activating and
resistance mutations in EGFR.
Upon examination of the KrasWT lung cancer cell line, NCI-H1975, inhibiting
DHHC20 increased gefitinib-induced cell death (41.7% vs. 13.4%) (Fig. 4A). The
increase of sensitivity of the NCI-H1975 shDHHC20 cell line to gefitinib is quite
unexpected since this line harbors an activating mutation L858R and the acquired
secondary mutation, T790M, in the kinase domain imparting gefitinib resistance.
To address if the increase in cell death in the gefitinib resistant line is associated
with an increase in EGFR sensitivity to gefitinib, we examined EGFR signaling in the
shDHHC20 cells. When DHHC20 was silenced in NCI-H1975, cells exhibited increased
EGFR, AKT and ERK phosphorylation (Fig. 4B). The increase in signaling suggests that
the palmitoyl transferase inhibits the mutant EGF receptor. After treatment of NCI-H1975
shDHHC20 cells with gefitinib, the elevated levels of pEGFR were reduced within 1 hour,
suggesting that the increase in EGFR phosphorylation upon DHHC20 inhibition was not
caused by decreased dephosphorylation. The simplest explanation for the increased
EGFR autophosphorylation upon DHHC20 silencing is the high basal kinase activity of
the activating mutation. Similarly, levels of pERK and pAKT decreased after 1 hour and
remain low for 24 hours after treatment (Fig. 4B). In the NCI-H1975 shControl cells, the
gefitinib treatment increased pAKT and pERK levels as well as total levels of AKT and
ERK at 6-24 hours of treatment through a mechanism that is still unclear (Fig. 4B). This
suggests that reduction of DHHC20 by shRNA increases the sensitivity of these gefitinib
resistant cells to inhibitor treatment.
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Palmitate analog 2-bromopalmitate synergizes with gefitinib to induce cell death
in gefitinib resistant cells.
Silencing DHHC20 by shRNA causes chronic inhibition of DHHC20 and
constitutively elevated levels of EGFR signaling. The immediate effects of acute
DHHC20 inhibition through pharmacologic inhibition would provide greater insight into
the utility of DHHC20 as a therapeutic target. Although currently there is not a specific
inhibitor to palmitoyl transferases, the palmitate analog 2-bromopalmitate (2-BP) has
been shown to inhibit DHHC domain containing palmitoyl transferases at micromolar
concentrations (17). Our previous study showed that 2-BP was sufficient to increase
sensitivity of MDA-MB-231 cells to gefitinib-induced cell death (16). We wanted to
examine the effect of 2-BP on gefitinib sensitivity in greater detail, specifically on gefitinib
resistant cells.
We asked if acute treatment of cancer cells with 2-BP is sufficient to sensitize the
gefitinib resistant NCI-H1975 cells to gefitinib-induced cell death in and if the sensitivity
is comparable to the wild type EGFR expressing MDA-MB-231 cells. The combination
treatment increased cell death compared to either gefitinib or 2-BP alone in both MDAMB-231 and NCI-H1975 cells. Based on these responses to treatment with gefitinib and
2-BP, we assessed the effects of combining 2-BP and gefitinib using the Chou-Talalay
method (18). With half-maximal inhibitory concentrations of gefitinib (IC50 = 3.5 µM for
MDA-MB-231 and 12.67 µM for NCI-H1975) and 2-BP (IC50 = 11.74 µM for MDA-MB231 and 11.46 µM for H1975), these compounds were tested alone for effects on MDAMB-231 and NCI-H1975 cell growth at 1/8X, 1/4X, 1/2X, 1X, 2X, and 4X the IC50 values
and at equipotent concentrations at the same ratios in combination. Isobologram
analysis of the data at ED50, ED75 and ED90 values showed an additive effect of the
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gefitinib/2-BP combination in MDA-MB-231 cells (data not shown), but showed synergy
of the gefitinib/2-BP combination in NCI-H1975 cells with CI values of less than 1 (Fig.
4C). Upon examination of downstream signaling in NCI-H1975, we found 2-BP treatment
increased pEGFR, pAKT(T308) and pERK consistent with the shDHHC20 condition (Fig.
4D). With gefitinib treatment in combination with 2-BP, pEGFR and pAKT(T308) notably
reduced and pERK is modestly reduced in contrast to the MDA-MB-231 in which there
was no detectable change between treatment groups. Therefore, the signaling
mechanism behind the observed synergy between drugs may be through regulation of
combined AKT(T308) and ERK phosphorylation. This shows that targeting DHHC20 may
be an effective approach to overcoming EGFR TKI resistance in NSCLC.
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Figure 4. Palmitoyl transferase inhibitor 2-bromopalmitate synergizes with gefitinib in
inducing cell death in gefitinib resistant cells. (A) shControl and shDHHC20 NCI-H1975 cells
were treated with DMSO or 5 µM gefitinib. Cell viability was measured by Trypan Blue staining at
72 hours. Gefitinib increases cytotoxicity in H1975 DHHC20 silenced cells. All graphs show mean
+/-StDev. (B) Treatment of NCI-H1975 DHHC20 silenced cells with gefitinib decreases EGFR,
AKT and ERK phosphorylation. (C) NCI-H1975 cells were treated with (i) fixed IC50 ratios of
gefitinib alone at 24 hours post-seeding, (ii) fixed IC50 ratios of 2-BP alone at 24 hours postseeding, or (iii) Gefitinib in combination with 2-BP. The multiple effect-level isobologram analyses
at 72 hours post-treatment are shown for the ED50 (open circle), ED75 (closed square) and
ED90 (closed triangle) values. The combination of Gefitinib and 2-BP is synergistic in NCI-H1975
cells. (D) NCI-H1975 cells were treated with 5 µM Gefitinib, 500 nm 2-BP or both at 24 hours
post-seeding. Cells were harvested after the indicated treatment time points and lysates were
immunoblotted with indicated antibodies.
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Discussion
We observe increased gefitinib sensitivity in cells expressing EGFR harboring
both activating L858R and a resistance mutation T790M, an acquired secondary
mutation that imparts resistance to EGFR TKIs, such as gefitinib. Our results also reveal
a requirement for oncogenic Kras for increased inhibitor sensitivity mediated by blocking
EGFR palmitoylation in cells with wild type EGFR. Expression of a mutant form of EGFR
that is resistant to palmitoylation at cysteine 1025 leads to increased sensitivity to
gefitinib-induced cell death, but only in the presence of oncogenic KrasG12V. Expression
of activated PIK3CA was insufficient to induce sensitivity to gefitinib, confirming the
selectivity for KrasG12V (Supp. Fig. 1D).
The alterations in EGFR signaling that lead to increased gefitinib-induced cell
death are still not entirely clear. Inhibition of DHHC20 in EGFR mutant background
increases both pERK and pAKT levels and are both effectively inhibited by gefitinib. One
possibility it is the change in signaling from the artificially high levels induced by
DHHC20 inhibition or EGFRC1025A expression down to the gefitinib inhibited levels that
causes the cells to crisis and die. Cells with activated Kras become sensitized to gefitinib
with DHHC20 inhibition, but the resulting increase in pERK caused by DHHC20
inhibition is not reduced by gefitinib. It is therefore unclear why the MDA-MB-231 cells
become sensitive to gefitinib when DHHC20 is knocked down.
Furthermore, the combined effect of DHHC20 and EGFR inhibition is greater in
the cells with mutant EGFR than cells with mutant Kras. The synergy between gefitinib
and 2-bromopalmitate (2-BP) in the NCI-H1975 cells compared to the additive effect in
MDA-MB-231 cells is particularly surprising. Gefitinib targets EGFR harboring the L858R
activating mutation, which increases the affinity of the drug for activated EGFR relative
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to ATP, in NCI-H1975. It is therefore not surprising that the gefitinib/2-BP combination
treatment is more effective in this cell line than the EGFR wild type cell line, MDA-MB231. What is surprising is that these cells are resistant to gefitinib because of the T790M
secondary acquired resistance mutation. The T790M mutation increases the affinity of
the ATP binding pocket for ATP over gefitinib. Due to toxicity, we have been unable to
express EGFRC1025A in the NCI-H1975 cells or express EGFRL858R/T790M also harboring
the C1025A mutation in any cell type. We therefore can’t conclusively demonstrate that
the increased gefitinib sensitivity in the NCI-H1975 cells is through EGFR palmitoylation
directly.
Our results reveal two potential vulnerabilities in the EGFR/MAPK pathway
mediated by DHHC20 inhibition. First is the gefitinib-induced sensitivity of Kras mutant
cancers to inhibition of DHHC20 or blocking EGFR palmitoylation. Oncogenic mutation
in Kras is one of the most common mutations in cancer and yet targeting Kras
therapeutically has been elusive. Therefore, inducing sensitivity of Kras mutant cells to
EGFR inhibitor therapy is an unprecedented alternative approach. The second is the resensitization of gefitinib resistant cancer cells by inhibition of DHHC20. While we have
not yet shown that this effect is through EGFR, the synergistic effect between 2-BP and
gefitinib is striking. The fact we have been unable to express the C1025A mutant with
the activating L858R mutant suggests there may be a form of synthetic lethality possibly
from hyperactivation of the pathway. Future studies will determine how palmitoylation
effects the gate-keeper mutation in the kinase domain and if it is through the C-terminal.
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Supplemental Figure 1. (A) DHHC20 expression is silenced using shRNA or sgRNA and the
CRISPR/Cas9 system. MDA-MB-231, MCF-7, H1975 MCF10a shControl and shDHHC20 stable
cell lines were generated by lentiviral infection. Immunoblotting with a DHHC20 specific antibody
shows reduction of the DHHC20 band (arrow). (B) Treatment of MCF7 DHHC20 silenced cells
significantly decreases ERK phosphorylation. (C) Treatment of MCF10A shControl and
shDHHC20 cells decreases EGFR and ERK phosphorylation. (D) Expression of EGFRC1025A in
NIH3T3 stably expressing PIK3CAE545K had no effect on gefitinib-induced cell death. Cells were
treated with doxocycline (1µg/ml) every 24 hours for 72 hours and with DMSO or 5µM Gefitinib at
24 hours post-seeding. Cell viability was measured by Trypan Blue at 72 hours post-treatment
(mean +/-StDev).
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Materials and Methods
Cell culture
MDA-MB-231, MCF7, and NIH3T3 cells (ATCC) were cultured in DMEM containing 10%
FBS. NCI-H1975 cells (ATCC) were maintained in RPMI supplemented with 10% FBS.
Cells were treated with gefitinib (Selleck Chemicals) and 2-bromopalmitate (2-BP)
(Sigma).
Immunoblot analysis
Cell lysates were prepared in 1% Triton-X-100 buffer, including Tris-HCl (pH 7.5) and
sodium chloride solution (NaCl). Lysates were analyzed by immunoblotting with the
following antibodies: Anti-DHHC20 (HPA014702) and anti-FLAG M2 antibodies were
purchased from Sigma-Aldrich. Anti-pY1068-EGFR, EGFR-XP, pERK, ERK, pS473AKT, pT308-AKT, AKT, β-actin were obtained from Cell Signaling Technologies. Anti-HA
antibodies were purchased from Biolegend. Immune complexes were detected with
horseradish peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence (ECL) (Thermo Scientific).
Silencing of Human DHHC20
The oligonucleotides for shControl and shDHHC20 constructs were synthesized
(Integrated DNA Technologies) and inserted into the pLKO.1 vector. shControl encodes
the non-targeting sequence of SHC002 (Sigma); the shRNA target sequence of human
DHHC20 is 50-GAGCTCTGCGTGTTTACTATT-30. MDA-MB-231, MCF7 and NCIH1975 cells were transduced with lentivirus encoding shControl or shDHHC20 and
selected by puromycin treatment (1 mg/ml) for several passages.
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Cell Viability
Cells were treated with gefitinib (5 µM) and/or 2-BP (500 nM) for 72 hr, and viability was
measured by trypan blue staining. Quantification was done using a 1-way ANOVA with
Tukey’s multiple comparison post-test.
Determination of IC50 Values and Isobologram analysis
Cells were seeded on a 96-well plate in 100 µl growth media at a density of 1500 cells
per well. After 24 hours post-seeding, the cells were treated with gefitinib and/or 2-BP for
an additional 72 hours. Cell viability was assessed using the alamar blue viability assay
(Invitrogen). Triplicate wells for each experiment were analyzed and the experiment was
performed three times. The IC50 values were determined by a non-linear regression of
the dose-response effect data using Prism for MacOSX (GraphPad Software). Cells
were exposed to 1:1 ratios of the respective IC50s for gefitinib and 2-BP at ¼ xIC50, ½
xIC50, IC50, 2 xIC50, and 4 xIC50. The assessment of synergy was performed using
CalcuSyn software (Biosoft). The combination index (CI) was evaluated to assess
synergism (CI<1), additive effect (CI~1) or antagonism (CI>>1).
Plasmids and generation of stable cell lines
To generate inducible cell lines, wildtype EGFR and EGFR C1025A cDNA was first
subcloned into the inducible pTRIPZ backbone with a puromycin resistance marker and
FLAG tag. Empty pTRIPZ, which expresses the rtTA3, puromycin resistance marker,
and FLAG tag was used as a negative control. Virus production was performed by
transfecting HEK293T cells with the pTRIPZ constructs, psPAX2 and pMD2.G plasmids
(Addgene) using TransIT-LT1 (Mirus) according to the manufacturer’s instructions. MDAMB-231 and NIH3T3 were infected with pTRIPZ virus using polybrene and incubated for
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24 hours. Post-infection, fresh media was added on infected cells and incubated for an
additional 48 hours before selection. Cells infected with the pTRIPZ constructs were
selected with 1 µg/ml puromycin for several passages. Expression of EGFR cDNA was
induced with 1μg/ml doxycycline. Lentivirus of human mutant Kras4B(G12V) in pLentiPGK-hygromycin resistance with an HA tag (Addgene plasmid #35633, [Singh et al. Cell,
2012]) was generated using HEK293T cells, Gag, VSVG and Rev. NIH3T3 cells infected
with pTRIPZ constructs and selected with puromycin were subsequently infected with
Kras4B(G12V)-HA. NIH3T3 pTRIPZ-plenti-Kras4B(G12V) cells were selected with
puromycin (1 µg/ml) and hygromycin (500 µg/ml) together for several passages.
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CHAPTER 4: BLOCKING EGFR PALMITOYLATION
SUPPRESSES PI3K SIGNALING AND MUTANT KRAS LUNG
TUMORIGENESIS.
Akriti Kharbanda, David Walter, Andrea Guidel, Nancy Schek, David Feldser, Eric S.
Witze. Loss of palmitoylated EGFR blocks mutant Kras tumorigenesis through loss of
Myc expression. In Press. (2019)

Abstract
Non-Small Cell Lung Cancer (NSCLC) is often characterized by mutually
exclusive mutations in epidermal growth factor receptor (EGFR) (26%) or KRAS (37%)
(1, 2). Here we show that in the presence of oncogenic KRAS, blocking EGFR
palmitoylation severely reduces PI3K signaling, Myc expression and decreases cancer
cell growth. In vivo, either genetic ablation of the palmitoyl-transferase DHHC20 or
expression of a palmitoylation-resistant EGFR mutant blocks tumorigenesis in a KRAS
mouse model of lung adenocarcinoma, suggesting that in KRAS mutant cells the PI3K
pathway is vulnerable to loss of EGFR palmitoylation. Furthermore, acute inhibition of
DHHC20 is sufficient to halt the growth of existing tumors derived from human cells.
Inhibition of DHHC20 either genetically in KRAS mutant lung cancer cells increases their
sensitivity to PI3K inhibitor treatment, accentuating the clinical potential of this
vulnerability. Our findings reveal a molecular mechanism in which palmitoylated EGFR
associates with the PI3K regulatory subunit PIK3R1 (p85), recruiting the PI3K
heterodimer to the plasma membrane. Blocking palmitoylation increases the association
of EGFR with the adaptor Grb2 and decreases EGFR association with p85. The binary
switching between MAPK and PI3K signaling, modulated by EGFR palmitoylation, is
only observed in the presence of oncogenic KRAS. These findings suggest a
mechanism where oncogenic KRAS saturates signaling through unpalmitoylated EGFR,
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displacing the PI3K signaling complex. The identification of the palmitoyl-transferase
DHHC20 as a vulnerability in EGFR expressing, KRAS mutant cancer could have
substantial therapeutic potential.

Introduction
Non-small cell lung cancers (NSCLC) account for 15% of all cancer related
deaths in the United States (3) NSCLCs are characterized by mutually exclusive
activating mutations of epidermal growth factor receptor (EGFR) or of KRAS. EGFR is
one of four members of the ErbB family and is known to facilitate tumorigenesis and
cancer progression. EGFR is structurally comprised of an extracellular ligand binding
domain, a transmembrane region, a tyrosine kinase domain, and an unstructured Cterminal tail that harbors receptor auto-phosphorylation sites (4). Ligand binding induces
activation of the tyrosine kinase domain leading to auto-phosphorylation of tyrosine
residues in the C-terminal domain. The phosphorylated tyrosine residues serve as
docking sites for adaptor proteins that link the receptor to the downstream signaling
pathways RAS/MAPK and PI3K/AKT which promote cell growth and survival. Activating
mutations in EGFR increase both MAPK and PI3K signaling and promote oncogenesis.
Mutations in KRAS, predominantly an amino acid substitution at codon 12 or 13, lead to
upregulation of MAPK signaling. However, in the mutant KRAS setting tumor growth
requires increased PI3K signaling through a mechanism dependent on a KRAS-PI3K
interaction mediated by the Ras-Binding Domain of PIK3CA (5). Therefore, essential
mechanisms are in place to maintain levels of PI3K signaling during tumorigenesis in the
mutant KRAS background.
Our lab discovered that EGFR is palmitoylated on the C-terminal tail by the
palmitoyl-transferase DHHC20 (6). Reduction of DHHC20 increases MAPK signaling by
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a mechanism that is independent of EGFR kinase activity suggesting palmitoylation
modulates assembly of the MAPK signaling complex on the C-terminal tail. Furthermore,
a palmitoylation-defective EGFR point mutant (EGFRC1025A) activates downstream MAPK
signaling with increased Grb2 receptor association confirming the mechanism is through
the palmitoylated cysteine residues. Although MAPK signaling was increased in in cells
with reduced DHHC20 we observed a cell growth defect in mutant-KRAS cells caused
by reduced EGFR palmitoylation (7). The mechanism by which unpalmitoylated EGFR is
hindering mutant-KRAS growth remains unresolved.
Here, we demonstrate that loss of DHHC20 or expression of the palmitoylationdefective EGFRC1025A in a mutant-KRAS background enhances the KRAS/MAPK
pathway whilst hindering the PI3K/AKT pathway leading to a reduction in Myc
expression and reducing cell proliferation and blocking tumorigenesis. Our results
indicate that in cells expressing EGFR and oncogenic KRAS, EGFR must be
palmitoylated to allow PI3K signal complex formation, downstream signaling and
tumorigenesis.

Results
DHHC20 inhibition reduces tumor burden in KRAS-mutant mice
We have previously demonstrated that inhibition of the palmitoyl-transferase
DHHC20 or mutation of the palmitoylation site Cys 1025 on EGFR, induces EGFR
receptor activation and thereby presents with increased downstream signaling to MAPK
in KRAS mutant lung cancer cells SW1573 (KRASG12V) (6). We therefore asked if
DHHC20 loss affects KRAS mediated lung tumorigenesis. To study KRAS mutant tumor
initiation, we used the genetically engineered KrasLSL-G12D/+; p53flox/flox; Rosa26LSL-YFP
(KPY) autochthonous mouse model of lung cancer. In the model, tumors are initiated by
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endotracheal delivery of viral particles that transduce lung epithelial cells to express Cre
recombinase to activate KrasG12D and delete p53 expression. To additionally ablate
DHHC20 expression in vivo, we transduced KPY mice with LentiCRISPRv2Cre, a
construct that expresses Cre recombinase, Cas9, and a sgRNA targeting DHHC20
(sgDHHC20#1/#2) or an inert sgRNA targeting β-galactosidase (sgInert) (Fig. 1A, B) (8).
Twelve weeks after tumor initiation, animals transduced with LentiCRISPRv2Cre
targeting DHHC20 harbored 10-fold less tumor burden compared to sgInert mice
(10.14% vs. 1.16% with a P-value= 0.0008) (Fig. 1C, D). Inactivation of DHHC20 had a
durable effect on tumor growth, as 24 weeks post-transduction there was still no
increase in tumor burden (Supplemental Fig. 1B). Although significantly fewer tumors
emerged when DHHC20 was targeted, we found a similar frequency of YFP-positive
transduction sites in the lungs of each cohort of KPY mice (Fig. 1E, F). We observed
airway epithelial cells that were YFP positive and DHHC20 negative indicating nontumor cells are viable in the absence of DHHC20 (Fig. 1E). Consistent with the lack of
tumor outgrowth, YFP-labelled sgDHHC20#1 infected cells persisted twelve-weeks posttransduction, but a lower percentage expressed the proliferation-associated antigen Ki67
than tumors initiated with the sgInert expressing vector (Fig. 1H, I). Inhibition of
DHHC20 increases MAPK signaling in human KRAS-driven cancer cells (6).
Consistently, we observed a marked increase in phosphorylated Erk in focal areas of the
lung tissue of sgDHHC20#1 mice compared to the lung tissue of sgInert mice (Fig. 1J).
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Figure 1. Inhibition of DHHC20 leads to decreased tumour burden in mutant KRAS driven tumorigenesis.
A. Diagram of the LentiCRISPRv2Cre vector. B. Depiction of lentiviral lung tumor induction by intratracheal intubation. C.
CRISPR of DHHC20 in KRASLSL-G12D; Trp53flox/flox, Rosa26LSL-YFP (KPY) mice virally introduced to lung leads to a
significant decrease in tumour burden. Hematoxylin and Eosin (H&E) 4X stitched images of sgInert, sgDHHC20#1 and
sgDHHC20#2 lungs from infected mice. D. Average tumor burden (value indicated by boxed number) of sgInert (n=6),
sgDHHC20#1 (n=8), and sgDHHC20#2 (n=6) in KRASG12D/+; p53Δ/Δ; Rosa26L-YFP mice 13 weeks following infection
with LentiCRISPRv2Cre, ** P < 0.05, Anova Two-Way. E. IHC staining for YFP in lungs from KPY mice 13 weeks after
infection with LentiCRISPRv2Cre. Representative images sgInert and sgDHHC20#1 at 20X magnification (arrows indicate
sites of infection). F. YFP positive regions in 4X stiches of IHC images for sgInert vs. sgDHHC20 were quantified using
ImageJ. Graphs represent average number of YFP positive sites ±SD of 5 mice per cohort. G. Deleting DHHC20
decreases proliferation of YFP positive cells in mouse lung tissue measured by Ki67 immunofluorescence staining. sgInert
and sgDHHC20#1. tissue sections were stained for YFP (green), Ki67 (red) and DAPI (blue). All scale bars represent
25µm. H. Graph representing the percentage of YFP expressing cells staining positive for Ki67 in lung tissue of 4 mice
from each of the sgInert and sgDHHC20#1 cohorts. (A total of 40 fields per cohort were quantified. ± s.e.m (n=40), *** P <
0.001, Anova Two-Way. I. IHC staining for pERK in lungs from KPY mice 13 weeks following infection with
LentiCRISPRv2Cre. Right panels show 20X magnification image of region indicated in the red box.
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The palmitoylation resistant EGFR point mutant blocks KRAS-driven tumor
growth.
As previously discussed, expression of the palmitoylation-deficient EGFR
cysteine point mutation, EGFRC1025A, also induces EGFR and subsequent MAPK
activation. We sought to determine if specific loss of EGFR palmitoylation blocks mutant
KRAS tumorigenesis in vivo phenocopying the result seen with inhibition of DHHC20.
To assess whether EGFRC1025A is sufficient to block mutant KRAS tumorigenesis in vivo,
we transduced KPY mice with lentiviral vectors to induce oncogenic KrasG12D, delete p53
due to Cre-mediated recombination, and stably express either mCherry or
palmitoylation- defective EGFRC1025A (Fig. 2A). We included expression of oncogenic
EGFRL858R as a positive-control (Fig. 2A), which has been previously shown to induce
synthetic lethality in the presence of mutant KRAS in NSCLC cell lines (9-11).
EGFRC1025A and EGFRL858R expressing cohorts stained positively for EGFR compared to
the minimal endogenous expression of EGFR in the control cohort (Supplemental Fig.
2A, B). Expression of EGFRC1025A or EGFRL858R reduced the tumor burden by greater
than 10-fold compared to control (0.9%, 3.7% vs. 11.7%) (Fig. 2B, C). Despite the lack
of tumor formation in KPY mice with enforced EGFRC1025A or EGFRL858R, a similar
frequency of YFP-positive transduction sites was evident in lungs. (Fig. 2D, E). These
results demonstrate that it is the unpalmitoylated form of EGFR that is incompatible with
oncogenic KrasG12D-driven tumor formation, similar to the synthetic lethality observed
with expression of EGFRL858R in the mutant KRAS background (12).
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Figure 2. Specific loss of EGFR palmitoylation blocks KRAS-driven tumour growth.
A. Diagram of pCREator lentiviral EGFR overexpression construct introduced directly to the lung
in KRASLSL-G12D; Trp53flox/flox, Rosa26LSL-YFP (KPY) mice via intratracheal intubation. B. Average
tumour burden of mCherry (n=9), EGFRC1025A (n=10), and EGFRL858R (n=9) in KPY mice 13
weeks following infection with Lenti-pCREator *** P < 0.001, Anova Two-Way. C. Expression of
EGFRC1025A in KPY mice significantly decreases tumour burden compared to expression of the
negative control mCherry or expression of the positive control EGFRL858R. Hematoxylin and Eosin
(H&E) staining at 4X magnification of lungs from mCherry, EGFRC1025A and EGFRL858R expressing
mice. D. Images of IHC staining detecting YFP expressing cells in lungs from KPY mice 13
weeks following Lenti-pCREator infection. Representative images of mCherry, EGFRC1025A and
EGFRL858R at 10X magnification. E. YFP positive regions in 4X stiches of IHC images of mCherry
vs. EGFRC1025A or EGFRL858R expression were quantified using ImageJ. Graphs represent
average number of YFP positive sites ±SD of 5 mice per cohort.
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DHHC20 inhibition reduces PI3K/AKT signaling and Myc expression
Although the increase in MAPK signaling upon DHHC20 inactivation in vivo is
consistent with our previous in vitro results, the pro-proliferative function of MAPK
signaling is in conflict with the observed inhibition of tumor growth. Similarly, when we
examined cell proliferation in KRAS mutant, EGFR positive cancer cell lines, H23
(KRASG12V) and MDA-MB-231 (KRASG12D), we found cell proliferation decreased
significantly in both cell lines when DHHC20 is silenced by shRNA (Fig. 3A, B). We
therefore examined PI3K-AKT, a parallel branch of the EGFR signaling pathway and
found a marked decrease in AKT phosphorylation at Threonine 308 (T308) when
DHHC20 is inhibited by shRNA (Fig. 3C). T308 is the primary activating phosphorylation
site on AKT and is mediated by the PI3K pathway. The PI3K-AKT pathway inactivates
glycogen synthase kinase 3β (GSK3β) via phosphorylation on Ser9, preventing GSK3β
mediated Myc phosphorylation and subsequent proteosomal degradation (13, 14).
Consistent with a reduction in the PI3K-AKT pathway, DHHC20 silencing in both MDAMB-231 and H23 cells decreases GSK3β phosphorylation at Ser9 and severely reduces
Myc expression (Fig. 3C). Treating MDA-MB-231 and H23 shDHHC20 cells with MG132,
a potent proteasome inhibitor, fully restores Myc expression indicating that inhibiting
DHHC20 promotes Myc proteosomal degradation (Fig. 3D). Similarly, pharmacologic
inhibition of GSK3β with CHIR-90021 also restored Myc protein levels, confirming Myc
degradation caused by loss of DHHC20 requires GSK3β activity (Fig. 3E). Silencing
DHHC20 did not decrease Myc mRNA levels indicating that the decrease in Myc
expression is not a result of changes in Myc transcription (Supplemental Fig. 1A).
Finally, we asked if restoring Myc expression could rescue the DHHC20-induced growth
defect. Mutating the GSK3β phosphorylation site on Myc (MycT58A) inhibits Myc
degradation. When MycT58A was expressed in H23 shDHHC20 cells the growth rate was
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fully restored to that of the shCon cells confirming that the reduction in cell growth
caused by DHHC20 inhibition is due to reduced Myc expression (Fig. 3F, G).
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Figure 3. Inhibition of DHHC20 results in depletion of Myc expression in KRAS mutant cells that
is restored by inhibition of the proteasome or GSK3β
β.
A and B. H23 and MDA-MB-231 cells were stably infected with lentiviruses containing a control
scrambled shRNA (shCon) or an shRNA targeting DHHC20 (shD20). Immunoblotting for DHHC20 with
anti-DHHC20 antibodies confirms a reduction in DHHC20 expression (left). Silencing DHHC20
decreases cell proliferation in both H23 and MDA-MB-231 cells (right). C. Silencing DHHC20 in MDAMB-231 and H23 cells increases pERK but decreases pAKT and pGSK3β as well as Myc protein
expression. D and E. Treatment of MDA-MB-231 and H23 shDHHC20 cells with 5 μM MG132 (D) or 3
μM CHIR-99021 (E) for 6 hours restored Myc protein levels to shCon levels as determined by
immunoblotting with anti-Myc antibody. F. Immunoblotting shows that stably transducing H23
shControl (shCon) and shDHHC20 cells (shD20) with the stable MycT58A mutant partially restores Myc
protein levels. G. Expression of MycT58A in H23 shDHHC20 cells rescues the growth defect from loss of
DHHC20. H23 shCon and shD20 cells, and H23 shCon/MycT58A and H23 shD20/MycT58A cells were
plated at a density of 6 x 104 cells on day 0. Cells were counted once a day for 72 hours. Cell number
is expressed as the mean ± s.d of three replicates. *** P < 0.001, Student’s T-Test.
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Palmitoylation-resistant EGFR antagonizes oncogenic KRAS signaling and cell
growth
The results thus far suggest PI3K signal activation is inhibited in the presence of
unpalmitoylated EGFR. To test this, EGFR was silenced by shRNA in MDA-MB-231 and
H23 shCon and shDHHC20 cells to restore PI3K signaling and Myc expression (Fig.
4A). We found that when EGFR expression was inhibited phosphorylated AKT and Myc
expression were increased and cell growth was completely restored in both MDA-MB231 and H23 shDHHC20 cells (Fig. 4A, B and C). Therefore, the loss of Myc and the
growth defect in KRAS mutant cells caused by the DHHC20-loss is dependent on the
presence of EGFR (Fig. 4B, C).
We next asked if the unpalmitoylated form of EGFR is the cause of reduced Myc
expression when DHHC20 is silenced. We used a conditional system for expressing wild
type EGFR (EGFRWT) or EGFRC1025A, the palmitoylation-deficient mutant (7). Although,
treatment of the cells with doxycycline for 72 hours induced equal levels of EGFRWT and
EGFRC1025A, Myc protein levels were reduced in the EGFRC1025A-expressing cells
compared to EGFRWT (Fig. 4D). Similarly, EGFRC1025A expression decreased levels of
pAKT(T308) and pGSK3β(S9) compared to EGFRWT, phenocopying the results
observed with DHHC20 inhibition (Fig. 4C).
Thus far all the cell contexts examined were in an activated mutant KRAS
background. We therefore asked if the reduction in cell growth and Myc expression
mediated by EGFRC1025A specifically requires mutant KRAS by measuring Myc levels
after inducing EGFRWT or EGFRC1025A in NIH3T3 cells expressing KRASWT or activated
KRASG12V. When EGFRC1025A was induced in the presence of KRASG12V there was a
decrease in pAKT(T308), pGSK3β(S9) and Myc that was not observed with KRASWT
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(Fig. 5A). Expression of EGFRC1025A in the presence of KRASG12V also decreased cell
growth confirming that the mechanism for reducing Myc expression and cell proliferation
requires oncogenic KRAS (Fig. 5B).
These results indicate that expression of EGFRC1025A in a mutant Kras
background is leading to a deficit of PI3K signaling due to lack of access of PIK3R1 to
the membrane where it is required to facilitate downstream signaling. The PI3K catalytic
subunit p110α, is also often mutated in lung cancer, but unlike mutant KRAS does not
appear to be mutually exclusive with EGFR mutations in NSCLC patients (15, 16). We
asked if expressing a constitutively active mutant of p110 in EGFRC1025A expressing cells
can bypass the requirement of PIK3R1 at the membrane. Co-expression EGFRWT or
EGFRC1025A with either PIK3CAWT or the oncogenic mutant PIK3CAE454K in NIH3T3 cells
(17) had no effect on the levels of pAKT(T308) and pGSK3β(S9) (Fig. 5C). In contrast to
the effect seen in KRAS mutant cells, co-expression of EGFRC1025A with PIK3CAE545K
markedly increased Myc expression (Fig. 5C). However, there was no increase in cell
proliferation between cells expressing EGFRC1025A and those expressing EGFRWT,
suggesting that the Myc protein is not limiting for cell growth in the mutant PIK3CAE545Kexpressing cells (Fig. 5D). We next examined the lung adenocarcinoma cell line
SW1573 which harbors both activating KRAS and PIK3CA mutations. We found that
induction of EGFRC1025A expression in SW1573 was unable to reduce AKT or GSK3β
phosphorylation (Fig. 5E). EGFRC1025A expression also had no effect on Myc expression
or cell growth, indicating PIK3CA activating mutations are sufficient to restore PI3K
signaling, on which the cells are now dependent, and cell growth in mutant KRAS cells
expressing unpalmitoylated EGFR (Fig. 5E, F).
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Figure 4. DHHC20-loss induced depletion of Myc requires the presence of palmitoylated
EGFR
A. MDA-MB-231 and H23 shCon and shDHHC20 cells were stably infected with lentiviruses
expressing a control scrambled shRNA (shCon) or an shRNA targeting EGFR (shEGFR). Lysates
were immunoblotted with the indicated antibodies. EGFR inhibition rescues shDHHC20 induced
Myc depletion. B and C. Silencing EGFR by shRNA in MDA-MB-231 (B) and H23 (C) shDHHC20
cells rescues the shDHHC20 (shD20) induced growth defect. Control shRNA (left) shCon (D20);
shCon (EGFR) (black) and shCon (EGFR); shD20 (red) cells or EGFR knockdown (right)
shEGFR; shCon (D20) (black) and shEGFR; shD20 (red) cells were plated on day 0 and counted
after 24, 48 and 72 hours. Cell number is expressed as the mean ± s.d of three replicates. *** P <
0.001, Student’s T-test. D. MDA-MB-231 cells expressing inducible EGFR wildtype (WT), EGFR
palmitoylation defective mutant cysteine 1025 to alanine (C1025A) or an empty vector control
(EV), were treated with doxycycline (1 µg/ml) for 15 hours. Lysates were immunoblotted with the
indicated antibodies. Expression of EGFRC1025A decreased pAKT and pGSK3β as well as Myc
expression.
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Figure 5. Presence of mutant KRAS is required to induce loss of PI3K/AKT pathway, Myc
expression and reduction of cell growth from loss of EGFR palmitoylation
A. NIH3T3 cells expressing wildtype KRAS (KRASWT) or mutant KRAS (KRASG12V) were stably
infected with lentivirus to express doxycycline inducible EGFRWT (WT), EGFRC1025A (C1025A) or
the empty vector (EV). After induction with doxycycline (1 µg/ml) for 15 hours, co-expression of
EGFRC1025A with KRASG12V decreased pAKT, pGSK3β and Myc expression compared to EGFRWT
co-expressed with KRASG12V. B. Growth curve of NIH3T3 cells co-expressing KRASWT (black
squares) or KRASG12V (red triangles) with doxycycline inducible, EGFRWT (left) or EGFRC1025A
(right) or empty vector (data not shown). Co-expression of EGFRC1025A with KRASG12V cells (right,
red triangles) reduces cell growth compared to cells co-expressing EGFRC1025A with KRASWT
(right, black squares) or cells co-expressing EGFRWT with KRASG12V (left, red triangles). Cell
number is expressed as the mean ± s.d of three replicates. C. NIH3T3 cells expressing wildtype
PIK3CA (PIK3CAWT) or PIK3CA harboring the activating mutation E545K (PIK3CAE545K) were
stably infected with lentivirus to express doxycycline inducible EGFRWT, EGFRC1025A or empty
vector. After induction with doxycycline (1 ug/ml) overnight, co-expression of EGFRC1025A with
PIK3CAE545K increased Myc protein expression compared to EGFRWT co-expressed with
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PIK3CAE545K. D. Growth curve of NIH3T3 cells co-expressing either PIK3CAWT (black squares) or
PIK3CAE545K (red triangles) with doxycycline inducible EGFRWT (left), EGFRC1025A (right) or empty
vector control (data not shown). Co-expression of EGFRC1025A or EGFRWT with either PIK3CAWT
or PIK3CAE545K (right and left, black squares and red triangles) has no effect on cell proliferation.
Cell number is expressed as the mean ± s.d of three replicates. E. SW1573 cells harboring both
mutant KRASG12C and the activating mutation, PIK3CAK111E, were stably infected with lentivirus to
express doxycycline inducible EGFRWT, EGFRC1025A or empty vector. After induction with
doxycycline (1 ug/ml) overnight, expression of EGFRC1025A did increases Myc protein expression
compared to EGFRWT. F. Growth curve of SW1573 cells expressing doxycycline inducible,
EGFRWT (triangles), EGFRC1025A (diamonds) or empty vector (squares). Expression of EGFRC1025A
(diamonds) does not change cell growth compared to cells expressing EGFRWT (triangles) or to
cells expressing empty vector (squares). Cell number is expressed as the mean ± s.d of three
replicates.
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Palmitoylated EGFR recruits PI3K signaling components to the plasma membrane
We reasoned that in the presence of oncogenic KRAS, EGFR palmitoylation is
required to promote PI3K complex formation at the membrane, biasing downstream
signaling towards PI3K/AKT signaling. The PI3K heterodimer is made up of a regulatory
subunit PIK3R1 (p85) and the catalytic subunit PIK3CA (p110α) (16). To detect
recruitment of signaling components to the membrane, we isolated the membrane
fraction of NIH3T3 cells expressing either EGFRWT or EGFRC1025A together with either
KRASWT or KrasG12V. Immunoblotting of the membrane fractions revealed an increase in
the abundance of the MAPK adapter Grb2 and a decrease in PI3K regulatory subunit
p85 in EGFRC1025A-expressing cells compared to EGFRWT-expressing cells in the
presence of KrasG12V. The decrease in p85 was not observed in cells expressing
EGFRC1025A together with KrasWT (Fig. 6A). We asked if the preferential binding of
EGFRC1025A for Grb2 over p85 is also observed in the KRAS mutant cell line. We again
found a consistent decrease in p85 and increase in Grb2 association with the plasma
membrane in cells expressing EGFRC1025A compared to EGFRWT (Fig. 6B, C). We then
probed the membrane fraction for the presence of KRAS and found that EGFRC1025A
increased KRASWT membrane association beyond that of EGFRWT, but we found equally
high levels of KRASG12V at the membrane in all three conditions empty vector, EGFRWT
and EGFRC1025A. This may indicate that the cycling of KRAS between the GTP and GDP
bound forms causes a transient association with EGFRC1025A allowing both Grb2 and
PI3K to associate with EGFRC1025A in the presence of wild type KRAS.
Our findings reveal that palmitoylated EGFR is required for PI3K activation and
Myc expression in the presence of oncogenic KRAS. As shown, unpalmitoylated EGFR
leads to a deficiency of PI3K signaling due to a reduction of p85 at a membrane
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complex, but what remains to be determined is how palmitoylated EGFR recruits the
PI3K complex and if EGFR engages PI3K directly. We reasoned that EGFR
palmitoylation directs PI3K signal complex formation by interacting with the PI3K
signaling complex. To measure interactions between PI3K and the palmitoylated form of
EGFR, we synthesized biotinylated peptides encompassing Cys 1025, in both
palmitoylated and unpalmitoylated forms and incubated them with lysates from PIK3R1
expressing cells (Fig. 6D). PIK3R1 associated with increasing concentrations of
palmitoylated peptide, but not the unpalmitoylated peptide or a palmitoylated peptide
with a scrambled sequence (Fig. 6D). These results suggest that sequence specific
palmitoylated motifs can be recognized as docking sites on proteins that may modulate
signal complex formation.

124

C1025A

WT

EV

EV

WT

C1025A

B.

C1025A

WT

EV

WT

C1025A

EV

C1025A

WT

EV

WT

EV

A.

C1025A

Figure 6

PIK3R1(p85)

PIK3R1
(p85)

Grb2

Grb2
Ras
Ras
β-Catenin
β-Catenin

Tubulin
Membrane

Cytosol
WT

Kras

C.

Membrane
NIH3T3

(G12V)

Tubulin

Cytosol

Kras

Membrane

Cytosol

MDA-MB-231

D.

(WT) Biotin-SNNSTVACIDRNGLQS
(Scr) Biotin-SVNASSRCGNDITNLQ

0

[WT]

[Scr- Palm]

[WT- Palm]

PD
Input
PIK3R1 (p85)

Figure 6. Expression of unpalmitoylated EGFR in the presence of mutant KRAS leads to
loss of PIK3R1 (p85) recruitment to the membrane A. NIH3T3 cells expressing wildtype KRAS
(KRASWT) or mutant KRAS (KRASG12V) were stably infected with lentivirus to express doxycycline
inducible EGFRWT (WT), EGFRC1025A (C1025A) or the empty vector (EV). After induction,
membrane fractions from NIH3T3 cells expressing mutant KRAS(KRASG12V) and EGFRC1025A has
reduced levels of PIK3R1 (p85) compared to cells expressing EGFRC1025A and KRASWT. α-tubulin
and β-catenin were positive controls for cytosolic and membrane enrichment respectively. B. The
membrane fraction from MDA-MB-231 cells expressing EGFRC1025A has reduced levels of PIK3R1
(p85) and increased amounts of Grb2 compared to cells expressing EGFRWT. α-tubulin and βcatenin were positive controls for cytosolic and membrane enrichment respectively. C.
Densitometric quantification of PIK3R1 or Grb2 amounts at the membrane. Density of PIK3R1 or
Grb2 bands was normalized to the band density of the loading control β-catenin and expressed
as the mean ± s.e.m of seven experiments. D. Lysates from NIH3T3 cells expressing WT KRAS
or KRASG12V and inducibely expressing empty vector, EGFRWT or EGFRC1025A cells were
subjected to immunoprecipitation with anti-PI3K(p110α). The precipitates were immunoblotted
with the indicated antibodies. Lysates not subjected to immunoprecipitation were used as input
controls. E. Lysates from NIH3T3 cells expressing V5-tagged PIK3R1 were incubated for 15
hours with increasing concentrations of biotinylated peptide encompassing the sequence around
either palmitoylated or unpalmitoylated Cys 1025 or a palmitoylated scrambled (Scr) control.
Peptides were isolated on streptavidin beads and the washed beads were boiled, and proteins
were separated by SDS-PAGE and immunoblotted with anti-PIK3R1. Binding reactions prior to
streptavidin pull-down were used as input controls. PIK3R1 interacts with wildtype palmitoylated
peptide but not the palmitoylated scrambled peptide or the unpalmitoylated wildtype peptide.
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Loss of DHHC20 sensitizes KRAS mutant cells to PI3K inhibitors
The results thus far indicate that blocking EGFR palmitoylation, reduces PI3K
signaling. Consequently, KRAS mutant cancer cells are unable to proliferate due to a
dependency on higher PI3K signaling needed to balance the hyperactivation of MAPK.
Therefore, we hypothesized that KRAS mutant cancer cells where DHHC20 is inhibited
by shRNA will be sensitive to elimination of the residual PI3K signaling by treating cells
with a PI3K inhibitor. Stable knockdown of DHHC20 in the KRAS mutant SW1573 and
H23 cells increases sensitivity to the PI3K inhibitor, BKM120. (Fig. 7A and Supp. Fig.
4A). BKM120, also known as, Buparlisib, is a pan PI3K inhibitor currently in clinical
development for various solid tumors. Inhibition by BKM120 proves more effective in
inducing cell death than gefitinib in KRAS mutant cells where DHHC20 is inhibited using
both stable knockdown and acute doxocycline-induced shRNA driven knockdown, (Fig.
7A, B and Supp. Fig. 4B).Furthermore, prolonged DHHC20 inhibition in SW1573 and
H23 cells reduced the IC50 concentrations of BKM120 by 2-fold indicating increased
sensitivity of the KRAS mutant cell lines to inhibition of PI3K signaling (Fig. 7C and
Supp. Fig. 4A). Relevant to the clinic, simulating acute drug inhibition, knockdown of
DHHC20 using doxocycline to induce expression of shRNA targeting DHHC20 in A549GFP-Luciferase (A549-GL) and H23-GFP-Luciferase (H23-GL) cells reduced the IC50
concentrations of BKM120 by 3- and 5-fold, respectively. (Fig. 7D and Supp. Fig 4B).
These results corroborate the finding that KRAS mutant cells become sensitive to the
loss of PI3K signaling when EGFR is not palmitoylated. This facet of the mechanism can
be translated to the clinic by developing a pharmacologic inhibitor of DHHC20 to use in
combination with a PI3K inhibitor.

126

Inhibition of DHHC20 blocks growth of established KRAS-mutant lung tumors
To determine the potency of targeting DHHC20 in existing tumors we generated
xenografts using the KRAS-mutant cell line, A549, expressing GFP and luciferase and
doxocycline-inducible shRNA targeting a control scrambled sequence or DHHC20.
Doxocycline treatment was initiated when tumors reached 100 mm3 in size, and was
administered every day for 10 days. Tumor growth was measured by luciferase imaging.
Induction of shRNA targeting DHHC20 abrogated the growth of all xenograft tumors by
day 2 of treatment whereas induction of shRNA targeting control scrambled was unable
to inhibit tumor growth. (Fig. 7 E, F) . These results set up a strong rationale for
developing specific small molecule inhibitors to the enzyme DHHC20.
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Figure 7. Loss of DHHC20 sensitizes KRAS mutant cells to PI3K inhibitors
A and B. Gefitinib (5 uM) (gray) and BKM120 (500 nm) (black) treatment increases
cytotoxicity in DHHC20 silenced SW1573 cells and inducibely silenced A549-GFPLuciferase (A549-GL) cells (mean +/−StDev). ** P < 0.05 C and D. Dose-response
curves for SW1573 shCN and shDHHC20 and A549-GL with inducible shRNA against a
control scrambled sequence (shCN) and shD20 cells treated with either Gefitinib or
BKM120 at various doses for 72 h (n=3) to determine IC50 differences. *** P < 0.001 for
2
all IC50 pairs, Two-Way Anova. R value =0.98. E. Tumor volume of each shControl
xenograft (left, black) and each shDHHC20 xenograft (right, red) represented as the day
0 normalized bioluminescence intensity (photons/sec). n=10. F. Bioluminescence
images of A549-GL xenograft bearing mice. Representative image of one shControl and
one shDHHC20 mouse through all days of measurement.
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Discussion
Taken together, our findings indicate that in a mutant KRAS background the PI3K
heterodimer associates with palmitoylated EGFR at the plasma membrane to activate
PI3K/AKT signaling. As a result, there is an increase in Myc expression that activates
pro-proliferative transcription programs supporting cancer cell growth (Fig. 9A, left).
Using a genetically engineered mouse model for Kras driven lung cancer, we find that in
the absence of this mechanism tumorigenesis is blocked.
Our previous studies on EGF stimulation of shDHHC20 cells showed that without
EGF stimulation there is high basal Erk phosphorylation and increased AKT is
dependent on ligand stimulation. EGF stimulation also increases EGFR palmitoylation at
C1025, but phosphorylation at Y1068, the main Grb2 binding site that mediates MAPK
signaling is reduced considerably when C1025 is palmitoylated (6). This suggests EGF
stimulation mediated EGFR palmitoylation at C1025 antagonizes MAPK signaling. The
studies presented here examine the consequence of losing EGFR palmitoylation in
either a wild type or oncogenic KRAS setting. In a wild type KRAS setting there is an
increase in KRAS at the membrane upon expression of EGFRC1025A, but the rapid cycling
of KRAS activity allows association of the PI3K complex at the membrane. However, in
the mutant KRAS setting, KRAS is locked in the active GTP bound state, therefore when
EGFR is not palmitoylated there is constitutive binding of Grb2, and hyperactivation of
the KRAS/MAPK pathway downstream. Under these conditions, PI3K is unable to
interact with EGFR to form a stable signaling complex and the PI3K/AKT signaling
cascade is impeded. As a result, GSK3β is active and promotes rapid degradation of
Myc leading to a loss of pro-proliferation signals and attenuation of cancer cell growth
(Fig. 9A, right).
130

Recent studies show that cancer cells are dependent on signaling mechanisms
for undergoing oncogenic transformation that are dispensable in normal cells (5). For
example, mutations in the Ras binding domain of PIK3CA have no discernible effects on
mouse development or cell homeostasis but this mutation reduces oncogenic KRAS
driven tumor formation and maintenance through a loss of PI3K signaling (5). This
demonstrates that oncogenic KRAS requires interaction with PIK3CA for downstream
signaling to MAPK and PI3K to initiate tumorigenesis. We find a similar requirement for
EGFR palmitoylation to maintain PI3K signaling during KRAS driven tumorigenesis since
expressing EGFRC1025A has no effect on Myc expression in cells with wild type KRAS.
Additionally, our previous studies showed that although knockdown of DHHC20 reduces
cell proliferation of the breast cancer cell line MDA-MB-231, knockdown of DHHC20 has
no effect on the growth of the normal breast epithelial cell line MCF10A (7).
The growth defect in the shDHHC20 cells is restored by shEGFR indicating
unpalmitoylated EGFR is itself inhibitory in the presence of oncogenic KRAS. In general,
the mechanism of PI3K activation by EGFR is unclear as EGFR lacks the canonical
PI3K binding motif (pYXXM) present in other receptor tyrosine kinases and it has been
proposed another adaptor like Gab1 mediates PI3K signaling by EGFR (18). We
propose an alternative mechanism where cells expressing EGFR may be dependent on
DHHC20 mediated palmitoylation to sustain PI3K signaling in the presence of oncogenic
KRAS.
Our findings show that reducing DHHC20 levels blocks tumor formation in a
KRAS-mutant GEMM and arrests growth of existing human KRAS-mutant tumors. One
would predict that low DHHC20 levels in KRAS-mutant NSCLC tumors would predict
improved prognosis of survival of patients. Our experimental data is validated by the
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analysis of large lung adenocarcinoma patient datasets revealing a strong correlation
between low DHHC20 expression and improved probability of survival (Supplemental
Fig. 3A) (19). This clinical impact is strengthened by the improved efficacy of pan-PI3K
inhibitor, Buparlisib, induced by DHHC20 inhibition. Buparlisib monotherapy has resulted
in modest efficacy in the clinic so far, thereby, the focus of clinical trials rests in
combination therapy. These findings reveal DHHC20, an enzyme, as a susceptible drug
target for use in combination with clinically available PI3K inhibitors as a strategy for
targeted treatment of KRAS-driven adenocarcinoma.
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A. Model

Figure 8

Figure 8. Mechanistic Model
A. Model: EGFR palmitoylation (Left) promotes PI3K/AKT signaling leading to stable Myc
production and cell proliferation. Loss of EGFR palmitoylation (Right) promotes binding of Grb2SOS leading to hyperactivation of KRAS/MAPK, but impedes PI3K/AKT signaling, causing Myc
depletion and reduced cell proliferation.
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Supplemental Figure 1

A.

B.

crDHHC20#1 at 24 weeks post-infection

Supplemental Figure 1.
A. Fold change in Myc mRNA levels in MDA-MB-231 and H23 shCon versus shDHHC20 (shD20)
cells. Graph represents average calculated fold change ± s.d of 6 replicates. B. Hematoxylin and
Eosin (H&E) 4X stitched images of 3 sgDHHC20#1 mice lungs 24 weeks post-infection. Tumour
burden does not increase after 24 weeks. Control mice had to be sacrificed at 13 weeks due to
extensive tumour burden.
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Supplemental Figure 2
B.

DAPI

YFP

Merge

mCherry

mCherry
C1025A

EGFR

C1025A

EGFR

75 um

25 um

EGFR

L858R

EGFR

L858R

250 um

EGFR

C1025A

L858R

EGFR

EGFR

mCherry

A.

25 um

Supplemental Figure 2.
A. IHC images of lungs stained for EGFR from KPY mice 13 weeks following Lenti-pCreator-Cre
infection. Representative images mCherry (top), EGFRC1025A (middle) and EGFRL858R (bottom) at
10X magnification. Red square shows 20X magnification image of indicated region. B. mCherry,
EGFRC1025A and EGFRL858R cohort tissue sections were stained for YFP (green), EGFR (red) and
DAPI (blue). Red square shows 20X magnification image of indicated region.
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Supplemental Figure 3

A.

Supplemental Figure 3.
A. Representative KM plot for survival probability of low vs. high DHHC20 expression from triplenegative breast cancer (TNBC) patients. Meta-Z Score = 2.03 from 16 different data sets. B.
Representative KM plot for survival probability of low vs. high DHHC20 expression from lung
adenocarcinoma. Meta-Z Score = 3.03 from 16 different data sets.
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Supplemental Figure 4
A.

B.

Supplemental Figure 4. A. Dose-response curves for H23 shCN and shDHHC20
treated with either Gefitinib or BKM120 at various doses for 72 h (n=3) to determine IC50
differences. B. Gefitinib (5 uM) (gray) and BKM120 (500 nm) (black) treatment increases
cytotoxicity in inducibely silenced H23-GL cells (mean +/−StDev). Dose-response curves
H23-GL with inducible shRNA against a control scrambled sequence (shCN) and shD20
cells treated with either Gefitinib or BKM120 at various doses for 72 h (n=3) to determine
IC50 differences.
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Materials and Methods
Cell culture
MDA-MB-231 and NIH3T3 cells (ATCC) were cultured in DMEM containing 10% FBS.
H23 and SW1573 cells (ATCC) were maintained in RPMI supplemented with 10% FBS.
GSK3β inhibitor (CHIR-99021), Gefitinib, and BKM120 was purchased at Selleck
Chemicals. 2-Bromopalmitate (2-BP) was purchased at Sigma Aldrich.
Silencing of Human DHHC20
The oligonucleotides for shControl and shDHHC20 constructs were synthesized
(Integrated DNA Technologies) and inserted into the pLKO.1 vector. shControl encodes
the non-targeting sequence of SHC002 (Sigma); the shRNA target sequence of human
DHHC20 is 50-GAGCTCTGCGTGTTTACTATT-30. MDA-MB-231 and H23 cells were
transduced with lentivirus encoding shControl or shDHHC20 and selected by puromycin
treatment (1 mg/ml) for several passages.
Plasmids and Generation of Stable Cell Lines
Human mutant MycT58A from pLV-tetO with an HA tag (Addgene plasmid #19763) (20)
was gateway cloned into the pLX304 backbone with a blasticidin resistance marker and
V5 tag (Addgene). Lentivirus of pLX305-MycT58A was generated using HEK293T cells
with Gag, VSVG and Rev plasmids using TransIT-LT1 (Mirus) according to
manufacturer’s instructions. H23 cells that were transduced with lentivirus encoding
shControl or shDHHC20 and selected by puromycin treatment were subsequently
infected with MycT58A-V5. H23 shControl or shDHHC20 and Lenti-pLX304-MycT58A
were selected with puromycin (1 µg/ml) and blasticidin (10 µg/ml) together for several
passages. To generate inducible cell lines, wildtype EGFR and EGFRC1025A cDNA was
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first subcloned into the inducible pTRIPZ backbone with a puromycin resistance marker
and FLAG tag. Empty pTRIPZ, which expresses the rtTA3, puromycin resistance
marker, and FLAG tag was used as a negative control. Virus production was performed
by transfecting HEK293T cells with the pTRIPZ constructs, psPAX2 and pMD2.G
plasmids (Addgene) using TransIT-LT1 (Mirus) according to the manufacturer’s
instructions. MDA-MB-231 and NIH3T3 were infected with pTRIPZ virus using polybrene
and incubated for 24 hours. Post-infection, fresh media was added on infected cells and
incubated for an additional 48 hours before selection. Cells infected with the pTRIPZ
constructs were selected with 1 µg/ml puromycin for several passages. Expression of
EGFR cDNA was induced with 1μg/ml doxycycline overnight before proceeding with
experiments. Lentivirus of human KRAS4B(WT) or mutant KRAS4B(G12V) in pLentiPGK-hygromycin resistance with an HA tag (Addgene plasmid #35633) (20) was
generated using HEK293T cells with Gag, VSVG and Rev plasmids using TransIT-LT1
(Mirus) according to manufacturer’s instructions. NIH3T3 cells infected with pTRIPZ
constructs and selected with puromycin were subsequently infected with KRAS4B(WT)HA or KRAS4B(G12V)-HA. NIH3T3 pTRIPZ-plenti-KRAS4B (WT) or (G12V) cells were
selected with puromycin (1 µg/ml) and hygromycin (500 µg/ml) together for several
passages. Lentivirus of human mutant PI3KCA-E545K in pcw107-PGK-puromycin
resistance (Addgene plasmid #64605) (21) generated using HEK293T cells with Gag,
VSVG and Rev plasmids using TransIT-LT1 (Mirus) according to manufacturer’s
instructions. NIH3T3 cells infected with pTRIPZ constructs and selected with puromycin
were subsequently infected with PI3KCA-E545K.
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Immunoblot analysis
Cell lysates were prepared in 1% Triton-X-100 buffer, including Tris-HCl (pH 7.5) and
sodium chloride solution (NaCl). Lysates were analyzed by immunoblotting with the
following antibodies: Anti-DHHC20 (HPA014702) antibody was purchased from SigmaAldrich. Anti-EGFR-XP, pERK, ERK, pS473-AKT, pT308-AKT, AKT, pGSK3β(Ser9),
GSK3β, PI3K(p110α), PIK3R1 (p85), Ras, β-catenin and β-actin were obtained from Cell
Signaling Technologies. Anti-Myc and α-tubulin were purchased from Santa Cruz.
Immune complexes were detected with horseradish peroxidase-conjugated secondary
antibodies and enhanced chemiluminescence (ECL) (Thermo Scientific).
Membrane Fractionation
Cell lysates were prepared in hypotonic lysis buffer including Tris-HCl (pH 8),
magnesium chloride (MgCl2), potassium chloride (KCl) and dithiothreitol (DTT). Lysates
were disrupted using passage through 25-gauge needle. Lysates were subject to
centrifugation at 800 xg for 10 min at 4C to pellet nuclei. The resulting supernatant was
then subject to centrifugation with a tabletop ultracentrifuge at 42000 rpm for 1 hour at
4C. The resulting supernatant was kept as the cytosolic fraction and pellet contained the
membrane fraction. Membrane fraction was resuspended in 1% NP-40 lysis buffer
including Tris-HCl (pH 8), sodium chloride (NaCl), sodium dodecyl sulfate (SDS) and
glycerol. Sample loading buffer was added to the membrane samples and the samples
were boiled for 8 minutes followed by western analysis and immunoblotting.
Drug Proliferation Assays
Cells were plated in a solid white 96-well plate at 5000 cells per well in 90 ul of 10% FBS
RPMI media. Serial dilutions of gefitinib and BKM120 were made in media and 10 ul of
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the diluted compounds were transferred to the cells. After 72 hours, cell viability was
measured by CellTiter-Glo (Promega) according to manufacturer’s instructions.
Luminescent readout was normalized to DMSO-treated control cells and empty wells.
Data was analyzed by nonlinear regression curve fitting on Prism 8 and IC50 values
were reported.
Myc qPCR
Total RNA was isolated using the RNeasy Extraction Kit (Quiagen). To quantify Myc
expression levels, equal amounts of cDNA were synthesized using the SuperScript™ III
First-Strand Synthesis System (Invitrogen) and mixed with the Power SYBR Green PCR
master mix (Applied Biosystems, Carlsbad, CA) and 5 pmol of both forward and reverse
primers. GAPDH was amplified as an internal control.
Primers pairs used for qPCR
The sequences of the human primers used for qPCR, listed from 5’ to 3’, were:
Gene

Forward and reverse primers’ sequence

MYC

CCTACCCTCTCAACGACAGC

CTCTGACCTTTTGCCAGGAG

B-Actin

AATCTGGCACCACACCTTCTAC

ATAGCACAGCCTGGATAGCAAC

Peptide streptavidin pull-down
Cell lysates were made as described above. Lysates were incubated with various
concentrations of biotinylated scrambled-palmitoylated, unpalmitoyled C1025 containing
EGFR C-terminal tail, and palmitoylated C1025 containing EGFR C-terminal tail peptides
dissolved in DMSO overnight at 4 degrees Celsius. The streptavidin agarose beads
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(Thermo Scientific) were washed three times with aforementioned lysis buffer. Lysates
with peptides were incubated with 20μl of the prewashed streptavidin agarose beads for
2 hours at 4 degrees Celsius with rotation. The beads-lysate-peptide mix was spun down
at 6000 x g for 1 minute. The beads were washed 3 times with cold lysis buffer. Loading
sample buffer containing β-mercaptoethanol was added to beads and the beads were
then boiled for 10 minutes at 100 degrees Celsius. The boiled sample was centrifuged at
16000 x g for 1 minute and supernatant was collected for western blotting.
Vector design and production
LentiCRISPRv2Cre is described in D. Walter et al. Can. Res., 2017 (10) and is available
from Addgene (#82415). DHHC20 sgRNAs were designed to target exons in the first
one-third of the gene using the CRISPR Design Tool (http://crispr.mit.edu/about) to
minimize off-target effects in the mouse genome. DHHC20 sgRNAs were cloned into
LentiCRISPRv2Cre vector by Golden Gate assembly using BsmBI (New England
BioLabs R0580S). The sgRNAs used for targeting Cas9 are: DHHC20 1, 5′CACCGAGTACGTGGAACTTTGCGCTGTTT-3′ and DHHC20 2, 5′CACCGGCGCTGCTGCCAACGCGTGGGTTT-3′. The sensor assay reporter was
generated by synthesizing sgRNA targets in series and cloning them upstream of
mCherry in the pCHK-mCherry vector using Gibson assembly as discussed in D. Walter
et al. Can. Res., 2017. (10) pCreatorBsmBI was constructed by synthesis of a gene
block encoding a KpnI cloning site, the eukaryotic elongation factor short promoter (EFS)
followed by a 2xBsmBI golden gate cloning site, P2a peptide sequence, and CreNLS.
The fragment was obtained from Genescript and cloned into pUC57mini vector. The
KpnI-ClaI fragment of the gene block was subsequently subcloned into the vector
backbone portion of a KpnI-ClaI digested pLentiCRISPRv2Cre to create pCreatorBsmBI.
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mCherry and EGFR mutants were PCR amplified with primers containing BsmBI tails
and appropriate restriction sequences for Golden Gate cloning such that the 5’ (left)
overhang is 5’-CACC-3’, and the 3’ (right) overhang is 5’-ATCC-3’ after BsmBI digest.
Lentivirus production
HEK293 FT cells were transfected with LentiCRISPRv2Cre or pCreator EGFR WT,
C1025A, L858R, and Δ8.2, and VSV-G plasmids in a 4:3:1 ratio using polyethylenimine.
Twenty-four hours after transfection, the media were replaced with fresh DMEM
supplemented with 25 mmol/L HEPES (Gibco 15630-080) and 3 mmol/L caffeine (Sigma
C0750). Lentivirus-containing supernatant was collected from the cells at 48 and 72
hours following transfection, filtered through 0.45-μm filters (Thermo Scientific 7232545), and centrifuged at 107,000 ×g. The viral pellet was soaked in 100-μL PBS for 16
hours at 4°C, triturated, vortexed for 15 minutes at 4°C, and finally centrifuged at 16,000
× g for 30 seconds to remove insoluble debris. Lentivirus was then aliquoted and frozen
at −80°C for later use. Lentivirus was titered on Green-Go cells, an NIH3T3 derivative
harboring an integrated Cre-dependent GFP reporter. These cells are validated for
reporter activity by flow cytometry during viral tittering. A total of 2 × 105 cells were plated
in 6-well plates, and 24 hours later lentivirus was added at 10, 1, and 0.1 μL per well.
Cells were analyzed by flow cytometry for GFP expression 48 hours following infection,
and viral titer was calculated accordingly.
Animal work
KRASLSL-G12D; p53flox/flox; Rosa26LSL-YFP (KPY) mice are maintained on a mixed
C567B6/129Sv4 background and were treated as previously described (22). Mice were
given lentivirus at 6 × 104 pfu per mouse by intratracheal intubation at 6–10 weeks of
age as described previously (23). Mouse lungs were harvested at 12 weeks.
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Histologic analysis
Tumor number was counted on hematoxylin and eosin–stained slides. Tumor area was
quantified using ImageJ software. Tumor burden percentage was calculated as tumor
area over total lung area multiplied by 100.
Immunohistochemistry (IHC) and Immunofluorescence (IF)
Mouse tissues were fixed in 10% neutral buffered formalin (Fisher Scientific 23-245-685)
for 16 hours and dehydrated in a series of ethanol washes up to 100%. Samples were
paraffin embedded and sectioned at 4-μm thickness. For IHC, slides were deparaffinized
in xylene and rehydrated with a series of ethanol washes. Antigen retrieval was
performed using citrate buffer (Electron Microscopy Sciences 62706-10) and slides were
stained using antibodies against GFP that cross-react with YFP (1:200, Abcam), pERK
(1:500, CST) and EGFR-XP (1:200, CST). Primary antibody was incubated on slides for
16 hours at 4°C, and biotinylated secondary antibody (Vector Laboratories) was
incubated at room temperature for 1 hour. ABC reagent and ImmPACT DAB were
prepared as directed (Vector Laboratories PK-4001 and SK-4105). Slides were analyzed
on a Leica DMI6000B inverted microscope. For IF, slides were again deparaffinized in
xylene and rehydrated with a series of ethanol washes. Antigen retrieval was performed
using citrate buffer (Electron Microscopy Sciences 62706-10) and slides were stained
using antibodies against GFP (1:200, Abcam), Ki67 (1:200, Abcam) and EGFR-XP
(1:200, CST) and counterstained with DAPI using Fluoro-Gel II with DAPI (EMS Catalog
#17985-50). Detection was by Alexa 488nm or Alexa 594nm conjugated secondary
antibodies (Molecular Probes, Eugene, OR). Slides were analyzed on a Leica DMI6000B
inverted microscope.
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NSCLC Xenografts
Four- to 6 week SCID beige mice (CB17.Cg-PrkdcscidLystbg-J/Crl) purchased from
Charles River were injected subcutaneously with 5 x 106 cells in 1:1 solution with
matrigel in both flanks. Mice with established A549-GFP-Luciferase tumors (100mm3)
were treated intraperiotoneally each day with doxocycline (20 mcg in 0.5 cc water) to
induce expression of shRNA targeting either a control scramble sequence or DHHC20.
Tumors were measured on day -2, 0, 5, and 8 using in vivo bioluminescent imaging. To
image, mice were anesthetized and intraperitoneally injected with D-Luciferin (GoldBio
LUCNA-1G) in PBS at 150mg/kg. Luminescent signals were acquired 15 minutes postinjection with the IVIS Spectrum (Caliper Life Sciences). Analysis was done using Living
Image 4.5 (Perkin Elmer).
Statistics
Statistical analyses were performed using Prism software version 7.0 (GraphPad).
Experiments are reported as mean ± SD or SEM as noted in the legends. Data were
analyzed using a 2-tailed Student’s t-test for comparison between 2 data sets. Multiple
comparisons were analyzed by 1-way ANOVA and 2-way ANOVA, followed by Tukey’s
multiple-comparison correction. A P-value of less than 0.05 was considered statistically
significant.
Study Approval
All experiments involving live animals were performed in compliance with the guidelines
set forth in the Public Health Service Policy on the Humane Care and Use of Laboratory
Animals. Mice were housed in a pathogen-free facility at the American Association for
Laboratory Animal Science–accredited Animal Facility at the University of Pennsylvania
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Perelman School of Medicine. All studies were performed under protocols approved by
the Institutional Animal Care and Use Committee (IACUC) at the University of
Pennsylvania Perelman School of Medicine (#804774).
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CHAPTER 5: DISCUSSION
Overview
The origins of this thesis lie in our discovery that the receptor tyrosine kinase,
EGFR, is palmitoylated on the C-terminal tail which was discovered in a breast cancer
cell line overexpressing EGFR and, to some extent, overexpressing the
palmitoyltransferase, DHHC20. From this initial discovery rose the overarching question:
what is the regulatory role of EGFR palmitoylation in tumorigenesis? Upon study, the
research question became: what is the mechanism by which loss of EGFR
palmitoylation hinders tumorigenesis, specifically KRAS-driven tumorigenesis? Into this
set of questions, we tried to incorporate one of the main drivers of cancer research: can
EGFR palmitoylation be manipulated to develop a new therapeutic strategy?
EGFR palmitoylation occurs at three critical cysteines, Cys1025, Cys1034 and
Cys1122, on the C-terminal tail. We have determined that palmitoylation of the Cterminal tail inhibits receptor activity, perhaps as a negative feedback mechanism or as
mitigation of access activity upon ligand binding. Upon the loss of palmitoylation, EGFR
is activated with or without EGF stimulation indicating that palmitoylation is an activity
suppressant. Mutation of Cys1025 and Cys1122 alone or in combination increases the
phosphorylation and thereby activity of EGFR. Loss of EGFR palmitoylation at Cys1122
exhibited increased presence of EGFR at the membrane, sustained phosphorylation of
EGFR in response to EGF, and endocytotic dysregulation indicating that palmitoylation
at Cys1122 is involved in promoting receptor turnover. However, mutation of Cys1025
significantly increases the binding of the adapter protein, Grb2, to EGFR, leading to the
RAS/MAPK pathway. Thereby, we focused our energy towards understanding the
signaling mechanism in the presence of the Cys1025 mutation (EGFRC1025A).
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These results specifically showed that the EGFRC1025A and EGFRC1122A mutation
alone or in combination increase the phosphorylation of EGFR and subsequently ERK,
and one particular phosphorylation site of AKT (Ser473). However, upon further
inspection, we discovered that the Thr308 phosphorylation of AKT, directly downstream
of PI3K, decreases upon expression of the EGFRC1025A mutation. Therefore, we found
that loss of EGFR palmitoylation in a mutant KRAS setting specifically leads to an
increase in the MAPK signaling cascade, but also a significant decrease in PI3K/AKT
signaling. With further study, we discovered that due to this decreased PI3K/AKT
signaling, GSK3β remains active and promotes rapid degradation of Myc, the critical cell
proliferation associated transcription factor. Now we understand mechanistically why
loss of EGFR palmitoylation leads to disrupted cell growth; the degradation of Myc leads
to a loss of pro-proliferative transcription and subsequent loss of cancer cell growth.
Structurally, we found that the regulatory subunit of PI3K (p85) specifically associates
with palmitoylated EGFR and p85 is required to be in the vicinity of the membrane to
interact with catalytic subunit of PI3K, p110alpha. Thereby, on the loss of EGFR
palmitoylation in a mutant KRAS setting, PI3K is unable to form a stable signaling
complex at the membrane in the vicinity of EGFR, but there is constitutive binding of
Grb2 to EGFR and hyperactivation of the KRAS/MAPK pathway. We speculate that
KRAS mutant cancer cells require balanced activity of both the MAPK and PI3K cascade
to proliferate through Myc stabilization. Moderate disruption of PI3K signaling from loss
of EGFR palmitoylation leads to a significant growth defect of tumor cells. We
hypothesized that further inhibition of the remaining PI3K activity would kill the cancer
cells. As such, we found that inhibiting DHHC20 with either stable knockdown or acute
inducible knockdown in mutant KRAS cells induced sensitivity to the clinically used PI3K
inhibitor, BKM120. Finally, we showed that DHHC20 ablation or expression of
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EGFRC1025A in a mutant KRAS-driven mouse model blocks tumorigenesis. This
correlation is consistent with our findings that DHHC20 ablation in KRAS driven mouse
model drastically blocks tumorigenesis. These findings reveal that loss of EGFR
palmitoylation from inhibition of DHHC20 makes the untreatable KRAS-driven
adenocarcinoma susceptible to treatment with a clinically available inhibitor against
PI3K, such as BKM120.
Additional data suggests that DHHC20 inhibition may make KRAS-driven
adenocarcinoma susceptible to EGFR inhibition as well as PI3K inhibition. We found that
inhibition of DHHC20 or expression of the EGFRC1025A point mutant leads to increased
sensitivity to gefitinib-induced cell death in the KRAS mutant MDA-MB-231 cells.
Gefitinib is a potent TKI and functionally, blocks EGFR kinase activity by binding to the
ATP binding site. Currently, the alterations in EGFR signaling that lead to increased or
decreased sensitivity to gefitinib is still not entirely clear. Inhibition of DHHC20 in
wildtype KRAS MCF-7 and non-transformed MCF-10a cells had no effect on gefitinib
sensitivity. This result prompted the question: is this phenotype of increased gefitinib
sensitivity upon loss of EGFR palmitoylation dependent on the presence of mutant
KRAS? In addressing this question, we discovered that expression of the palmitoylationresistant EGFRC1025A mutant in NIH3T3 cells leads to increased sensitivity to gefitinibinduced cell death, but only in the presence of oncogenic KRASG12V, whereas expression
of mutant PI3KCA did not change the sensitivity to gefitinib. This suggests that the
phenotype of increased gefitinib sensitivity when EGFR palmitoylation is lost is
dependent on the presence of specifically mutant KRAS. We were unable to determine
the mechanism by which loss of EGFR palmitoylation is causing sensitivity to gefitinib
and why this requires the presence of mutant KRAS. As we previously observed,
inhibition of DHHC20 or expression of EGFRC1025A activates the receptor and further
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increases MAPK signaling that is already high due to the presence of mutant KRAS.
Thereby, inhibition of DHHC20 or loss of EGFR palmitoylation may be making KRAS
mutant cells dependent on EGFR signaling and this may be one reason for the
increased gefitinib sensitivity. The cells now dependent on EGFR signaling and
artificially high levels of MAPK signaling could be sensitive to an EGFR inhibitor, such as
gefitinib, that is inhibiting MAPK levels causing the cells to crisis and die. However, we
did not observe a decrease in MAPK levels upon gefitinib treatment suggesting that the
increased sensitivity is not due to the cells newfound dependency on EGFR signaling.
More intriguingly, we found that cells harboring both the EGFR activating L858R
and drug resistant T790M mutant, H1975 cells, exhibit a synergistic effect when treated
with gefitinib and 2-bromopalmitate (2-BP). 2-BP is a palmitate analogue that has the
ability to block palmitoyltransferases by competing out the palmitic acid. Although
sufficient to inhibit DHHC enzymes, 2-BP is not specific to DHHC20 and requires high
doses to cause an effect. The EGFRL858R mutation is uniquely sensitive to gefitinib, but
upon prolonged treatment, the cells acquire the secondary EGFRT790M mutation, aptly
named the gatekeeper mutation, which is strongly resistant to gefitinib. Therefore,
inhibition of DHHC20 is resensitizing gefitinib-resistant cells to gefitinib. However, we
were unable to express EGFRC1025A in H1975 cells or express EGFRL858R/T790M in cells
with the EGFRC1025A mutation due to severe toxicity. Therefore, we could not claim that
the increased gefitinib sensitivity in the H1975 cells is directly dependent on the loss of
EGFR palmitoylation. Our palmitoylated EGFR mass spectrometry studies also identified
a potentially modified cysteine in the kinase domain, cysteine 751. However, the data
acquired from the acyl-biotin exchange method followed by mass spectrometry was
unclear as to if the modification was palmitoylation or another cysteine modification,
such as nitrosylation, due to the complete protection of thioester linkages to
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hydroxylamine (HAM) treatment at that site. Regardless, this site could regulate
conformational changes based on the presence or lack of a fatty acid chain, which will in
turn effect the kinase activity of the receptor. A modification at cysteine 751 could add to
the conformational changes associated with the gatekeeper mutation that cause an
increase in the affinity of ATP again leading to drug resistance. If the cysteine 751 is in
fact palmitoylated, loss of this palmitoylation could cause the gatekeeper mutation to be
ineffective leading to a return in sensitivity to gefitinib. Many future studies are required
to determine how potential palmitoylation in the kinase domain effects the gatekeeper
mutation or if palmitoylation of the C-terminal tail is indirectly affecting the kinase
domain. However, the resensitization of a drug-resistant cell line to a tyrosine kinase
inhibitor by inhibition of a palmitoyltransferase is therapeutically compelling and warrants
further scientific examination.
The work described in this thesis demonstrates a novel mechanism of tyrosine
kinase receptor, specifically EGFR, regulation through DHHC20-mediated palmitoylation
of the C-terminal tail. Sequence analysis has identified that other receptors implicated in
tumorigenesis, such as HER2 in breast cancer and FLT3 in leukemia, have critical
cysteines in the C-terminal tail that could be palmitoylated. ABE analysis and metabolic
labeling followed by click chemistry of HER2 and FlT3 confirm that these receptors are
palmitoylated, but the critical cysteines are yet to be determined (unpublished data,
Witze Laboratory). Additionally, unpublished data from the Witze Laboratory
demonstrates that in fact many receptors are palmitoylated on the C-terminal tail by
specific DHHC enzymes, such as insulin receptor (INSR) by DHHC19 and vascular
endothelial growth factor receptor (VEGFR) by DHHC13. Furthermore, other groups
have shown that DHHC13 palmitoylates melanocortin-1 receptor (MC1R) and inhibition
of MC1R palmitoylation by expression of a cysteine point mutation in vivo leads to a loss
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of mouse coat color and follicular degeneration (1). Therefore, palmitoylation could be
involved in regulating the signaling faculty of these receptors as well as EGFR.
Potentially, disruption of the palmitoylation of these receptors, such as FLT3, may be
detrimental to the cancers dependent on these receptors. As such, there is a necessity
to further study the palmitoylation of receptors and to identify the responsible
palmitoyltransferases. Furthermore, as determined, loss of palmitoylation activates
EGFR, which induces synthetic lethality in the presence of mutant KRAS. Many groups
are searching for targets of synthetic lethality specifically in the incurable mutant KRAS
cancers. We have shown that activating EGFR is a means to induce synthetic lethality in
mutant-KRAS adenocarcinoma, however, it is challenging to therapeutically activate a
protein. We have also identified the enzyme responsible for palmitoylating EGFR
demonstrated in this thesis to be DHHC20. We have observed that pharmacologic
inhibition of DHHC20 in KRAS-driven adenocarcinoma allows therapeutic efficacy of
readily available inhibitors, such as BKM120 and gefitinib. Taken together, the work in
this thesis sets up a strong precedence to develop small molecule inhibitors specific to
DHHC20 to potentially eradicate the aggressive KRAS-driven adenocarcinoma.

Challenges
Studying the Comprehensive Loss of EGFR Palmitoylation or DHHC20
The true extent of the regulatory abilities of EGFR palmitoylation could be studied
through complete loss of EGFR palmitoylation. In order to allow complete loss of EGFR
palmitoylation, a triple mutation of all three critical cysteines must be expressed. The
EGFRC1025A or EGFRC1122A reduced EGFR palmitoylation compared to wild type EGFR
when expressed in HEK293T cells, but the double mutation is not sufficient to
completely eliminate palmitoylation. The EGFR ABE followed by mass spectrometry
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directly showed that both Cys1025 and Cys1034 sites exist as palmitoylated and
unpalmitoylated, which is understandable as palmitoylation is a reversible modification.
However, Cys1122 was never identified by the mass spectrometry as palmitoylated due
to experimental technicality as the peptide containing Cys1122 was too large to be
measured. Cys1122 was shown to be palmitoylated by generating the EGFRC1122A
mutation and performing an ABE to show a decrease in overall EGFR palmitoylation.
Unfortunately, the EGFRC1034A mutation was only detected by immunofluorescence (IF)
as expressed in a small number of cells that seemed to be dying. These cells contained
extremely high levels of phosphorylated ERK as seen by IF and taken together with the
deteriorating morphology of the cells, these indications suggested that EGFRC1034A
expressing cells were unable to progress through mitosis. As a result, we could not
perform many studies concerning signaling effects using the EGFRC1034A mutant.
Given the immediate deteriorating phenotype observed upon the minimal
expression of EGFRC1034A, we speculated that Cys1034 may be a primary palmitoylation
site. Many kinases have a priming phosphorylation site that is required to be
phosphorylated before other sites can be phosphorylated, including but not limited to
cyclin-dependent kinase 2 (CDK2), Interferon-gamma factor 1 receptor (IGF1R) and
protein kinase b (PKB), which are required to be phosphorylated in an activation
segment with a conserved arginine and aspartate (thus named RD kinases) preceding
phosphorylation for catalytic activity (2). Similarly, we believe that there are priming
palmitoylation sites; cysteines that require palmitoylation before any other cysteines can
be palmitoylated. As such, if Cys1034 is in fact a prime site for palmitoylation, then upon
expression of the EGFRC1034A perhaps neither Cys1025 nor Cys1122 would be able to
get palmitoylated leaving EGFR completely unpalmitoylated. Given this potential
understanding of Cys1034, we hypothesized that a complete loss of EGFR
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palmitoylation is detrimental to the cell due to unstainable ERK activity. As we could not
express EGFRC1034A, it was impossible to generate a viable triple mutant of EGFR
Cys1025, Cys1122 and Cys1034.
A further hurdle arises in the fact that the wildtype, endogenous receptor is still
being produced upon the expression of the aforementioned point mutants. The
expression of the EGFRC1025A mutant is exogenous. EGFRC1025A receptor can
homodimerize with other EGFRC1025A receptors, losing palmitoylation at Cys1025
completely, or with wildtype, endogenous EGFR receptors. Whether one monomer of
EGFRC1025A has the capacity to impair the palmitoylation of its potentially wildtype
monomer pair in a dominant negative manner remains unstudied. To study this, tagged
EGFRC1025A and tagged wildtype EGFR can be co-expressed in HEK293T cells followed
by a tag specific immunoprecipitation of the respective EGFR receptors, an ABE, and
the SDS-PAGE analysis of the ABE samples. Western analysis using antibodies against
the different tags will indicate the palmitoylation or lack thereof of the wildtype receptor
upon association with the EGFRC1025A receptor. Regardless, the expressed wildtype
receptor still has the capacity to homodimerize with other wildtype EGFR receptors or
heterodimerize with other ERBB family members, such as HER2 (ERBB2) (3). Upon the
expression of a palmitoylation point mutant, these wildtype receptors will be normally
palmitoylated and may compensate for the signaling capacity lost by the expressed
unpalmitoylated receptors. Consequently, the growth defect and hindered signaling
phenotype we observe upon expression of EGFRC1025A may be a subdued result given
the compensation from the normally palmitoylated wildtype EGFR. As such, generating
and expressing a triple palmitoylation EGFR mutant will still not phenotypically represent
a complete loss of EGFR palmitoylation. To fully understand how palmitoylation
regulates EGFR or even other receptors, we will have to find a way to completely inhibit
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the specific palmitoylation of the receptors. One possible way to eliminate EGFR
palmitoylation would be to inhibit the enzyme responsible, in this case DHHC20.
However, other complications will follow this route.
We observed that shRNA knockdown of DHHC20 was never complete. As a
result, knockdown of DHHC20 is also insufficient to produce a complete loss of EGFR
palmitoylation. Knockout of the DHHC20 gene using the CRISPR/Cas9 system can be a
method to overcome incomplete loss of DHHC20. However, with complete loss of
DHHC20, there may be compensatory palmitoylation activity from other
palmitoyltransferases. Expression analyses show that many other DHHC enzymes are
expressed in lung tissue and cells, including DHHC5 and DHHC21 at the plasma
membrane. In fact, almost all tissue types express multiple DHHCs both at the RNA and
protein level (4, 5). Upon complete loss of DHHC20, expression of these other
palmitoyltransferases could become amplified to subsequently be recruited to
palmitoylate EGFR as a mechanism of signaling recovery especially in transformed
cells.
To fully study the requirement of DHHC20, a DHHC20 conditional knockout
mouse must be generated. There are no studies as of yet that have generated a
DHHC20 knockout mouse and therefore, developmental phenotypes have not been
observed and it remains unknown whether loss of DHHC20 is embryonic lethal. There
are very few in vivo studies that have been performed involving any DHHC enzyme. The
few examples that exist include studies with a targeted DHHC11 knockout mouse or a
mouse that generates a spontaneous DHHC21 mutation. The DHHC11 knockout mice
are viable and present with simply a decreased threshold for an auditory response (6).
The DHHC21 mutant mouse that generate the aptly named dep (depilated) mutation
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present with disoriented hair follicles and damaged hair (7). Therefore, to determine the
requirement of DHHC20 in vivo in the context of development or tumorigenesis, creation
of a complete or conditional DHHC20 knockout mouse is a future necessity in this field.
Discrepancies in AKT Phosphorylation
As mentioned, we originally fount that the EGFRC1025A mutation increases the
phosphorylation of EGFR and subsequently ERK, and AKT phosphorylation at Ser473.
However, we then discovered that expression of EGFRC1025A decreases the
phosphorylation of AKT at Thr308, which is directly downstream of PI3K. The Thr308
phosphorylation site of AKT has proven to be the initial site of AKT phosphorylation
allowing AKT activity, however, the second phosphorylation at Ser473 allows for
complete activation of AKT. The human AKT family of proteins consists of three major
isoforms, AKT1, AKT2, and AKT3. Studies have shown that AKT1 and AKT3 have
phosphorylation sites on both Thr308 and Ser473, whereas AKT2 apparently can only
be phosphorylated at Thr308, suggesting that these isoforms are differentially regulated
and are not redundant. Furthermore, these studies show that phosphorylation at Thr308
is critical for AKT function as all isoforms must be phosphorylated at Thr308 at the least
(8). Other studies have shown that key phosphatases, such as PP2A, are preferentially
targeted to dephosphorylate AKT at Thr308 rather than Ser473, again indicating that
AKT phosphorylation at Thr308 is critical for AKT activity (9). Some studies have gone
as far as to say that phosphorylation of AKT at Thr308 is a more reliable in vivo
biomarker to predict tumor response to therapeutics. These studies found that the
phosphorylation of Thr308 correlates with poor survival in NSCLC and acute myeloid
leukemia, but there was no such correlation with AKT phosphorylation at Ser473. One
group performed a detailed and quantitative examination of the activation of AKT in
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normal and patient-matched tumor tissue from NSCLC patients. The concluded that
Thr308 phosphorylation of AKT was a better predictor than Ser473 phosphorylation of
AKT for poor overall survival in NSCLC and more importantly, Thr308 phosphorylation is
a stronger indicator of AKT activity in tumor samples (10). Our results were contradictory
in terms of AKT activation as we saw an increase in Ser473 phosphorylation originally
but then saw a drastic decrease in Thr308 phosphorylation. Taking these studies
together with the context of our study, we determined that the loss of Thr308
phosphorylation upon loss of EGFR palmitoylation more accurately determined the
activity of AKT as the observed phenotype alluded to a loss of AKT activity.
Spatial Functionality of Palmitoylation
A palmitic acid moiety is a large hydrophobic entity. As can be assumed, this
moiety will have steric or spatial consequences on the cellular surroundings.
Furthermore, palmitic acid is strongly hydrophobic indicating that the palmitic acid moiety
cannot reside in the hydrophilic cytoplasm and must be situated in hydrophobic
surroundings, such as the plasma membrane or a pocket of a protein. In fact, upon
discovery, palmitoylation was thought to specifically function as a modification that
allowed proteins to anchor into the plasma membrane. Many integral and peripheral
membrane proteins require palmitoylation to increase their hydrophobicity and localize to
the membrane from the golgi apparatus; a well-known example is the membrane
localization of the RAS protein isoforms (11). More recently, in the nanoparticle realm,
researchers have created a superhydrophobic coating material for the nanoparticles by
modifying already hydrophobic zinc oxide with palmitic acid, generating a surface on
which water will form a complete spherical droplet identified as superhydrophobic (12).
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Thereby, the scientific community has identified palmitoylation as a means to generate
hydrophobicity in proteins allowing them to associate with membrane compartments.
Given this understanding of palmitoylation, we originally hypothesized that the
palmitoylated C-terminal tail of EGFR is associating or “pinning” the tail to the plasma
membrane. The C-terminal tail of EGFR is canonically depicted in crystal structures and
in subsequent images as unstructured, extending away from the plasma membrane and
the kinase domain. As such, we thought that the palmitic acid moiety could be adding
structure to the C-terminal tail by promoting peripheral association with the plasma
membrane, allowing the existing hydrophobic palmitic acid to bury itself into the
hydrophobic lipid bilayer. We tested this hypothesis by adding a thrombin cleavage site
at the start of the C-terminal tail of EGFR and performing a membrane isolation with and
without the presence of DHHC20. Upon cleavage of the tail in the presence of DHHC20,
there was a strong presence of the C-terminal tail in the membrane fraction which was
partially lost when DHHC20 was removed from the equation (Refer to Page 64). This
experiment suggested that in part the palmitoylated C-terminal tail of EGFR is
associated with the plasma membrane. However, to accurately determine if the
palmitoylated C-terminal tail is associated with the membrane, a crystal structure of
EGFR in the presence of palmitoylation must be isolated. If so, the proposed inhibitory
(to EGFR downstream activity) function of palmitoylation of the C-terminal tail can be
understood because if the C-terminal tail is looped into the plasma membrane,
scaffolding and other signaling proteins will have no access to the necessary binding
motifs (Figure 1).
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The result aforementioned indicated that upon the loss of DHHC20, there is still
some presence of C-terminal tail in the membrane fraction (Refer to Page 64). As
discussed above, we know that DHHC20 inhibition using shRNA is not a complete
inhibition. As such, there may still be palmitoylated EGFR present contributing to that
result. Ideally, this experiment can be advanced by adding a thrombin cleavage site to
the beginning of the C-terminal tail of a triple palmitoylation mutant EGFR. This
experiment will show that the unpalmitoylated EGFR C-terminal tail can no longer
associate with the plasma membrane. However, as discussed, we were not able to
generate a triple palmitoylation mutant of EGFR. Furthermore, the result aforementioned
indicated that not all of the expressed EGFR C-terminal tail was isolated in the
membrane fraction because the amount of full-length EGFR expressed was higher than
the level of isolated C-terminal tail (Refer to Page 64). Firstly, the result will show only
the cleaved C-terminal tails in the membrane fraction signifying that this could be a
technical issue of the experiment in that the thrombin enzyme may not be efficient
enough to cleave all EGFR molecules expressed. Secondly and more likely, the result
indicates that not all palmitoylated C-terminal tails are anchored to the plasma
membrane. The palmitic acid moiety may adjust the C-terminal tail in another manner.
As we progressed through the study, we determined that in fact there may be
another structural function of palmitoylation. Recent studies have shown that some
proteins have hydrophobic pockets where specifically acyl-moieties can interact. An
example that has already been mentioned is the myristoylated N-terminal tail of the Src
kinase, c-Abl. The myristoyl group can penetrate into a deep pocket in the kinase
domain of c-Abl formed by a congregation of hydrophobic amino acid side chains. This
loop of the N-terminal tail and myristoyl binding to the pocket is necessary to generate a
critical inhibitory conformation of c-Abl. The residues that make up the myristate binding
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pocket in c-Abl are conserved in the Abl paralog, Arg. In fact, the general structure of
this kinase domain base incorporating the hydrophobic pocket is conserved amongst the
Src kinases, suggesting that acylated moieties on these other kinases may interact with
hydrophobic binding sites in the kinase domains. (13,14). Recently, a group showed that
a polypeptide conjugated to a small-molecule ligand binds to the enzyme glycogen
phosphorylase a (GPa) at a hydrophobic binding site on the surface of the protein
composed of hydrophobic amino acids (15).
Given these examples of the existence of hydrophobic binding sites on proteins,
we speculated that the EGFR kinase domain could also have a hydrophobic binding site
where the C-terminal palmitoyl groups can interact. Groups in the EGFR dynamics field
have shown that there are several states of tyrosine kinase activation. There is an
inactive monomer and dimer state, a catalytically competent dimer that precedes
phosphorylation and finally, an active conformation post-phosphorylation. These
demonstrated that the inactive and catalytically competent states are defined by the
presence of hydrophobic “spines” within the kinase domain composed of hydrophobic
amino acid side chains. In particular, there is a small hydrophobic core that is formed by
the structural helices required to maintain the kinase in the inactive conformation.
Activation of the receptor requires conformational changes that specifically disrupt these
hydrophobic spines and cores. (16,17) As we have determined that palmitoylation of the
C-terminal tail is inhibitory to the activation of EGFR, it is possible that palmitoylation
allows the C-terminal tail to loop and interact with these hydrophobic cores in the kinase
domains keeping the receptor in the inactive conformation. Furthermore, as mentioned,
we identified a cysteine in the kinase domain that has the capacity to be acylated.
Although the palmitoylation of this cysteine, Cys751, was not experimentally confirmed,
the presence of a modified cysteine furthers the notion that the kinase domain has a
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deep hydrophobic capacity. Therefore, the palmitoylated EGFR C-terminal tail could be
associating with the kinase domain. Further study of the EGFR structure in the presence
of palmitoylation will shed light on this possibility.
Finally, we also speculated that the palmitic acid moiety on the C-terminal tail
could be motif to which other proteins can interact. Other proteins might have a similar
hydrophobic binding pocket as the above-mentioned examples. These proteins could
have an affinity to the palmitic acid moiety on the C-terminal tail and thereby promote
interaction with the receptor. One of the primary functions of palmitoylation is to
modulate protein-protein interactions. Therefore, the requirement of palmitoylation for
the necessary recruitment of interacting proteins to modulate signaling is extremely
feasible and, as we have discovered, is occurring.
PI3K-Receptor Complex Formation
PI3K/AKT signaling is one of the main component cascades downstream of
EGFR. PI3K is composed of two subunits, the catalytic p110 subunit and the regulatory
p85 subunit, which mediates binding to the receptor. The regulatory subunit, p85, has
two SH2 domains that must be phosphorylated in order to induce the catalytic activity of
p110 and initiate the remaining cascade. It is known that PI3K p85 binds to ERBB3 and
ERBB4 directly at a recognized C-terminal tail motif, a phosphorylated Tyr-X-X-Met
(PYXXM) motif (18). Interestingly, EGFR (ERBB1) and ERBB2 do not contain the
PYXXM motif on the C-terminal tail. Thus far, it has been shown that p85 interacts with
EGFR indirectly through the adaptor protein, GAB1 (GRB2-associated binder), which
bind the scaffold protein Grb2 (19). It has also been proposed that PI3K is activated
perhaps directly upon formation of EGFR heterodimers with other ERBB family
members. We believe that we have found another mechanism by which p85 perhaps
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interacts directly with EGFR or in the least, allows recruitment of p85 to the vicinity of
EGFR in order to make necessary interactions.
We discovered that p85 preferentially binds to a generated palmitoylated Cterminal tail peptide of EGFR. Moreover, immunoprecipitation of p85 shows an
interaction with wildtype EGFR that is completely lost upon expression of the
palmitoylation-deficient EGFRC1025A mutation. We have seen that inhibition of EGFR
palmitoylation significantly decreases PI3K/AKT signaling. Taken together, these data
suggest that p85 in part requires the presence of palmitoylation on the C-terminal tail to
be able to activate the pathway, although much more work is required to confirm this
direct association. Work done on early signaling dynamics of EGFR in response to EGF
stimulation shows that PI3K phosphorylation levels increase rapidly within 10-20
seconds of EGF stimulation followed by equilibration. Contrastingly, GAB1 show slower
but more sustained increases in phosphorylation of relevant sites. Interestingly, the
phosphorylation timing of the key phosphorylation sites on the C-terminal tail drastically
differs from the rapid phosphorylation of PI3K. Specifically, the phosphorylation of the
EGFR tyrosines take upwards to 80 seconds of EGF stimulation to reach the levels
equivalent to PI3K phosphorylation at 10 seconds. (20) This indicates that something
else on EGFR that is unconnected to the phosphorylation sites is allowing activation of
PI3K prior to activation of the receptor or even GAB1. If PI3K is phosphorylated before
GAB1 is phosphorylated, then GAB1 cannot be the only adaptor that is allowing
activation of PI3K. This work adds precedence to the discovery that p85 binds to the
palmitoylated EGFR tail early and this interaction could allow activation of PI3K.
Interestingly, it is well-studied that RAS interacts with PI3K at a RAS-binding
domain (RBD) in p110. This binding and the subsequent stimulation of the PI3K pathway
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is specific to the GTP-bound form of RAS. (21) Disruption of the RAS-PI3K interaction in
progressed KRAS-driven NSCLC. showed partial regression suggesting the requirement
of this interaction in the maintenance of KRAS-driven NSCLC. However, these data
could not prove that this interaction was required for tumor initiation or development (22).
Very recently, another group showed that the RAS-PI3K interaction is required for the
tumor onset and maintenance of EGFR-driven NSCLC despite the lack of presence of
mutant KRAS (23). Thus, the PI3K pathway is activated by interaction with RAS in both
mutant-KRAS and mutant-EGFR settings. The background of most of our studies has
been the presence of mutant KRAS. By inhibition EGFR palmitoylation in a mutant
KRAS background, we discovered a significant loss of PI3K signaling. Given the studies
discussed above, it would follow that activation of PI3K from its interaction with active
RAS should compensate for the loss of PI3K signaling from unpalmitoylated EGFR.
However, the above studies show that the interaction between RAS and PI3K is
specifically between RAS and the RBD of the p110 subunit. These studies indicate, as it
is not explicitly demonstrated, that the catalytic p110 subunit can be activated by its
interaction with RAS and no longer requires the regulatory p85 subunit. However, we
speculate that activity of PI3K, whether it be through interaction with a receptor or RAS,
requires association with p85. This speculation can explain the drastic loss of PI3K
signaling that we have observed upon the loss of EGFR palmitoylation. As there is no
longer efficient recruitment of p85 due to the loss of palmitoylation, there is no PI3K
signaling even from the interaction of RAS and p110. In order to demonstrate this
speculation, RAS-p110 binding studies in the presence and absence of p85 need to be
performed. However, given our results, we have revealed that loss of EGFR
palmitoylation drastically affects recruitment of p85 to the vicinity of its activator and thus
hinders PI3K activation.
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Challenges of In Vivo Genetic Manipulation
For scientists in cancer research field, in order to understand how cancer
develops and metastasizes throughout the body and to discover more effective ways to
diagnose and treat cancer, it is critical to conduct live animal research. Using live
animals, we can understand how the active immune system and metabolism will affect
the efficacy of manipulating a specific target. There are many advantages of using mice
over other live animals or model organisms. For instance, their genome is 99% similar to
that of the human genome and their small size allows for large scale/high throughput
studies in a cost-efficient manner. To best recapitulate the genetics and histology of
human tumors, genetically engineered mice models (GEMMs) were developed. In the
most recent GEMMs, oncogenes are activated and/or tumor-suppressor genes are
inactivated somatically at a chosen time and in a tissue-specific manner with expression
of CRE recombinase. These GEMMs have become valuable tools to study the pathways
and mechanisms underlying human disease on a cellular and molecular level; complex
processes, such as cancer initiation, progression, metastasis formation, and the
involvement of the tumor microenvironment. Thereby, studies using GEMMs have also
been crucial to enable the development of novel targeted treatments.
However, like many scientific methods, GEMMs also have limitations and
technical challenges. A major limitation of germline GEMMs is that development and
validation of these models is time‐consuming and laborious. For example, introducing a
novel germline mutation into an existing multi-allelic mouse model requires extensive
breeding and genotypic validation after each round. We were lucky enough to have a
readily available GEMM that ideally served the purposes of the work in this thesis. This
mouse model is called the KrasLSL-G12D/+; Trp53flox/flox; Rosa26LSL-YFP. In this model,
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expression of Cre recombinase is induced virally in the lung to turn on expression of
KrasG12D, delete the p53 gene and turn on expression of the YFP reporter in the same
cell. This model recapitulates the initiation and progression of mutant KRAS lung
adenocarcinoma.
We manipulated the viral plasmid housing the promoter driven Cre recombinase
by introducing gene components of the CRISPR/Cas9 system driven by a EF1alpha
promoter and a guideRNA (sgRNA) targeting the DHHC20 gene driven by a U6
promoter. Thereby, the virus generated using this CRISPR-Cre plasmid can be used to
infect lung cells subsequently deleting DHHC20 in the same cells that have KRASG12D
expressed and p53 deleted. Using the CRISPR/Cas9 system brought upon its own set of
challenges. Primarily, Cas9 enzymes have the ability to cut the wrong genes even when
driven by a nucleotide guided sequence preceding the sgRNA producing potential offtarget cleavage events. To minimize these events, we generated two very specific
sgRNAs targeting DHHC20 and validated these sgRNAs in cell lines prior to introduction
into the mice. Deletion of DHHC20 using both sgRNAs resulted in a drastic decrease in
mutant KRAS tumorigenesis measured by analysis of tumor burden in the lung.
In cell lines, we were able to test the requirement of the presence of EGFR when
DHHC20 is deleted to produce the growth defect phenotype in a KRAS mutant
background. Ideally, we sought to recapitulate this result in vivo. We generated a
plasmid that contained the CRISPR/Cas9 system, Cre recombinase and sgRNAs
targeting both DHHC20 and EGFR. We expected that deletion of EGFR and DHHC20
would rescue the tumor burden similar to the results observed in vitro. However, we did
not observe a significant return of tumor growth upon deletion of both EGFR and
DHHC20 (Figure 2). On further inspection, we determined that this result was due to
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limitations of the CRISPR/Cas9 system with two sgRNAs. As the sgRNAs are driven by
the same promoter, placement of the sgRNAs with respect to the promoter seems to
affect the efficiency of the guide. As the sgRNA targeting DHHC20 was placed right next
to the promoter, the CRISPR/Cas9 system was more efficient in deleting DHHC20 and
could not effectively delete the EGFR gene. Furthermore, the length of the EGFR gene
is significantly larger (4 kb) than that of DHHC20 (<1 kb). The CRISPR/Cas9 system has
limitations on the length of the gene that can be deleted efficiently. However, deletions of
up to 60kb in length have been generated (24).
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Figure 2
sgInert

sgDHHC20

sgDHHC20 + sgEGFR

Discussion Figure 2: Deletion of EGFR and DHHC20 does not rescue KPY tumor
burden unlike in vitro, where inhibition of EGFR and DHHC20 rescued the cell growth
defect seen upon loss of DHHC20.
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To confirm deletion of DHHC20 in the lung tissue upon introduction of the ViralCRISPR/Cre, immunohistochemistry (IHC) and immunofluorescence (IF) using the
available antibodies to DHHC20. Unfortunately, there are no antibodies against mouse
DHHC20 and the available antibodies against human DHHC20 have not been tested for
use in IHC or IF. As a result, DHHC20 could not be detected by even in the control lung
tissue. Therefore, we could not determine by IHC or IF that DHHC20 was deleted in the
experimental cohort. Furthermore, the lack of tumor lesions in the DHHC20 deleted
cohort made it difficult to stain anything. To step around this challenge, we stained lung
tissues from the control cohort and DHHC20 deleted cohort with antibodies against
pERK. Given our in vitro results showing an increased expression of pERK upon
inhibition of DHHC20 in KRAS mutant cells, we expected that the small tumor lesions
that we observed in the DHHC20 deleted lung tissues would stain higher for pERK than
the control tissue. In fact, that was the result we observed. Taking the drastic phenotype
of lost tumor burden and the increased expression of pERK in the DHHC20 deleted lung
tissues, we determined that the CRISPR/Cas9 system efficiently deleted DHHC20. We
faced a similar challenge with the overexpression vector that we generated. This plasmid
contains Cre recombinase gene driven by the PGK promoter and gene encoding
wildtype EGFR or EGFRC1025A or EGFRL858R driven by an Actin promoter. This viral
vector was named pCREator. We observed that expression of EGFRC1025A drastically
reduced lung tumor burden more than even expression of EGFRL858R, which has been
shown previously to hinder mutant KRAS tumorigenesis. The pCREator viral vectors
were tested and validated for EGFR and Cre expression in vitro. However, to validate
the phenotype in vivo, we had to show expression of human EGFR in the EGFR
overexpressing cohorts. Antibodies against human EGFR were used to detect
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overexpression of EGFR via IF but the overexpression was more difficult to determine
using IHC.
Another challenge we faced was quantifying the infection efficiency of both the
CRISPR-Cre and the pCREator viruses. The phenotype of a drastic loss in tumor burden
that we see upon deletion of DHHC20 or expression of EGFRC1025A could be result of
unequal infection between the control and the experimental viruses. Therefore, it was
critical to prove that the viruses infect cells at the same efficiency. Each virus was
generated and titered before being introduced into the mice. Viral titers are calculated by
performing a plaque-forming assay using different volumes at 10-fold dilutions of the
generated virus. Plaques formed are counted and the virus is given a titer of plaqueforming units (PFU) per milliliter. The mice cohorts were given equivalent amounts of
virus (60000 PFU/ml) according to the calculated titer. However, equivalent amount of
virus does not equate with the efficiency of the virus or the infection rate. To
approximately determine if the different viruses being compared had a similar infection
rate, the Rosa26LSL-YFP reporter in the mouse model was utilized. Each cell in the lung
infected with any of the viral vectors will express Cre recombinase and Cre will remove
the stop cassette flanked by the loxP sites in the Rosa26 gene, thereby turning on
expression of yellow fluorescent protein (YFP) that can be easily detected by IHC and
IF. After IHC staining using antibodies against YFP, we counted the YFP positive spots
in each cohort of mice representing infection locales. In the control cohort, a tumor was
counted as one infection site. Similarly, in the DHHC20 deleted or EGFRC1025A
expressing cohorts, each visible lesion was considered one infection site. We observed
that between the control and experimental cohorts, there were an equivalent number of
YFP positive sites. Taking this data, we determined that the viral vectors had
approximately the same infection rate.
174

The GEMM and the genetic manipulation using viral vectors represents the
effects of DHHC20 deletion or expression of EGFRC1025A on tumor initiation as DHHC20
is deleted at the same time that KRASG12D is expressed and p53 is deleted. Therefore,
the question still remains whether loss of DHHC20 effects the progression of mutant
KRAS cancer. It will be more clinically relevant to determine if the loss of DHHC20
effects tumor progression, whether that be regression or stability, as patients often
present with already progressed disease. To study cancer progression, we chose to use
mice xenografts generated by subcutaneous transplantation of human KRAS mutant
lung cancer cell lines into which we stably introduced doxocycline-inducible shRNA
targeting DHHC20. In this model, human mutant KRAS cancer can be generated
followed by induction of the DHHC20 shRNA using doxocycline treatment to test if
inhibition of DHHC20 in an established tumor can cause regression. There are several
advantages of the xenograft model. Xenografts utilize human cells or tissue allowing the
study of the complex genetic and epigenetic abnormalities that exist in human disease.
Results from xenografts are acquired in a few weeks whereas GEMM often take months
to a year to develop and test. Finally, xenografts can be used to help in the development
and to quickly test the efficacy of targeted molecular therapies. (25) Although we have
not yet acquired results from this model, we have been able to generate viable
xenografts and have optimized doxocycline treatment for the mice to obtain the most
efficient expression of the inducible shRNA against DHHC20. This model will be critical
in the future to test the small molecule inhibitors against DHHC20 that we are aiming to
eventually develop.
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Future Ideas
Universality of Palmitoylation
Throughout the course of this thesis work, many enlightening facets of
palmitoylation and its newfound role in regulation of receptor signaling have been
discovered. However, there is much more work to be done to understand the full
molecular scope of palmitoylation and its role in regulating signaling cascades. As we
have discovered, palmitoylation seems to be inhibitory for EGFR activity as when we
remove palmitoylation, EGFR is hyperactivated. As aforementioned, work done in the
Witze lab demonstrates that many other receptor tyrosine kinases have cysteines on the
C-terminal tails and in fact, we have found that receptor involved in critical signaling
cascades, such as the insulin receptor (IR) and fms-like tyrosine kinase 3 (FLT-3) in the
hematopoietic environment, are palmitoylated. Often, the innate sources of disease
initiation and progression are a mutation in the receptor rendering it hyperactive or
subsequent distortions in the signaling cascades downstream of these receptors. For
example, a FLT-3 internal tandem duplication (ITD) mutation renders FLT-3 and the
subsequent cascades downstream, primarily PI3K/AKT and MAPK, constitutively
hyperactive. These distortions drive generation and progression of acute myeloid
leukemia (AML). FLT-3 inhibitors are currently first line therapy for AML patients with the
FLT3-ITD mutation. However, as with many TKIs, prolonged treatment can generate
secondary mutations causing drug resistance. (26) As such, there is a need to study
alternate mechanism of receptor signaling control and manipulating palmitoylation may
be a new therapeutic approach. Our work on palmitoylation of various receptors and
how it affects the activity of these receptors is being continued. As these receptors are
expressed in different cell types, such as FLT-3 in hematopoietic cells, and different
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locations, it is likely that different DHHC enzymes palmitoylate different receptors and
much work is needed to identify these enzyme-substrate pairs. Additionally, the 23
DHHC enzymes palmitoylate thousands of protein substrates in the cell. Thus, there
must be a mechanism of substrate recognition that is also to be determined. Taken
together, this future work may identify a potential universal function of receptor
palmitoylation that can be manipulated to treat a plethora of signaling dependent
diseases.
Temporal Dynamics of Palmitoylation
Another primary question that arose after the discovery that EGFR is
palmitoylated was the temporal dynamics of palmitoylation with respect to
phosphorylation. In other words, the connection between palmitoylation, given that it is
inhibitory for EGFR activity, and phosphorylation, which transmits activity of the receptor,
remains unclear. Palmitoylation is reversible indicating that there is an on/off rate. To
determine the on/off rate of EGFR palmitoylation, a pulse-chase experiment with 17ODYA metabolic labeling followed by click chemistry at various time points can be used.
We have crudely determined that the total wildtype EGFR population, in active or
inactive conformation, is palmitoylated before ligand stimulation. Ligand stimulation
induces a modest increase in the level of palmitoylation, which then gradually return to
basal levels. By isolating specifically phosphorylated EGFR and performing an ABE, we
observed that dual palmitoylated/phosphorylated EGFR exists at some given time and
this receptor is turned over as dually palmitoylated/phosphorylated. However, we still do
not know if ligand binding and/or phosphorylation of the receptor induces palmitoylation
as a means to inhibit the activity or if palmitoylation is temporarily displaced by
phosphorylation. Ideally, the temporal dynamics of palmitoylation could be determined
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using immunofluorescence and live cell imaging if an antibody to palmitoylated EGFR
were developed. Currently, we are attempting to isolate phosphorylated EGFR at early
timepoints after ligand stimulation and performing the ABE assays to measure the
amount of dual palmitoylated/phosphorylated EGFR over time.
Development of Inhibitor against DHHC20
The foremost proposal for the future is the development of an inhibitor against
DHHC20. DHHC20 is an enzyme that has the capacity to be inhibited. Furthermore,
DHHC20 resides on the plasma membrane allowing accessibility to compounds. On the
plasma membrane, DHHC20 has transmembrane loops that are exposed in the
extracellular matrix and in the context of lung adenocarcinoma, DHHC20 is
overexpressed. As such, it is possible to take a monoclonal antibody approach to
inhibiting DHHC20, specifically in cancer cells. Monoclonal antibodies interact with a
larger region of the target molecule’s surface, allowing for better discrimination between
closely related targets and providing higher affinity. This high specificity that can be
established using monoclonal antibodies is the basis for their lack off-target toxicity,
which is a major concern with small-molecule drugs. However, this approach will require
that the exposed loops have a functional responsibility for the protein. As of yet, our
DHHC20 sequence studies suggest that the residues on the loop are largely responsible
for protein shape as opposed to having a functional purpose. Furthermore, these
residues seem to be conserved across all DHHC enzymes further indicating their role in
simply connecting secondary structures. Without a distinct target region, generating a
monoclonal antibody specifically targeting DHHC20 is difficult. Thereby, a monoclonal
antibody against DHHC20 may not be the ideal therapeutic approach.
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Current inhibitors of palmitoylation have been limited to 2-bromopalmitate (2-BP),
cerulenin, and tunicamycin. The most commonly used is 2-BP, which is a nonmetabolizable palmitate analog with a bromide group. The exact mechanism of action of
2-BP is not fully understood, but it is speculated that it binds to palmitoyl-transferases
and the bromide prevents the transfer of 2-BP to the substrate. It has been shown that 2BP inhibits palmitoylation in cells and activity of DHHC proteins in vitro using an
established palmitoyl-acyltransferase (PAT) activity assay (27). However, 2-BP inhibits
all DHHC enzymes without specificity. Furthermore, 2-BP also inhibits fatty acid CoA
ligase and many other enzymes involved in lipid metabolism. Cerulenin and tunicamycin
are even more non-specific inhibitors of palmitoylation. Cerulenin is mainly used to
inhibit fatty acid synthesis and tunicamycin is mainly used to inhibit N-glycosylation. A
group has developed a high throughput screen (HTS) for inhibitors of palmitoylation.
High-throughput screening (HTS) involves the screening of an entire compound library
directly against the drug target or in a cell-based assay, whose activity is dependent
upon the target. In this cell-based assay, membranes isolated from MCF-7 cells were
used as the source of PAT activity. The substrates for the activity included fluorescentlylabeled peptides mimicking myristoylated and palmitoylated proteins, such as c-Src, or
farnesylated and palmitoylated proteins, such as N- and H-RAS, to evaluate the ability of
screened compounds to inhibit palmitoylation in vitro. (28) Five compounds inhibited
palmitoylation of either the myristoylated/palmitoylated or farnesylated/palmitoylated
peptides. As cell membranes were used in this case as the source of PAT activity, this
assay did not demonstrate that the inhibitors reduced palmitoylation by directly blocking
DHHC proteins as opposed to any other acyltransferases. Another group used four
different purified DHHC enzymes with larger protein fragments as substrates for in vitro
PAT assays to evaluate if these compounds can inhibit DHHC-mediated palmitoylation
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of protein substrates. Furthermore, the level of DHHC inhibition of these inhibitors was
compared to that of 2-BP. They found that compound V (CV), behaved similarly to 2-BP
as it inhibited all four of the tested DHHCs. They also unfortunately discovered that,
unlike 2-BP, inhibition by CV is reversible and requires a higher concentration of inhibitor
compared to 2-BP. (29) As such, CV is still not clinically viable and is not specific to
individual DHHCs. However, this study has now provided a candidate that can be used
as a starting point to rationally reduce compound libraries for HTS and can be
manipulated with structural/side-chain substitutes focused on enhancing potency and
specificity.
The crystal structure of DHHC20 was recently isolated providing necessary
structural insight into direct and indirect binding sites of the enzyme potentiating
structural-aided drug design (30). Now we can collaborate with the Banerjee group that
discovered the structure of DHHC20 to isolate a DHHC20 crystal with CV docked to
provide understanding of the enzyme-inhibitor binding location. Our in vitro/in vivo
mechanism of action studies allow the development of a high-throughput compound
screen (HTS) (similar to that used to isolate CV) to identify potential inhibitory small
molecules. HTS are fairly effective in quickly discovering new compounds, however,
HTS is only as effective as the assay format chosen for the output. This assay is
dependent upon the biology of the drug target protein, the equipment and financial
infrastructure in the laboratory, whether an inhibitor or activator molecule is needed, and
the scale of the compound screen. Another important factor to consider when designing
an assay is the pharmacological relevance of the assay. Relevant cell types and
conditions must be used to understand the effect of the screened compounds on the
biological disease state. Furthermore, the assay must be reproducible so that multiple
compounds can be screened with comparable results across the experiments. Lastly,
180

each assay should control for the organic solvents, such as ethanol or DMSO, in which
inhibitors are dissolved.
Currently, we are developing a cell-based assay that is dependent on the specific
presence and activity of DHHC20. In basic, we are designing a fluorometric assay using
expression of differentially tagged ERK and Myc in human mutant KRAS cancer cells
based on the mechanism we have postulated in this thesis. We have access to multiple
compound libraries from the screening core at the university and a library available
through the National Institute of Health (NIH). Here, we can use the structure of CV upon
binding to DHHC20 to help predict where modifications could be added to provide
increased potency or selectivity and to prune or tailor the extensive compound libraries.
Compounds that activate ERK and lose Myc expression will be selected for secondary
screening. In the colorimetric assay, we will be able to see the strengthening of the color
attributed to ERK and the diminishing of the color attributed to Myc. Subsequently, we
will design a DHHC20 activity assay for the secondary screening of selected compounds
to identify those that directly inhibit DHHC20 activity. In this in vitro assay, purified
DHHC20 and palmitoyl-CoA will be incubated with a EGFR C-terminal tail peptide with
present cysteines. DHHC20 will not be able to transfer the palmitoyl-CoA to the
substrate cysteine in the presence of compounds that will inhibit DHHC20. Then we will
have to test the efficacy of these compounds in inhibiting other DHHC enzymes to
solidify specificity to DHHC20. When a few compounds are isolated, we can test the
preclinical efficacy in our already designed and used experiments described in this
thesis. Additionally, we have an established mouse model in which we will be able to test
lead compounds in vivo.
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Concluding Remarks
The palmitoylation field is fairly new in the realm of scientific study especially in
the context of cancer. As such, there is much to do before the scientific community will
understand the cellular magnitude of palmitoylation. This thesis challenges the canonical
understanding of receptor signaling dynamics by showing that a seemingly
inconsequential post-translational modification can assert control on disease defining
signaling proteins, such as EGFR. Furthermore, loss of EGFR palmitoylation by
inhibition of DHHC20 has the capacity to block mutant KRAS tumorigenesis. Inhibiting
EGFR palmitoylation activates the receptor and active EGFR is incompatible with the
presence of mutant KRAS described as synthetically lethal. In other words, this thesis
has discovered and validated a novel therapeutic target that blocks the growth of KRASdriven adenocarcinoma, which is the most difficult form of NSCLC to treat. We believe
that using a DHHC20 inhibitor in combination with clinically available inhibitors to EGFR
or PI3K can lead to regression of KRAS-driven NSCLC and perhaps complete
remission. It is our hope that the work in this thesis will inspire further study of the
uncharted functions of protein palmitoylation and of the deep mechanistic dynamics of
tyrosine kinase receptor regulation still not fully understood.
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